AAV capsid variants and uses thereof

By inserting or replacing amino acids at specific locations in the AAV5 capsid variant, the formation of an amino acid sequence that enhances tendency solves the problem of low transduction efficiency of AAV capsid in certain organs and improves the delivery efficiency of target cells or tissues , used to treat neurological and muscle-related diseases.

CN119072486APending Publication Date: 2024-12-03VOYAGER THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031870.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-05-09
Filing Date
2023-02-07
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing AAV capsid variants are inefficient in transduction in some organs, and pre-existing neutralizing antibodies can prevent treatment, resulting in inefficient clinical application and difficult to effectively deliver to target cells or tissues, such as CNS cells or Muscle cells.

Method used

AAV5 capsid variants are provided to enhance their tendency to target cells or tissues by inserting or replacing amino acids at a specific location, such as inserting or replacing amino acids at a position 577 to form specific amino acid sequences such as YPAEV or VQK to enhance Transduction efficiency.

Benefits of technology

Enhanced the tendency of the AAV capsid to target cells or tissues, improves the efficiency of payload delivery, and is potentially used to treat neural, muscle or neuromuscular disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005066999360001481
    Figure BDA0005066999360001481
  • Figure BDA0005066999360001491
    Figure BDA0005066999360001491
  • Figure BDA0005066999360001492
    Figure BDA0005066999360001492
Patent Text Reader

Abstract

The present disclosure relates to compositions and methods for making, using and / or formulating adeno-associated viral capsid protein variants.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related applications

[0002] This application claims priority to U.S. Provisional Application No. 63 / 307,742, filed February 8, 2022, and U.S. Provisional Application No. 63 / 339,574, filed May 9, 2022, the entire contents of which are incorporated herein by reference.

[0003] sequence list

[0004] This application contains a sequence list, which has been submitted electronically in XML format and is incorporated herein by reference in its entirety. The XML copy was created on January 24, 2023, named V2071-1111PCT_SL.xml, and is 2,233,613 bytes in size. Technical Field

[0005] This disclosure relates to compositions and methods for preparing, using, and / or formulating adeno-associated virus capsid proteins and their variants. Background Technology

[0006] Gene delivery to the central nervous system (CNS) remains a major challenge in gene therapy. Engineered adeno-associated virus (AAV) capsids with improved brain tropism represent an attractive approach to addressing CNS delivery limitations.

[0007] AAV-derived vectors are promising tools for clinical gene transfer due to their non-pathogenic properties, low immunogenicity, low integration rate into the host genome, and long-term transgenic expression in non-dividing cells. However, the transduction efficiency of natural AAV variants in certain organs is too low for clinical application, and capsid neutralization by pre-existing neutralizing antibodies can prevent treatment in most patients. For these reasons, considerable effort has been devoted to obtaining capsid variants with enhancing properties. Among the many approaches tested to date, significant advances have come from the directed evolution of AAV capsids using in vitro or in vivo selection of capsid variants, generated through capsid sequence randomization using error-prone PCR, shuffling of various parental serotypes, or insertion of a completely randomized short peptide at a specified position.

[0008] Attempts have been made to provide AAV capsids with improved properties, such as enhanced tropism towards target cells or tissues after systemic administration, but with limited success. Therefore, there is a need for improved methods to generate AAV capsids and deliver the associated payload of the resulting AAV capsids to target cells or tissues, such as CNS cells or tissues or muscle cells or tissues. Summary of the Invention

[0009] This disclosure relates at least in part to compositions and methods for generating and using AAV particles comprising an AAV capsid polypeptide (e.g., an AAV capsid variant (e.g., the AAV5 capsid variant)). In some embodiments, the AAV capsid variant has an enhanced tropism for tissues or cells (e.g., CNS tissue, CNS cells, cardiac cells, cardiac tissue, muscle cells, muscle tissue, hepatocytes, or liver tissue). This tropism can be used to deliver a payload (e.g., the payload described herein) to cells or tissues to treat conditions such as neurological or neurodegenerative diseases, muscle or neuromuscular diseases, or neurotumor diseases.

[0010] Therefore, in one aspect, this disclosure provides an AAV capsid variant (e.g., the AAV5 capsid variant) comprising a non-T amino acid (e.g., Y, N, or C) at position 577 relative to SEQ ID NO:138. In some embodiments, the AAV capsid variant comprises Y at position 577 relative to SEQ ID NO:138. In some embodiments, the AAV capsid variant comprises N at position 577 relative to SEQ ID NO:138. In some embodiments, the AAV capsid variant comprises C at position 577 relative to SEQ ID NO:138.

[0011] On the other hand, this disclosure provides an AAV capsid variant (e.g., a variant of the wild-type AAV5 capsid) comprising more than one amino acid that replaces the threonine (T) at position 577 of SEQ ID NO:138. In some embodiments, inserts of two, three, four, five, six, seven, eight, nine, or ten amino acids replace the T at position 577 of SEQ ID NO:138. In some embodiments, inserts of eight amino acids replace the T at position 577 of SEQ ID NO:138.

[0012] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising the formula [N2]-[N3], wherein: (i) [N2] comprises positions X1, X2, X3, X4, and X5, wherein: (a) position X1 is Y, N, or C; (b) position X2 is P, K, T, or Q; (c) position X3 is A or P; (d) position X4 is E, S, or A; and (e) position X5 is V, L, or E; and (ii) the amino acid sequence of [N3] comprises the amino acid sequence of VQK, EQK, VKK, VHK, VQQ, or LQK; and optionally, wherein the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (i) and / or (ii); optionally, wherein [N2]-[N3] is present immediately after position 576 relative to SEQ ID NO:138 and replaces position 577 relative to SEQ ID NO:138. In some embodiments, [N2] comprises Y at position X1. In some embodiments, [N2] comprises P at position X2. In some embodiments, [N2] comprises A at position X3. In some embodiments, [N2] comprises E at position X4. In some embodiments, [N2] comprises V at position X5. In some embodiments, the amino acid sequence of [N3] is VQK. In some embodiments, X1 of [N2] is located at position 577, X2 of [N2] is located at position 578, X3 of [N2] is located at position 579, X4 of [N2] is located at position 580, and X5 of [N2] is located at position 581, these positions are numbered according to SEQ ID NO:982. In some embodiments, [N2] is located at positions 577-581, these positions are numbered according to SEQ ID NO:982. In some embodiments, [N3] is located at positions 582-584, these positions are numbered according to SEQ ID NO:982. In some implementations, [N2]-[N3] are present at positions 577-584, which are numbered according to SEQ ID NO:982.

[0013] In some embodiments, the amino acid sequence of [N2] consists of YPAEV (SEQ ID NO:1). In some embodiments, the amino acid sequence of [N3] consists of VQK. In some embodiments, [N2]-[N3] replaces threonine (T) at position 577 of wild-type AAV5 (e.g., SEQ ID NO:138). In some embodiments, [N2]-[N3] replaces threonine (T) at position 577 of wild-type AAV5 (e.g., SEQ ID NO:138), and the amino acid sequence of [N2] consists of YPAEV (SEQ ID NO:1), and the amino acid sequence of [N3] consists of VQK. In some embodiments, [N2] is present at positions 577-581, which are numbered according to SEQ ID NO:982. In some embodiments, [N3] is present at positions 582-584, which are numbered according to SEQ ID NO:982. In some implementations, [N2]-[N3] are present at positions 577-584, which are numbered according to SEQ ID NO:982.

[0014] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising one, two, three, or all of the following: (i) [N0], wherein the amino acid sequence of [N0] comprises TNN, TNT, INN, TNS, NNN, or TNK; (ii) [N1], wherein the amino acid sequence of [N1] comprises QSS, QSK, TSL, SSS, QSR, AGA, IGS, QAS, ASS, LGS, QST, HSS, LSS, or QRS; (iii) [N2], wherein the amino acid sequence of [N2] comprises YPAEV (SEQ ID NO:1), YPPSL (SEQ ID NO:2), NKAEV (SEQ ID NO:3), YTAEV (SEQ ID NO:4), YPAEE (SEQ ID NO:5), YQAEV (SEQ ID NO:6), YTPSL (SEQ ID NO:7), YPAAV (SEQ ID NO:8), NPAEV (SEQ ID NO:9), CPAEV (SEQ ID NO:9), YPAEV (SEQ ID NO:1), YPPSL (SEQ ID NO:2), YPAAV (SEQ ID NO:8), NPAEV (SEQ ID NO:9), CPAEV (SEQ ID NO:1), YPAEV (SEQ ID NO:2), YPAEV (SEQ ID NO:3), YPAEV (SEQ ID NO:4), YPAEE (SEQ ID NO:5), YQAEV (SEQ ID NO:6), YTPSL (SEQ ID NO:7), YPAAV (SEQ ID NO:8), NPAEV (SEQ ID NO:9), CPAEV (SEQ ID NO:1), YPAEV (SEQ ID NO:2), YPAEV (SEQ ID NO:3), YPAEV (SEQ ID NO:4), YPAEV (SEQ ID NO:5), YQAEV (SEQ ID NO:6), YTPSL (SEQ ID NO:7), YPAAV (SEQ ID NO:8), NPAEV (SEQ ID NO:9), CPAEV (SEQ ID NO:1), YPAEV (SEQ ID NO:2), YPAEV (SEQ ID NO: (i) [N0] or YQAEE (SEQ ID NO:11); (iv) [N3], wherein the amino acid sequence of [N3] comprises VQK, EQK, VKK, VHK, VQQ, or LQK; and / or (v) [N4], wherein the amino acid sequence of [N4] comprises TA, PA, or NA; and optionally, wherein the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (i)-(v); optionally, wherein [N0] is present immediately after position 570 relative to the number SEQ ID NO:138. In some embodiments, the amino acid sequence of [N0] is TNN. In some embodiments, the amino acid sequence of [N1] is QSS. In some embodiments, the amino acid sequence of [N2] is YPAEV (SEQ ID NO:1). In some embodiments, the amino acid sequence of [N3] is VQK. In some embodiments, the amino acid sequence of [N4] is TA. In some embodiments, the amino acid sequence of [N0] is TNN, the amino acid sequence of [N1] is QSS, the amino acid sequence of [N2] is YPAEV (SEQ ID NO:1), the amino acid sequence of [N3] is VQK, and / or the amino acid sequence of [N4] is TA. In some embodiments, the amino acid sequence of [N0] is TNN, the amino acid sequence of [N1] is QSS, the amino acid sequence of [N2] is YPAEV (SEQ ID NO:1), the amino acid sequence of [N3] is VQK, and the amino acid sequence of [N4] is TA. In any of these embodiments, [N0] is immediately following position 570 relative to the number in SEQ ID NO:138.In any of these embodiments, [N0] replaces positions 571-573 (e.g., T571, N572, and N573), which are numbered relative to SEQ ID NO:138. In any of these embodiments, [N0] exists immediately after position 570, and [N0] exists at positions 571-573 (e.g., T571, N572, and N573), which are numbered relative to SEQ ID NO:138. In any of these embodiments, [N1] exists immediately after position 573, which is numbered relative to SEQ ID NO:138. In any of these embodiments, [N1] replaces positions 574-576 (e.g., Q574, S575, and S576), which are numbered relative to SEQ ID NO:138. In any of these embodiments, [N1] is present immediately after position 573, and [N1] replaces positions 574-576 (e.g., Q574, S575, and S576) relative to SEQ ID NO:138. In any of these embodiments, [N2] is present immediately after position 576 relative to SEQ ID NO:138. In any of these embodiments, [N2] replaces position 577 relative to SEQ ID NO:138 (e.g., T577). In any of these embodiments, [N2] is present immediately after position 576, and [N2] replaces position 577 (e.g., T577) relative to SEQ ID NO:138. In any of these embodiments, [N2]-[N3] are present immediately after position 576 relative to SEQ ID NO:138. In any of these embodiments, [N2]-[N3] replaces position 577 (e.g., T577) relative to SEQ ID NO:138. In any of these embodiments, [N2]-[N3] immediately follows position 576, and [N2]-[N3] replaces position 577 (e.g., T577) relative to SEQ ID NO:138. In any of these embodiments, [N2]-[N3]-[N4] replaces positions 577-579 (e.g., T577, T578, and A579) relative to SEQ ID NO:138. In any of these embodiments, [N2]-[N3]-[N4] immediately follows position 576, and [N2]-[N3]-[N4] replaces positions 577-579 (e.g., T577, T578, and A579), which are numbered relative to SEQ ID NO:138. In any of these embodiments, [N0]-[N1]-[N2]-[N3]-[N4] immediately follows position 570, which is numbered relative to SEQ ID NO:138.In some embodiments, [N0]-[N1]-[N2]-[N3]-[N4] replaces positions 571-579 (e.g., T571, N572, N573, Q574, S575, S576, T577, T578, and A579), these positions being numbered relative to SEQ ID NO:138. In some embodiments, [N0]-[N1]-[N2]-[N3]-[N4] exists immediately after position 570, and [N0]-[N1]-[N2]-[N3]-[N4] replaces positions 571-579 (e.g., T571, N572, N573, Q574, S575, S576, T577, T578, and A579), these positions being numbered relative to SEQ ID NO:138. For example, in some embodiments, [N0]-[N1]-[N2]-[N3]-[N4] is TNNQSSYPAEVVQKTA (SEQ ID NO: 1533) and is present immediately after position 570 relative to SEQ ID NO: 138, wherein [N2]-[N3] (YPAEVVQK (SEQ ID NO: 943)) replaces position 577 relative to SEQ ID NO: 138 (e.g., replaces T577). In some embodiments, [N0] is present at positions 571-573, which are numbered according to SEQ ID NO: 982. In some embodiments, [N1] is present at positions 574-576, which are numbered according to SEQ ID NO: 982. In some embodiments, [N2] is present at positions 577-581, which are numbered according to SEQ ID NO: 982. In some embodiments, [N3] is present at positions 582-584, which are numbered according to SEQ ID NO: 982. In some embodiments, [N4] is present at positions 585-586, which are numbered according to SEQ ID NO:982. In some embodiments, [N2]-[N3] are present at positions 577-584, which are numbered according to SEQ ID NO:982. In some embodiments, [N0]-[N1]-[N2]-[N3]-[N4] are present at positions 571-586, which are numbered according to SEQ ID NO:982.

[0015] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising the formula [B]-[C], wherein: (i) [B] comprises positions X1, X2, and X3, wherein: (a) position X1 is Q, T, S, A, I, L, or H; (b) position X2 is S, G, or A; and (c) position X3 is S, K, L, R, or A; and (ii) [C] comprises the amino acid sequence YPAEVVQK (SEQ ID NO: 943); and optionally, wherein the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (i) and / or (ii); and further optionally, wherein [B] is present immediately after position 573 relative to the number SEQ ID NO: 138. In some embodiments, [B] comprises Q at position X1. In some embodiments, [B] comprises S at position X2. In some embodiments, [B] comprises S at position X3. In some embodiments, the amino acid sequence of [B] is QSS. In some embodiments, [B] is present immediately after position 573 relative to the reference sequence numbered according to SEQ ID NO:138. In some embodiments, [B] replaces positions 574-576 (e.g., Q574, S575, and S576) relative to the reference sequence numbered according to SEQ ID NO:138. In some embodiments, [B] is present immediately after position 573 relative to the reference sequence numbered according to SEQ ID NO:138, and [B] replaces positions 574-576 (e.g., Q574, S575, and S576). In some embodiments, [C] is present immediately after position 576 relative to the reference sequence numbered according to SEQ ID NO:138. In some embodiments, [C] replaces position 577 (e.g., T577) relative to the reference sequence numbered according to SEQ ID NO:138. In some embodiments, [C] is present immediately after position 576 relative to the reference sequence numbered according to SEQ ID NO:138, and [C] replaces position 577 (e.g., T577). In some embodiments, [B]-[C] is present immediately after position 573 relative to the reference sequence numbered according to SEQ ID NO:138. In some embodiments, [B]-[C] replaces positions 574-577 (e.g., Q574, S575, S576, and T577) relative to the reference sequence numbered according to SEQ ID NO:138. In some embodiments, [B]-[C] is present immediately after position 573 relative to the reference sequence numbered according to SEQ ID NO:138, and [B]-[C] replaces positions 574-577 (e.g., Q574, S575, S576, and T577).In some embodiments, X1 of [B] is located at position 574, X2 of [B] is located at position 575, and X3 of [B] is located at position 576, these positions being numbered according to SEQ ID NO:982. In some embodiments, [B] is located at positions 574-576, these positions being numbered according to SEQ ID NO:982. In some embodiments, [C] is located at positions 577-584, these positions being numbered according to SEQ ID NO:982. In some embodiments, [B]-[C] are located at positions 574-584, these positions being numbered according to SEQ ID NO:982.

[0016] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising one, two, three, or all of the following: (i) [A], wherein the amino acid sequence of [A] comprises TNN, TNT, INN, NNN, TNS, or TNK; (ii) [B], wherein the amino acid sequence of [B] comprises QSS, TSL, SSS, QSR, QSK, AGA, IGS, QAS, ASS, LGS, or HSS; (iii) [C], wherein [C] comprises the amino acid sequence of YPAEVVQK (SEQ ID NO: 943); and (iv) [D], wherein [D] comprises the amino acid sequence of TA or PA; and optionally, wherein the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (i)-(v); optionally, wherein [A] is present immediately after position 570 relative to SEQ ID NO: 138 and [C] replaces position 577 relative to SEQ ID NO: 138. In some embodiments, the amino acid sequence of [A] is TNN. In some embodiments, the amino acid sequence of [B] is QSS. In some embodiments, the amino acid sequence of [A] is TNN and the amino acid sequence of [B] is QSS. In some embodiments, the amino acid sequence of [A] is TNN, the amino acid sequence of [B] is QSS, and the amino acid sequence of [C] is YPAEVVQK (SEQ ID NO: 943). In some embodiments, the amino acid sequence of [A] is TNN, the amino acid sequence of [B] is QSS, the amino acid sequence of [C] is YPAEVVQK (SEQ ID NO: 943), and the amino acid sequence of [D] is TA. In any of these embodiments, [A] is present immediately after position 570 relative to SEQ ID NO: 138. In any of these embodiments, [A] replaces positions 571-573 (e.g., T571, N572, and N573) relative to SEQ ID NO: 138. In any of these embodiments, [A] immediately follows position 570, and [A] replaces positions 571-573 (e.g., T571, N572, and N573) relative to SEQ ID NO:138. In any of these embodiments, [B] immediately follows position 573 relative to the reference sequence numbered according to SEQ ID NO:138. In any of these embodiments, [B] replaces positions 574-576 (e.g., Q574, S575, and S576) relative to SEQ ID NO:138.In any of these embodiments, [B] is present immediately after position 573, and [B] replaces positions 574-576 (e.g., Q574, S575, and S576) relative to SEQ ID NO:138. In any of these embodiments, [C] is present immediately after position 576 relative to SEQ ID NO:138. In any of these embodiments, [C] replaces position 577 relative to SEQ ID NO:138 (e.g., T577). In any of these embodiments, [C] is present immediately after position 576, and [C] replaces position 577 (e.g., T577) relative to SEQ ID NO:138. In any of these embodiments, [B]-[C] are present immediately after position 573 relative to SEQ ID NO:138. In any of these embodiments, [B]-[C] replace positions 574-577 (e.g., Q574, S575, S576, and T577), which are relative to SEQ ID NO:138. In any of these embodiments, [B]-[C] immediately follows position 573, and [B]-[C] replaces positions 574-577 (e.g., Q574, S575, S576, and T577), which are relative to SEQ ID NO:138. In any of these embodiments, [C]-[D] immediately follows position 576, which is relative to SEQ ID NO:138. In any of these embodiments, [C]-[D] replaces positions 577-579 (e.g., T577, T578, and A579), which are relative to SEQ ID NO:138. In any of these embodiments, [A]-[B]-[C]-[D] immediately follows position 570 relative to SEQ ID NO:138. In any of these embodiments, [A]-[B]-[C]-[D] replaces positions 571-579 (e.g., T571, N572, N573, Q574, S575, S576, T577, T578, and A579) relative to SEQ ID NO:138. In any of these embodiments, [A]-[B]-[C]-[D] immediately follows position 570, and [A]-[B]-[C]-[D] replaces positions 571-579 (e.g., T571, N572, N573, Q574, S575, S576, T577, T578, and A579), which are relative to SEQ ID NO:138.For example, in some embodiments, [A]-[B]-[C]-[D] is TNNQSSYPAEVVQKTA (SEQ ID NO: 1533) and is present immediately after position 570 relative to SEQ ID NO: 138, wherein [C] (YPAEVVQK (SEQ ID NO: 943)) replaces position 577 relative to SEQ ID NO: 138 (e.g., replaces T577). In some embodiments, [A] is present at positions 571-573, which are numbered according to SEQ ID NO: 982. In some embodiments, [B] is present at positions 574-576, which are numbered according to SEQ ID NO: 982. In some embodiments, [C] is present at positions 577-584, which are numbered according to SEQ ID NO: 982. In some embodiments, [D] is present at positions 585-586, which are numbered according to SEQ ID NO: 982. In some implementations, [A]-[B]-[C]-[D] are present at positions 571-586, which are numbered according to SEQ ID NO:982.

[0017] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising the formula [N2]-[N3], wherein: (i) [N2] comprises positions X1, X2, X3, X4, and X5, wherein: (a) position X1 is Y or T; (b) position X2 is Q, T, P, or E; (c) position X3 is A; (d) position X4 is E or D; and (e) position X5 is V or E; and (ii) [N3] comprises an amino acid sequence of VQK or VQN; and optionally, wherein the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (i) and / or (ii); and further optionally, wherein [N2]-[N3] is present immediately after position 576 relative to SEQ ID NO:138 and replaces position 577 relative to SEQ ID NO:138. In some embodiments, the amino acid sequence of [N2] consists of YPAEV (SEQ ID NO:1). In some embodiments, the amino acid sequence of [N3] consists of VQK. In some embodiments, [N2]-[N3] replaces position 577 (e.g., T577) of wild-type AAV5 (e.g., SEQ ID NO: 138). In some embodiments, [N2]-[N3] replaces the threonine (T) at position 577 of wild-type AAV5 (e.g., SEQ ID NO: 138), and the amino acid sequence of [N2] consists of YPAEV (SEQ ID NO: 1), and the amino acid sequence of [N3] consists of VQK. In some embodiments, X1 of [N2] is present at position 577, X2 of [N2] is present at position 578, X3 of [N2] is present at position 579, X4 of [N2] is present at position 580, and X5 of [N2] is present at position 581, these positions being numbered according to SEQ ID NO: 982. In some embodiments, [N2] is present at positions 577-581, which are numbered according to SEQ ID NO:982. In some embodiments, [N3] is present at positions 582-584, which are numbered according to SEQ ID NO:982. In some embodiments, [N2]-[N3] are present at positions 577-584, which are numbered according to SEQ ID NO:982.

[0018] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising one, two, three, four, or all of the following: (i) [N0], wherein [N0] comprises an amino acid sequence of TNN, TNS, TNT, or TNK; (ii) [N1], wherein [N1] comprises an amino acid sequence of QSS, SLS, SLY, SAT, or QTS; and (iii) [N2], wherein [N2] comprises YPAEV (SEQ ID NO:1), YQAEV (SEQ ID NO:6), YTAEV (SEQ ID NO:4), YPAEE (SEQ ID NO:5), TEAEV (SEQ ID NO:12), or YPADV (SEQ ID NO:1). (i) [N0], wherein [N0] comprises the amino acid sequence of VQK or VQN; and / or (v) [N4], wherein [N4] comprises the amino acid sequence of TA, PA, TD, NA or PA; and optionally, wherein the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (i)-(v); and further optionally, wherein [N0] is present immediately after position 570 relative to SEQ ID NO:138 and [N2]-[N3] replace position 577 relative to SEQ ID NO:138. In any of these embodiments, [N0] is present immediately after position 570 relative to SEQ ID NO:138. In any of these embodiments, [N0] replaces positions 571-573 (e.g., T571, N572, and N573) relative to SEQ ID NO:138. In any of these embodiments, [N0] is present immediately after position 570, and [N0] replaces positions 571-573 (e.g., T571, N572, and N573) relative to SEQ ID NO:138. In any of these embodiments, [N1] is present immediately after position 573 relative to SEQ ID NO:138. In any of these embodiments, [N1] replaces positions 574-576 (e.g., Q574, S575, and S576) relative to SEQ ID NO:138. In any of these embodiments, [N1] is present immediately after position 573, and [N1] replaces positions 574-576 (e.g., Q574, S575, and S576) relative to SEQ ID NO:138. In any of these implementations, [N2] is present immediately after position 576 relative to SEQ ID NO:138.In any of these embodiments, [N2] replaces position 577 (e.g., T577) relative to SEQ ID NO:138. In any of these embodiments, [N2] exists immediately after position 576, and [N2] replaces position 577 (e.g., T577) relative to SEQ ID NO:138. In any of these embodiments, [N2]-[N3] exists immediately after position 576 relative to SEQ ID NO:138. In any of these embodiments, [N2]-[N3] replaces position 577 (e.g., T577) relative to SEQ ID NO:138. In any of these embodiments, [N2]-[N3] exists immediately after position 576, and [N2]-[N3] replaces position 577 (e.g., T577) relative to SEQ ID NO:138. In any of these embodiments, [N2]-[N3]-[N4] replaces positions 577-579 (e.g., T577, T578, and A579), which are relative to SEQ ID NO: 138. In any of these embodiments, [N2]-[N3]-[N4] immediately follows position 576, and [N2]-[N3]-[N4] replaces positions 577-579 (e.g., T577, T578, and A579), which are relative to SEQ ID NO: 138. In any of these embodiments, [N0]-[N1]-[N2]-[N3]-[N4] immediately follows position 570, which is relative to SEQ ID NO: 138. In any of these embodiments, [N0]-[N1]-[N2]-[N3]-[N4] replaces positions 571-579 (e.g., T571, N572, N573, Q574, S575, S576, T577, T578, and A579) relative to the reference sequence numbered according to SEQ ID NO:138. In any of these embodiments, [N0]-[N1]-[N2]-[N3]-[N4] is present immediately after position 570 relative to the reference sequence numbered according to SEQ ID NO:138, and [N0]-[N1]-[N2]-[N3]-[N4] replaces positions 571-579 (e.g., T571, N572, N573, Q574, S575, S576, T577, T578, and A579). In some embodiments, [N0] is present at positions 571-573, which are numbered according to SEQ ID NO:982. In some embodiments, [N1] is present at positions 574-576, which are numbered according to SEQ ID NO:982.In some embodiments, [N2] is present at positions 577-581, which are numbered according to SEQ ID NO:982. In some embodiments, [N3] is present at positions 582-584, which are numbered according to SEQ ID NO:982. In some embodiments, [N4] is present at positions 585-586, which are numbered according to SEQ ID NO:982. In some embodiments, [N2]-[N3] are present at positions 577-584, which are numbered according to SEQ ID NO:982. In some embodiments, [N0]-[N1]-[N2]-[N3]-[N4] are present at positions 571-586, which are numbered according to SEQ ID NO:982.

[0019] In some embodiments, the amino acid sequence of [N0] is TNN, the amino acid sequence of [N1] is QSS, the amino acid sequence of [N2] is YPAEV (SEQ ID NO:1), the amino acid sequence of [N3] is VQK, and / or the amino acid sequence of [N4] is TA. In some embodiments, the amino acid sequence of [N0] is TNN, the amino acid sequence of [N1] is QSS, the amino acid sequence of [N2] is YPAEV (SEQ ID NO:1), the amino acid sequence of [N3] is VQK, and the amino acid sequence of [N4] is TA. In any of these embodiments, [N0]-[N1]-[N2]-[N3]-[N4] immediately follows position 570 relative to SEQ ID NO:138. In any of these embodiments, the amino acid sequences of [N2]-[N3] replace position 577 relative to SEQ ID NO:138. For example, in some embodiments, [N0]-[N1]-[N2]-[N3]-[N4] is TNNQSSYPAEVVQKTA (SEQ ID NO: 1533) and is present immediately after position 570 relative to SEQ ID NO: 138, wherein [N2]-[N3] (YPAEVVQK (SEQ ID NO: 943)) replaces position 577 relative to SEQ ID NO: 138 (e.g., replaces T577). In some embodiments, [N0] is present at positions 571-573, which are numbered according to SEQ ID NO: 982. In some embodiments, [N1] is present at positions 574-576, which are numbered according to SEQ ID NO: 982. In some embodiments, [N2] is present at positions 577-581, which are numbered according to SEQ ID NO: 982. In some embodiments, [N3] is present at positions 582-584, which are numbered according to SEQ ID NO: 982. In some embodiments, [N4] is present at positions 585-586, which are numbered according to SEQ ID NO:982. In some embodiments, [N2]-[N3] are present at positions 577-584, which are numbered according to SEQ ID NO:982. In some embodiments, [N0]-[N1]-[N2]-[N3]-[N4] are present at positions 571-586, which are numbered according to SEQ ID NO:982.

[0020] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising [B]-[C], wherein: (i) [B] comprises positions X1, X2, and X3, wherein (a) position X1 is Q or S; (b) position X2 is S, L, or A; and (c) position X3 is S, Y, or T; and (ii) [C] comprises the amino acid sequence YPAEVVQK (SEQ ID NO: 943); and optionally, wherein the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (i) and / or (ii); and further optionally, wherein [B] is present immediately after position 573 relative to SEQ ID NO: 138, and [C] replaces position 577 relative to SEQ ID NO: 138. In some embodiments, [B] is QSS. In some embodiments, [C] consists of YPAEVVQK (SEQ ID NO: 943), immediately following position 576 relative to SEQ ID NO: 138, and replacing position 577 relative to SEQ ID NO: 138. In some embodiments, [B] immediately follows position 573 relative to the reference sequence according to SEQ ID NO: 138. In some embodiments, [B] replaces positions 574-576 (e.g., Q574, S575, and S576) relative to the reference sequence according to SEQ ID NO: 138. In some embodiments, [B] immediately follows position 573 relative to the reference sequence according to SEQ ID NO: 138, and [B] replaces positions 574-576 (e.g., Q574, S575, and S576). In some embodiments, [C] immediately follows position 576 relative to the reference sequence according to SEQ ID NO: 138. In some embodiments, [C] replaces position 577 (e.g., T577) relative to the reference sequence numbered according to SEQ ID NO:138. In some embodiments, [C] immediately follows position 576 relative to the reference sequence numbered according to SEQ ID NO:138, and [C] replaces position 577 (e.g., T577). In some embodiments, [B]-[C] immediately follows position 573 relative to the reference sequence numbered according to SEQ ID NO:138. In some embodiments, [B]-[C] replaces positions 574-577 (e.g., Q574, S575, S576, and T577) relative to the reference sequence numbered according to SEQ ID NO:138.In some embodiments, [B]-[C] are present immediately after position 573 relative to the reference sequence numbered according to SEQ ID NO:138, and [B]-[C] replace positions 574-577 (e.g., Q574, S575, S576, and T577). In some embodiments, X1 of [B] is present at position 574, X2 of [B] is present at position 575, and X3 of [B] is present at position 576, these positions are numbered according to SEQ ID NO:982. In some embodiments, [B] is present at positions 574-576, these positions are numbered according to SEQ ID NO:982. In some embodiments, [C] is present at positions 577-584, these positions are numbered according to SEQ ID NO:982. In some embodiments, [B]-[C] are present at positions 574-584, these positions are numbered according to SEQ ID NO:982.

[0021] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising one, two, three, four, or all of the following: (i) [A], wherein [A] comprises an amino acid sequence of TNN, TNS, TNT, or TNK; (ii) [B], wherein [B] comprises an amino acid sequence of QSS, SLY, SAT, or SLS; (iii) [C], wherein [C] comprises an amino acid sequence of YPAEVVQK (SEQ ID NO: 943); and (iv) [D], wherein [D] comprises an amino acid sequence of TA, TD, NA, or PA; and optionally, wherein the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (i)-(v); and further optionally, wherein [A] is present immediately after position 570 relative to SEQ ID NO: 138, and [C] replaces position 577 relative to SEQ ID NO: 138. In any of these embodiments, [A] is present immediately after position 570 relative to SEQ ID NO:138. In any of these embodiments, [A] replaces positions 571-573 (e.g., T571, N572, and N573) relative to SEQ ID NO:138. In any of these embodiments, [A] is present immediately after position 570, and [A] replaces positions 571-573 (e.g., T571, N572, and N573) relative to SEQ ID NO:138. In any of these embodiments, [B] is present immediately after position 573 relative to the reference sequence according to SEQ ID NO:138. In any of these embodiments, [B] replaces positions 574-576 (e.g., Q574, S575, and S576) relative to the reference sequence according to SEQ ID NO:138. In any of these embodiments, [B] is present immediately after position 573 relative to the reference sequence numbered according to SEQ ID NO:138, and [B] replaces positions 574-576 (e.g., Q574, S575, and S576). In any of these embodiments, [C] is present immediately after position 576 relative to the reference sequence numbered according to SEQ ID NO:138. In any of these embodiments, [C] replaces position 577 relative to the reference sequence numbered according to SEQ ID NO:138 (e.g., T577). In any of these embodiments, [C] is present immediately after position 576 relative to the reference sequence numbered according to SEQ ID NO:138, and [C] replaces position 577 (e.g., T577).In any of these embodiments, [B]-[C] immediately follows position 573 relative to the reference sequence numbered according to SEQ ID NO:138. In any of these embodiments, [B]-[C] replaces positions 574-577 (e.g., Q574, S575, S576, and T577) relative to the reference sequence numbered according to SEQ ID NO:138. In any of these embodiments, [B]-[C] immediately follows position 573 relative to the reference sequence numbered according to SEQ ID NO:138, and [B]-[C] replaces positions 574-577 (e.g., Q574, S575, S576, and T577). In any of these embodiments, [C]-[D] immediately follows position 576 relative to the reference sequence numbered according to SEQ ID NO:138. In any of these embodiments, [C]-[D] replace positions 577-579 (e.g., T577, T578, and A579) relative to the reference sequence numbered according to SEQ ID NO:138. In any of these embodiments, [C]-[D] are present immediately after position 576 relative to the reference sequence numbered according to SEQ ID NO:138, and [C]-[D] replace positions 577-579 (e.g., T577, T578, and A579). In some embodiments, [A] is present at positions 571-573, which are numbered according to SEQ ID NO:982. In some embodiments, [B] is present at positions 574-576, which are numbered according to SEQ ID NO:982. In some embodiments, [C] is present at positions 577-584, which are numbered according to SEQ ID NO:982. In some embodiments, [D] is present at positions 585-586, which are numbered according to SEQ ID NO:982. In some embodiments, [A]-[B]-[C]-[D] are present at positions 571-586, which are numbered according to SEQ ID NO:982.

[0022] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising [K1]-[K2], wherein: (i) [K1] comprises LSY or LYY, and (ii) [K2] comprises positions X1, X2, X3, and X4, wherein (a) position X1 is Q, T, or P; (b) position X2 is A; (c) position X3 is E or D; and (d) position X4 is V or E; and optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conserved substitution) of any of the above-mentioned amino acids in (i) and / or (ii). In some embodiments, [K1]-[K2] is present immediately after position 574 relative to the reference sequence numbered according to SEQ ID NO:138. In some embodiments, [K1]-[K2] replaces positions 575-577 (e.g., S575, S576, and T577) relative to the reference sequence numbered according to SEQ ID NO:138. In some implementations, [K1]-[K2] are present immediately after position 574 relative to the reference sequence numbered according to SEQ ID NO:138, and [K1]-[K2] replace positions 575-577 (e.g., S575, S576 and T577).

[0023] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising one, two, three, four, or all of the following: (i) [K0] comprising TNNS (SEQ ID NO:14); (ii) [K1] comprising LSY or LYY; (iii) [K2] comprising QAEV (SEQ ID NO:15), TAEV (SEQ ID NO:16), PAEV (SEQ ID NO:17), PAEE (SEQ ID NO:18), or PADV (SEQ ID NO:19); (iv) [K3] comprising VQK or VQN; and (v) [K4] comprising TA, TD, NA, or PA; and optionally, wherein the AAV capsid variant comprises an amino acid modification (e.g., a conserved substitution) of any of the above-mentioned amino acids in (i)-(v). In some embodiments, [K0] is present immediately after position 570 relative to the reference sequence numbered according to SEQ ID NO:138. In some embodiments, [K0] replaces positions 571-574 (e.g., T571, N572, N573, and Q574) relative to the reference sequence numbered according to SEQ ID NO:138. In some embodiments, [K0] exists immediately after position 570 relative to the reference sequence numbered according to SEQ ID NO:138, and [K0] replaces positions 571-574 (e.g., T571, N572, N573, and Q574). In some embodiments, [K1] exists immediately after position 574 relative to the reference sequence numbered according to SEQ ID NO:138. In some embodiments, [K1] replaces positions 575-577 (e.g., S575, S576, and T577) relative to the reference sequence numbered according to SEQ ID NO:138. In some embodiments, [K1] is present immediately after position 574 relative to the reference sequence numbered according to SEQ ID NO:138, and [K1] replaces positions 575-577 (e.g., S575, S576, and T577). In some embodiments, [K1]-[K2]-[K3] are present immediately after position 574 relative to the reference sequence numbered according to SEQ ID NO:138. In some embodiments, [K1]-[K2]-[K3] replaces positions 575-577 (e.g., S575, S576, and T577) relative to the reference sequence numbered according to SEQ ID NO:138. In some implementations, [K1]-[K2]-[K3] is present immediately after position 574 relative to the reference sequence numbered according to SEQ ID NO:138, and [K1]-[K2]-[K3] replaces positions 575-577 (e.g., S575, S576 and T577).In some embodiments, [K1]-[K2]-[K3]-[K4] immediately follows position 574 relative to the reference sequence numbered according to SEQ ID NO:138. In some embodiments, [K1]-[K2]-[K3]-[K4] replaces positions 575-579 (e.g., S575, S576, T577, T578, and A579) relative to the reference sequence numbered according to SEQ ID NO:138. In some embodiments, [K1]-[K2]-[K3]-[K4] immediately follows position 574 relative to the reference sequence numbered according to SEQ ID NO:138, and [K1]-[K2]-[K3]-[K4] replaces positions 575-579 (e.g., S575, S576, T577, T578, and A579). In some embodiments, [K0]-[K1]-[K2]-[K3]-[K4] immediately follows position 570 relative to the reference sequence numbered according to SEQ ID NO: 138. In some embodiments, [K0]-[K1]-[K2]-[K3]-[K4] replaces positions 571-579 (e.g., T571, N572, N573, Q574, S575, S576, T577, T578, and T579) relative to the reference sequence numbered according to SEQ ID NO: 138. In some implementations, [K0]-[K1]-[K2]-[K3]-[K4] immediately follows position 570 relative to the reference sequence numbered according to SEQ ID NO 138, and [K0]-[K1]-[K2]-[K3]-[K4] replaces positions 571-579 (e.g., T571, N572, N573, Q574, S575, S576, T577, T578, and T579).

[0024] On the other hand, this disclosure provides an AAV capsid variant (e.g., the AAV5 capsid variant) comprising: (a) an amino acid sequence of any sequence provided in Tables 1, 2A, 2B, 9, or 15-20; (b) an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive amino acids from any sequence provided in Tables 1, 2A, 2B, 9, or 15-20; (c) an amino acid sequence comprising one, two, or three, but not more than four different amino acids relative to any amino acid sequence provided in Tables 1, 2A, 2B, 9, or 15-20; or (d) an amino acid sequence comprising one, two, or three, but not more than four modified (e.g., substitution (e.g., conservative substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence provided in Tables 1, 2A, 2B, 9, or 15-20.

[0025] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising: (a) an amino acid sequence comprising any one of SEQ ID NO: 943, 1021, 1024, 1027, 1112, 1142, 1214, 1232, 1254, 1300, 1310, 1327, 1331, 1342, 1419, 1453, 1533, 1538, 1539, 1575, 1578, 1583-1587, 1590, 1591-1593, 1598-1608, or 1610-1624; (b) comprising an amino acid sequence comprising SEQ ID NO: 943, 1021, 1024, 1027, 1112, 1142, 1214, 1232, 1254, 1300, 1310, 1327, 1331, 1342, 1419, 1453, 1533, 1538, 1539, 1575, 1578, 1583-1587, 1590, 1591-1593, 1598-1608, or 1610-1624; and (b) comprising an amino acid sequence comprising any one of SEQ ID NO: 943, 1021, 1024, 1027, 1112, 1142, 1214, 1232, 1254, 1300, 1310, 1590, 1591-1593 NO: An amino acid sequence of at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive amino acids from any one of SEQ ID NO: 943, 1021, 1024, 1027, 1112, 1142, 1214, 1232, 1254, 1300, 1310, 1327, 1331, 1342, 1419, 1453, 1533, 1538, 1539, 1575, 1578, 1583-1587, 1590, 1591-1593, 1598-1608, or 1610-1624; (c) Relative to SEQ ID NO: An amino acid sequence of any one of 943, 1021, 1024, 1027, 1112, 1142, 1214, 1232, 1254, 1300, 1310, 1327, 1331, 1342, 1419, 1453, 1533, 1538, 1539, 1575, 1578, 1583-1587, 1590, 1591-1593, 1598-1608, or 1610-1624, containing one, two, or three but no more than four different amino acids; or (d) relative to SEQ ID The amino acid sequence of any one of NO:943, 1021, 1024, 1027, 1112, 1142, 1214, 1232, 1254, 1300, 1310, 1327, 1331, 1342, 1419, 1453, 1533, 1538, 1539, 1575, 1578, 1583-1587, 1590, 1591-1593, 1598-1608 or 1610-1624, containing one, two or three but no more than four modified (e.g., substitution (e.g., conserved substitution), insertion or deletion) amino acid sequences.

[0026] On the other hand, this disclosure provides an AAV capsid variant (e.g., the AAV5 capsid variant) comprising (a) an amino acid sequence of any one of SEQ ID NO: 943 or 2064-2080; (b) an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive amino acids from any one of SEQ ID NO: 943 or 2064-2080; (c) an amino acid sequence comprising one, two, or three but not more than four different amino acids relative to an amino acid sequence of any one of SEQ ID NO: 943 or 2064-2080; or (d) an amino acid sequence comprising one, two, or three but not more than four modified (e.g., substitution (e.g., conservative substitution), insertion, or deletion) amino acid sequences relative to an amino acid sequence of any one of SEQ ID NO: 943 or 2064-2080.

[0027] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising the amino acid sequence of SEQ ID NO:943. In some embodiments, the amino acid sequence of SEQ ID NO:943 is present immediately after position 576 relative to a reference sequence numbered according to SEQ ID NO:138 or 982. In some embodiments, the amino acid sequence of SEQ ID NO:943 substitutes position 577 (e.g., substitutes T577) relative to a reference sequence numbered according to SEQ ID NO:138. In some embodiments, the amino acid sequence of SEQ ID NO:943 is present immediately after position 576 relative to a reference sequence numbered according to SEQ ID NO:138, wherein the amino acid sequence of SEQ ID NO:943 substitutes position 577 (e.g., substitutes T577).

[0028] On the other hand, this disclosure provides an AAV capsid variant (e.g., the AAV5 capsid variant) comprising YPAEVVQK (SEQ ID NO: 943), the sequence of which is immediately following position 576 relative to SEQ ID NO: 138 or 982. In some embodiments, the amino acid sequence of YPAEVVQK (SEQ ID NO: 943) is replaced at position 577 relative to SEQ ID NO: 138 (e.g., replacement T577).

[0029] On the other hand, this disclosure provides an AAV capsid variant (e.g., the AAV5 capsid variant) that includes YPAEVVQK (SEQ ID NO: 943), wherein YPAEVVQK (SEQ ID NO: 943) replaces position 577 relative to the number SEQ ID NO: 138 (e.g., replaces T577).

[0030] On the other hand, this disclosure provides an AAV capsid variant (e.g., the AAV5 capsid variant) comprising YPAEVVQK (SEQ ID NO: 943) immediately following position 576 relative to SEQ ID NO: 138, wherein YPAEVVQK (SEQ ID NO: 943) replaces position 577 relative to SEQ ID NO: 138 (e.g., replaces T577).

[0031] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) containing amino acid Y at position 577 and further containing the amino acid sequence PAEVVQK (SEQ ID NO:20), which is present immediately after position 577 relative to SEQ ID NO:138.

[0032] On the other hand, this disclosure provides an AAV capsid variant (e.g., the AAV5 capsid variant) comprising amino acid Y at position 577 and comprising the amino acid sequence PAEVVQK (SEQ ID NO: 20), which is present immediately after position 577 relative to SEQ ID NO: 982. In some embodiments, the AAV capsid variant further comprises the amino acid sequence of SEQ ID NO: 739, or an amino acid sequence that is at least 95% (e.g., at least 96, 97, 98, or 99%) identical thereto. In some embodiments, the AAV capsid variant further comprises the amino acid sequence of SEQ ID NO: 738, or an amino acid sequence that is at least 95% (e.g., at least 96, 97, 98, or 99%) identical thereto. In some embodiments, the AAV capsid variant further comprises the amino acid sequence of SEQ ID NO: 982, or an amino acid sequence that is at least 95% (e.g., at least 96, 97, 98, or 99%) identical thereto.

[0033] On the other hand, this disclosure provides an AAV capsid variant (e.g., the AAV5 capsid variant) comprising amino acid Y at position 577 and amino acid sequence PAEVVQK (SEQ ID NO: 20) at positions 578-584, these positions being numbered relative to SEQ ID NO: 982. In some embodiments, the AAV capsid variant further comprises the amino acid sequence of SEQ ID NO: 739, or an amino acid sequence that is at least 95% (e.g., at least 96, 97, 98, or 99%) identical thereto. In some embodiments, the AAV capsid variant further comprises the amino acid sequence of SEQ ID NO: 738, or an amino acid sequence that is at least 95% (e.g., at least 96, 97, 98, or 99%) identical thereto. In some embodiments, the AAV capsid variant further comprises the amino acid sequence of SEQ ID NO: 982, or an amino acid sequence that is at least 95% (e.g., at least 96, 97, 98, or 99%) identical thereto.

[0034] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising TNNQSSYPAEVVQKTA (SEQ ID NO: 1533), the sequence being immediately following position 570 relative to SEQ ID NO: 138 or 982. In some embodiments, the amino acid sequence of YPAEVVQK (SEQ ID NO: 943) is replaced at position 577 relative to SEQ ID NO: 138 (e.g., replacing T577).

[0035] On the other hand, this disclosure provides an AAV capsid variant (e.g., the AAV5 capsid variant) comprising TNNQSSYPAEVVQKTA (SEQ ID NO:1533), wherein YPAEVVQK (SEQ ID NO:943) replaces position 577 relative to the number SEQ ID NO:138 (e.g., replaces T577).

[0036] On the other hand, this disclosure provides an AAV capsid variant (e.g., the AAV5 capsid variant) comprising TNNQSSYPAEVVQKTA (SEQ ID NO: 1533), which is present immediately after position 570 relative to SEQ ID NO: 138, wherein YPAEVVQK (SEQ ID NO: 943) replaces position 577 relative to SEQ ID NO: 138 (e.g., replaces T577).

[0037] On the other hand, this disclosure provides an AAV capsid variant (e.g., the AAV5 capsid variant) containing TNNQSSYPAEVVQKTA (SEQ ID NO:1533), the sequence being present at positions 571-586, which are numbered according to SEQ ID NO:982.

[0038] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising the amino acid sequence SEQ ID NO:982. Alternatively, this disclosure provides an AAV capsid variant composed of the amino acid sequence SEQ ID NO:982.

[0039] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:984. Alternatively, this disclosure provides an AAV capsid variant comprising an amino acid sequence encoded by a nucleotide sequence having at least 95% identity with SEQ ID NO:984.

[0040] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising at least 90%, 95%, 96%, 97%, 98%, or 99% of the amino acid sequence at positions 193-731 of SEQ ID NO:982, wherein the AAV capsid variant comprises the amino acid sequence of YPAEVVQK (SEQ ID NO:943). In some embodiments, the AAV capsid variant comprises the amino acid sequence at positions 193-731 of SEQ ID NO:982.

[0041] On the other hand, this disclosure provides an AAV capsid variant (e.g., an AAV5 capsid variant) comprising at least 90%, 95%, 96%, 97%, 98%, or 99% of the amino acid sequence identical to that of SEQ ID NO:739, wherein the AAV capsid variant comprises the amino acid sequence of YPAEVVQK (SEQ ID NO:943). In some embodiments, the AAV capsid variant comprises the amino acid sequence of SEQ ID NO:739.

[0042] On the other hand, this disclosure provides a peptide comprising: (a) an amino acid sequence of any sequence provided in Tables 1, 2A, 2B, 9, or 15-20; (b) an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive amino acids from any sequence provided in Tables 1, 2A, 2B, 9, or 15-20; or (c) an amino acid sequence comprising one, two, or three, but not more than four different amino acids relative to any amino acid sequence provided in Tables 1, 2A, 2B, 9, or 15-20; or (d) an amino acid sequence comprising one, two, or three, but not more than four modified (e.g., substitution (e.g., conservative substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence provided in Tables 1, 2A, 2B, 9, or 15-20.

[0043] On the other hand, this disclosure provides a peptide comprising the amino acid sequence of YPAEVVQK (SEQ ID NO: 943). On the other hand, this disclosure provides a peptide comprising (i) an amino acid sequence comprising one, two, or three, but not more than four, different amino acids relative to the amino acid sequence of YPAEVVQK (SEQ ID NO: 943); (ii) an amino acid sequence comprising one, two, or three modified (e.g., substituted (e.g., conservative substitution)) but not more than four modified (e.g., substituted (e.g., conservative substitution)) amino acid sequences relative to the amino acid sequence of YPAEVVQK (SEQ ID NO: 943); or (iii) at least 3, 4, 5, 6, or 7 consecutive amino acids from the amino acid sequence of YPAEVVQK (SEQ ID NO: 943).

[0044] On the other hand, this disclosure provides a peptide encoded by the nucleotide sequence of SEQ ID NO:944 or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity). On the other hand, this disclosure provides a peptide encoded by: (i) a nucleotide sequence comprising one, two, three, four, five, six, or seven, but not more than ten, different nucleotides relative to the nucleotide sequence of SEQ ID NO:944; or (ii) a nucleotide sequence comprising one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but not more than ten modifications (e.g., substitution, insertion, or deletion) relative to the nucleotide sequence of SEQ ID NO:944.

[0045] On the other hand, this disclosure provides a peptide wherein the nucleotide sequence encoding the peptide comprises (i) the nucleotide sequence of SEQ ID NO:944 or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); (ii) a nucleotide sequence comprising one, two, three, four, five, six, or seven, but not more than ten, different nucleotides relative to the nucleotide sequence of SEQ ID NO:944; or (iii) a nucleotide sequence comprising one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but not more than ten modifications (e.g., substitution, insertion, or deletion) relative to the nucleotide sequence of SEQ ID NO:944.

[0046] On the other hand, this disclosure provides a polynucleotide encoding an AAV capsid variant (e.g., an AAV5 capsid variant), wherein the encoded AAV capsid variant comprises: (a) an amino acid sequence of any sequence provided in Tables 1, 2A, 2B, 9, or 15-20; (b) an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive amino acids from any sequence provided in Tables 1, 2A, 2B, 9, or 15-20; or (c) an amino acid sequence comprising one, two, or three, but not more than four different amino acids relative to any amino acid sequence provided in Tables 1, 2A, 2B, 9, or 15-20; or (d) an amino acid sequence comprising one, two, or three, but not more than four modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence provided in Tables 1, 2A, 2B, 9, or 15-20.

[0047] On the other hand, this disclosure provides a polynucleotide encoding an AAV capsid variant (e.g., an AAV5 capsid variant), wherein the encoded AAV capsid variant comprises the amino acid sequence of YPAEVVQK (SEQ ID NO: 943). Alternatively, this disclosure provides a polynucleotide encoding an AAV capsid variant, wherein the encoded AAV capsid variant comprises (i) an amino acid sequence comprising one, two, or three, but not more than four, different amino acids relative to the amino acid sequence of YPAEVVQK (SEQ ID NO: 943); (ii) an amino acid sequence comprising one, two, or three modifications (e.g., substitutions (e.g., conservative substitutions)) but not more than four modifications (e.g., substitutions (e.g., conservative substitutions)) relative to the amino acid sequence of YPAEVVQK (SEQ ID NO: 943); or (iii) at least 3, 4, 5, 6, or 7 consecutive amino acids from the amino acid sequence of YPAEVVQK (SEQ ID NO: 943).

[0048] On the other hand, this disclosure provides an AAV particle comprising the AAV capsid polypeptide described herein, such as an AAV capsid variant (e.g., an AAV5 capsid variant). In some embodiments, the AAV particle comprises a nucleic acid sequence encoding a payload. In some embodiments, the AAV particle further comprises a viral genome containing a promoter operatively linked to the nucleic acid sequence encoding the payload.

[0049] On the other hand, this disclosure provides a method for preparing AAV particles containing the AAV capsid polypeptide described herein, such as an AAV capsid variant (e.g., the AAV5 capsid variant). In some embodiments, the method includes providing a host cell containing a viral genome and culturing the host cell under conditions suitable for encapsulating the viral genome into an AAV capsid variant (e.g., the AAV capsid variant described herein), thereby preparing the AAV particles.

[0050] On the other hand, this disclosure provides a method for delivering a payload to cells or tissues (e.g., CNS cells, CNS tissues, muscle cells, or muscle tissue). The method includes administering an effective amount of AAV particles containing an AAV capsid variant described herein (e.g., the AAV5 capsid variant).

[0051] On the other hand, this disclosure provides a method for treating a subject who has or has been diagnosed with a genetic condition (e.g., a monogenic condition or a polygenic condition). The method includes administering an effective amount of AAV particles containing an AAV capsid variant described herein (e.g., the AAV5 capsid variant).

[0052] On the other hand, this disclosure provides a method for treating a subject who has or has been diagnosed with a neurological (e.g., neurodegenerative) condition. The method includes administering an effective amount of AAV particles comprising an AAV capsid variant (e.g., AAV5 capsid variant) as described herein.

[0053] On the other hand, this disclosure provides a method for treating a subject who has or has been diagnosed with a muscular or neuromuscular disorder. The method includes administering an effective amount of AAV particles comprising an AAV capsid variant described herein (e.g., the AAV5 capsid variant).

[0054] On the other hand, this disclosure provides a method for treating a subject who has or has been diagnosed with a heart condition, such as the heart conditions described herein (e.g., cardiomyopathy (e.g., arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, or hypertrophic cardiomyopathy), congestive heart failure, tachycardia (e.g., catecholamine-induced polymorphic ventricular tachycardia), ischemic heart disease, and / or myocardial infarction). The method comprises administering an effective amount of AAV particles containing an AAV capsid variant described herein (e.g., AAV5 capsid variant).

[0055] On the other hand, this disclosure provides a method for treating a subject who has or has been diagnosed with a neuro-oncological condition. The method includes administering an effective amount of AAV particles comprising an AAV capsid variant described herein (e.g., the AAV5 capsid variant).

[0056] Those skilled in the art will recognize or be able to determine many equivalents of the specific embodiments of the invention described herein using only conventional experiments. Such equivalents are intended to be covered by the embodiments listed below.

[0057] List of implementation plans

[0058] 1. An AAV capsid variant (e.g., an AAV5 capsid variant), said AAV capsid variant comprising an amino sequence comprising the following formula:

[0059] [N2]-[N3], where:

[0060] (i)[N2] contains positions X1, X2, X3, X4, and X5, where:

[0061] (a) Position X1 is Y, N, C or T;

[0062] (b) Position X2 is P, E, K, T or Q;

[0063] (c) Position X3 is A or P;

[0064] (d) Position X4 is E, S, D, or A; and

[0065] (e) Position X5 is V, L, or E; and

[0066] (ii) [N3] An amino acid sequence containing VQK, VQN, EQK, VKK, VHK, VQQ, or LQK; or

[0067] The AAV capsid variants described herein include amino acid modifications (e.g., conservative substitutions) of any of the above-mentioned amino acids in (i) and / or (ii).

[0068] 2. An AAV capsid variant (e.g., an AAV5 capsid variant), said AAV capsid variant comprising an amino sequence comprising the following formula:

[0069] [N2]-[N3], where:

[0070] (i)[N2] contains positions X1, X2, X3, X4, and X5, where:

[0071] (a) Position X1 is Y, N, or C;

[0072] (b) Position X2 is P, K, T, or Q;

[0073] (c) Position X3 is A or P;

[0074] (d) Position X4 is E, S, or A; and

[0075] (e) Position X5 is V, L, or E; and

[0076] (ii) [N3] An amino acid sequence containing VQK, EQK, VKK, VHK, VQQ, or LQK; or

[0077] The AAV capsid variants described herein include amino acid modifications (e.g., conservative substitutions) of any of the above-mentioned amino acids in (i) and / or (ii).

[0078] 3. An AAV capsid variant (e.g., an AAV5 capsid variant), said AAV capsid variant comprising one, two, three, four, or all of the following:

[0079] (i)[N0] contains TNN, TNT, INN, TNS, NNN or TNK;

[0080] (ii) [N1] contains QSS, QSK, TSL, SSS, QSR, AGA, IGS, QAS, ASS, LGS, QST, HSS, LSS or QRS;

[0081] (iii) [N2] includes YPAEV (SEQ ID NO: 1), YPPSL (SEQ ID NO: 2), NKAEV (SEQ ID NO: 3), YTAEV (SEQ ID NO: 4), YPAEE (SEQ ID NO: 5), YQAEV (SEQ ID NO: 6), YTPSL (SEQ ID NO: 7), YPAAV (SEQ ID NO: 8), NPAEV (SEQ ID NO: 8), NO:9), CPAEV (SEQ ID NO:10) or YQAEE (SEQ ID NO:11);

[0082] (iv)[N3] includes VQK, EQK, VKK, VHK, VQQ, or LQK; and

[0083] (v)[N4] includes TA, PA, or NA; and

[0084] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (i)-(v).

[0085] 4. AAV capsid variants as described in implementation 1 or 2, wherein:

[0086] (a) Position X1 is either Y or N;

[0087] (b) Position X2 is P, T, or Q;

[0088] (c) Position X3 is A;

[0089] (d) Position X4 is E or S; and / or

[0090] (e) Position X5 is V or L.

[0091] 5. AAV capsid variants as described in any of embodiments 1, 2 or 4, wherein [N2] comprises YP, NK, YT, YQ, NP, CP, TH, AE, PS, AA, AS, PA, PP, KA, TA, QA, TP, HA, EV, SL, EE, AV or SH.

[0092] 6. AAV capsid variants as described in any of embodiments 1, 2, 4 or 5, wherein [N2] comprises YPA, YPP, NKA, YTA, YQA, YTP, NPA, CPA, THA, PAE, PPS, KAE, TAE, QAE, TPS, PAA, HAS, AEV, PSL, AEE or AAV.

[0093] 7. AAV capsid variants as described in any of embodiments 1-2 or 4-6, wherein [N2] comprises YPAE (SEQ ID NO:21), YPPS (SEQ ID NO:22), NKAE (SEQ ID NO:23), YTAE (SEQ ID NO:24), YQAE (SEQ ID NO:25), YTPS (SEQ ID NO:26), YPAA (SEQ ID NO:27), NPAE (SEQ ID NO:28), CPAE (SEQ ID NO:29), THAS (SEQ ID NO:30), PAEV (SEQ ID NO:17), PPSL (SEQ ID NO:31), KAEV (SEQ ID NO:32), TAEV (SEQ ID NO:16), PAEE (SEQ ID NO:18), QAEV (SEQ ID NO:15), TPSL (SEQ ID NO:33), PAAV (SEQ ID NO:34), or QAEE (SEQ ID NO:35).

[0094] 8. AAV capsid variants of any of embodiments 1-7, wherein [N2] is or includes YPAEV (SEQ ID NO:1), YPPSL (SEQ ID NO:2), NKAEV (SEQ ID NO:3), YTAEV (SEQ ID NO:4), YPAEE (SEQ ID NO:5), YQAEV (SEQ ID NO:6), YTPSL (SEQ ID NO:7), YPAAV (SEQ ID NO:8), NPAEV (SEQ ID NO:9), CPAEV (SEQ ID NO:10), or YQAEE (SEQ ID NO:11).

[0095] 9. An AAV capsid variant of any of embodiments 1-2 or 4-8, wherein [N3] comprises the amino acid sequence of VQK, EQK, or VKK.

[0096] 10. AAV capsid variants as described in any of embodiments 1-2 or 4-9, wherein [N3] contains VQK.

[0097] 11. AAV capsid variants as described in any of embodiments 1-2 or 4-9, wherein [N3] contains EQK.

[0098] 12. AAV capsid variants as described in any of embodiments 1-2 or 4-9, wherein [N3] contains VKK

[0099] 13. An AAV capsid variant of any of embodiments 1-12, wherein [N2] is or contains an amino acid sequence of YPAEV (SEQ ID NO:1) and [N3] is or contains an amino acid sequence of VQK.

[0100] 14. AAV capsid variants as described in any of embodiments 1-12, wherein:

[0101] (i) [N2] is or contains the amino acid sequence YTPSL (SEQ ID NO:7) and [N3] is or contains the amino acid sequence VQK;

[0102] (ii) [N2] is or contains the amino acid sequence YPPSL (SEQ ID NO:2) and [N3] is or contains the amino acid sequence VQK;

[0103] (iii) [N2] is or contains the amino acid sequence of YPPS (SEQ ID NO:2)L and [N3] is or contains the amino acid sequence of EQK; or

[0104] (iv) [N2] is or contains an amino acid sequence of YPPSL (SEQ ID NO:2) and [N3] is or contains an amino acid sequence of VKK.

[0105] 15. An AAV capsid variant as described in any of embodiments 1-2 or 4-14, wherein [N2]-[N3] comprises:

[0106] (i) AEVVQK (SEQ ID NO: 36), PSLVQK (SEQ ID NO: 37), AEVEQK (SEQ ID NO: 38), AEEVQK (SEQ ID NO: 39), PSLEQK (SEQ ID NO: 40), PSLVKK (SEQ ID NO: 41), AEVVKK (SEQ ID NO: 42), AEVVHK (SEQ ID NO:43), AAVVQK (SEQ ID NO:44), AEVVQQ (SEQ ID NO:45) or AEVLQK (SEQ ID NO:46);

[0107] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4 or 5 amino acids, such as consecutive amino acids);

[0108] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0109] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0110] 16. An AAV capsid variant as described in any of embodiments 1-2 or 4-15, wherein [N2]-[N3] comprises:

[0111] (i) PAEVVQK (SEQ ID NO: 20), PPSLVQK (SEQ ID NO: 47), KAEVVQK (SEQ ID NO: 48), TAEVVQK (SEQ ID NO: 49), PAEVEQK (SEQ ID NO: 50), PAEEVQK (SEQ ID NO: 51), QAEVVQK (SEQ ID NO: 52), TPSLVQK (SEQ ID NO:53), PPSLEQK (SEQ ID NO:54), PPSLVKK (SEQ ID NO:55), PAEVVKK (SEQ ID NO:56), PAEVVHK (SEQ ID NO:57), PAAVVQK (SEQ ID NO:58), PAEVVQQ (SEQ ID NO:59), TAEVVKK (SEQ ID NO:60), PAEVLQK (SEQ ID NO:61) or QAEEVQK (SEQ ID NO:62);

[0112] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5 or 6 amino acids, such as consecutive amino acids);

[0113] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0114] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0115] 17. AAV capsid variants as described in any of embodiments 1-16, wherein [N2]-[N3] are or include:

[0116] (i) YPAEVVQK (SEQ ID NO:943), YPPSLVQK (SEQ ID NO:946), NKAEVVQK (SEQ ID NO:947), YTAEVVQK (SEQ ID NO:948), YPAEVEQK (SEQ ID NO:949), YPAEEVQK (SEQ ID NO:950), YQAEVVQK (SEQ ID NO:951), YTPSLVQK (SEQ ID NO:952), YPPSLEQK (SEQ ID NO:953), YPPSLVKK (SEQ ID NO:954), YPAEVVKK (SEQ ID NO:955), YPAEVVHK (SEQ ID NO:956), YPAAVVQK (SEQ ID NO:957), NPAEVVQK (SEQ ID NO:958), YPAEVVQQ (SEQ ID NO:959), CPAEVVQK (SEQ ID (SEQ ID NO:960), YTAEVVKK (SEQ ID NO:961), YPAEVLQK (SEQ ID NO:962), or YQAEEVQK (SEQ ID NO:963);

[0117] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6 or 7 amino acids, such as consecutive amino acids);

[0118] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0119] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0120] 18. An AAV capsid variant of any of embodiments 1-17, wherein the AAV capsid variant further comprises one, two, three, or all of the following: a non-Q amino acid at position 574 (e.g., T, S, A, I, L, or H), a non-S amino acid at position 575 (e.g., G, A, or R), and / or a non-S amino acid at position 576 (e.g., K, L, R, A, or T), relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982.

[0121] 19. An AAV capsid variant of any of embodiments 1-17, wherein the AAV capsid variant further comprises:

[0122] (i) Q at position 574, S at position 575 and / or S at position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0123] (ii) T at position 574, S at position 575 and / or L at position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0124] (iii) S at position 574, S at position 575 and / or S at position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0125] (iv) Q at position 574, S at position 575 and / or R at position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0126] (v) Q at position 574, S at position 575 and / or K at position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0127] (vi) A at position 574, G at position 575 and / or A at position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0128] (vii) I at position 574, G at position 575 and / or S at position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0129] (viii) Q at position 574, A at position 575 and / or S at position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0130] (ix) relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982, A at position 574, S at position 575 and / or S at position 576;

[0131] (x) L at position 574, G at position 575 and / or S at position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0132] (xi) Q at position 574, S at position 575 and / or T at position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0133] (xii) H at position 574, S at position 575 and / or S at position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0134] (xiii) L at position 574, S at position 575, and / or S at position 576 relative to the reference sequence numbered according to SEQ ID NO: 138 or 982; or

[0135] (xiv) Q at position 574, R at position 575 and / or S at position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138 or 982.

[0136] 20. An AAV capsid variant of any of embodiments 1-19, further comprising [N1], wherein [N1] comprises position X D X E and X F ,in:

[0137] (a) Location X D For Q, T, S, A, I, L, or H;

[0138] (b) Location X E It is S, G, A or R; and

[0139] (c) Position X F It can be S, K, L, R, A, or T; and

[0140] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (a)-(c).

[0141] 21. AAV capsid variants as described in embodiment 20, wherein [N1] comprises SK, SL, SS, SR, GA, GS, AS, ST, RS, QS, TS, AG, IG, QA, LG, HS, LS, or QR.

[0142] 22. AAV capsid variants as described in any of embodiments 3, 20 or 21, wherein [N1] is or includes QSS, QSK, TSL, SSS, QSR, AGA, IGS, QAS, ASS, LGS, QST, HSS, LSS or QRS.

[0143] 23. AAV capsid variants as described in any of embodiments 20-22, wherein [N1]-[N2] comprise:

[0144] (i) SSYPA (SEQ ID NO: 63), SKYPA (SEQ ID NO: 64), SLYPA (SEQ ID NO: 65), SRYPA (SEQ ID NO: 66), SSYPP (SEQ ID NO: 67), GAYPA (SEQ ID NO: 68), GSYPA (SEQ ID NO: 69), ASYPA (SEQ ID NO: 70), STNKA (SEQ ID NO: 70) NO:71), SSYTA (SEQ ID NO:72), SSYQA (SEQ ID NO:73), SSYTP (SEQ ID NO:74), SSNPA (SEQ ID NO:75), SLCPA (SEQ ID NO:76), RSYTA (SEQ ID NO:77) or SSTHA (SEQ ID NO:78);

[0145] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, or 4 amino acids, such as consecutive amino acids);

[0146] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0147] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0148] 24. AAV capsid variants as described in any of embodiments 20-23, wherein [N1]-[N2] comprise:

[0149] (i) SSYPAE (SEQ ID NO:79), SKYPAE (SEQ ID NO:80), SLYPAE (SEQ ID NO:81), SRYPAE (SEQ ID NO:82), SSYPPS (SEQ ID NO:83), GAYPAE (SEQ ID NO:84), GSYPAE (SEQ ID NO:85), ASYPAE (SEQ ID NO:86), STNKAE (SEQ ID NO:87), SSYTAE (SEQ ID NO:88), SSYQAE (SEQ ID NO:89), SSYTPS (SEQ ID NO:90), SSYPAA (SEQ ID NO:91), SSNPAE (SEQ ID NO:92), SLCPAE (SEQ ID NO:93), RSYTAE (SEQ ID NO:94), SSTHAS (SEQ ID NO:95);

[0150] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4 or 5 amino acids, such as consecutive amino acids);

[0151] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0152] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0153] 25. AAV capsid variants as described in embodiment 3 or any of 20-24, wherein [N1]-[N2] are or comprise:

[0154] (i) QSSYPAEV (SEQ ID NO:96), QSKYPAEV (SEQ ID NO:97), TSLYPAEV (SEQ ID NO:98), SSSYPAEV (SEQ ID NO:99), QSRYPAEV (SEQ ID NO:100), QSSYPPSL (SEQ ID NO:101), AGAYPAEV (SEQ ID NO:102), IGSYPAEV (SEQ ID NO:103), QASYPAEV (SEQ ID NO:104), ASSYPAEV (SEQ ID NO:105), LGSYPAEV (SEQ ID NO:106), QSTNKAEV (SEQ ID NO:107), HSSYPAEV (SEQ ID NO:108), SSSYTAEV (SEQ ID NO:109), TSLYPAEE (SEQ ID NO:110), ASSYQAEV (SEQ ID NO:111), QSSYTPSL (SEQ ID NO:112), QSRYPAEE (SEQ ID NO:113), LSSYQAEV (SEQ ID NO:114), HSSYPAAV (SEQ ID NO:115), QSSNPAEV (SEQ ID NO:116), QSSYTAEV (SEQ ID NO:117), TSLCPAEV (SEQ ID NO:118), QRSYTAEV (SEQ ID NO:119) or QSSYQAEE (SEQ ID NO:120);

[0155] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6 or 7 amino acids, such as consecutive amino acids);

[0156] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0157] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0158] 26. AAV capsid variants as described in any of embodiments 20-25, wherein [N1]-[N2]-[N3] comprise:

[0159] (i) SSYPAEVVQ (SEQ ID NO: 121), SKYPAEVVQ (SEQ ID NO: 122), SLYPAEVVQ (SEQ ID NO: 123), SRYPAEVVQ (SEQ ID NO: 124), SSYPPSLVQ (SEQ ID NO: 125), GAYPAEVVQ (SEQ ID NO: 126), GSYPAEVVQ (SEQ ID NO:127), ASYPAEVVQ (SEQ ID NO:128), STNKAEVVQ (SEQ ID NO:129), SSYTAEVVQ (SEQ ID NO:130), SKYPAEVEQ (SEQ ID NO:131), SLYPAEEVQ (SEQ ID NO:132), SSYQAEVVQ (SEQ ID NO:133), SSYTPSLVQ (SEQ ID NO:134), SRYPAEEVQ (SEQ ID NO:135), SSYPPSLEQ (SEQ ID NO:136), SSYPPSLVK (SEQ ID NO:140), SSYPAEVVK (SEQ ID NO:141), SKYPAEVVH (SEQ ID NO:142), SSYPAAVVQ (SEQ ID NO:143), SSNPAEVVQ (SEQ ID NO:144), SLCPAEVVQ (SEQ ID NO:145), RSYTAEVVQ (SEQ ID NO:146), SSYTAEVVK (SEQ ID NO:147), SSYPAEVLQ (SEQ ID NO:148) or SSYQAEEVQ (SEQ ID NO:149);

[0160] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7 or 8 amino acids, such as consecutive amino acids);

[0161] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0162] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0163] 27. AAV capsid variants as described in embodiment 3 or any of 20-26, wherein [N1]-[N2]-[N3] are or comprise:

[0164] (i) QSSYPAEVVQK (SEQ ID NO: 150), QSKYPAEVVQK (SEQ ID NO: 151), TSLYPAEVVQK (SEQ ID NO: 152), SSSYPAEVVQK (SEQ ID NO: 153), QSRYPAEVVQK (SEQ ID NO: 154), QSSYPPSLVQK (SEQ ID NO:155), AGAYPAEVVQK (SEQ ID NO:156), IGSYPAEVVQK (SEQ ID NO:157), QASYPAEVVQK (SEQ ID NO:158), ASSYPAEVVQK (SEQ ID NO:159), LGSYPAEVVQK (SEQ ID NO:160), QSTNKAEVVQK (SEQ ID NO:161), HSSYPAEVVQK (SEQ ID NO:162), SSSYTAEVVQK (SEQID NO:163), QSKYPAEVEQK (SEQ ID NO:164), TSLYPAEEVQK (SEQ ID NO:165), ASSYQAEVVQK (SEQ ID NO:166), QSSYTPSLVQK (SEQ ID NO:167), QSRYPAEEVQK (SEQ ID NO:168), QSSYPPSLEQK (SEQ ID NO:169), QSSYPPSLVKK (SEQ ID NO:170), LSSYQAEVVQK (SEQ ID NO:171), SSSYPAEVVKK (SEQ ID NO:172), QSKYPAEVVHK (SEQ ID NO:173), HSSYPAAVVQK (SEQ ID NO:174), QSSNPAEVVQK (SEQ ID NO:175), SSSYPAEVVQQ (SEQ ID NO:176), QSSYTAEVVQK (SEQ ID NO:177), TSLCPAEVVQK (SEQ ID NO:178), QRSYTAEVVQK (SEQ ID NO:179), QSSYTAEVVKK (SEQ ID NO:180), HSSYPAEVLQK (SEQ ID NO:181) or QSSYQAEEVQK (SEQ ID NO:182);

[0165] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, such as consecutive amino acids);

[0166] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0167] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0168] 28. AAV capsid variants as described in any of embodiments 1-27, further comprising [N0], wherein [N0] comprises position X A X B and X C ,in:

[0169] (a) Location X A For T, I, or N;

[0170] (b) Location X B Let N be the number of people in the group.

[0171] (c) Position X C It is N, T, S or K; and

[0172] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (a)-(c).

[0173] 29. AAV capsid variants as described in embodiment 28, wherein [N0] comprises TN, IN, NN, NT, NS, or NK.

[0174] 30. AAV capsid variants as described in embodiments 3, 28, or 29, wherein [N0] is or includes TNN, TNT, INN, TNS, NNN, or TNK.

[0175] 31. AAV capsid variants as described in embodiment 3 or any of 28-30, wherein [N0]-[N1] are or comprise:

[0176] (i) TNNQSS (SEQ ID NO: 183), TNNQSK (SEQ ID NO: 184), TNNTSL (SEQ ID NO: 185), TNNSSS (SEQ ID NO: 186), TNNQSR (SEQ ID NO: 187), TNNAGA (SEQ ID NO: 188), TNNIGS (SEQ ID NO: 189), TNNQAS (SEQ ID NO:190), TNTASS (SEQ ID NO:191), TNNLGS (SEQ ID NO:192), TNNQST (SEQ ID NO:193), TNNHSS (SEQ ID NO:194), TNNQSK (SEQ ID NO:184), TNNLSS (SEQ ID NO:195), INNQSS (SEQ ID NO:196), TNSQSS (SEQ ID NO:197), NNNQSR (SEQ ID NO:198), TNSTSL (SEQ ID NO:199), TNNQRS (SEQ ID NO:200) or TNKQAS (SEQ ID NO:201);

[0177] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4 or 5 amino acids, such as consecutive amino acids);

[0178] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0179] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0180] 32. AAV capsid variants as described in embodiment 3 or any of 28-31, wherein [N0]-[N1]-[N2]-[N3] are or comprise:

[0181] (i)TNNQSSYPAEVVQK(SEQ ID NO:500)、TNNQSKYPAE VVQK(SEQ ID NO:503)、TNNTSLYPAEVVQK(SEQ ID NO:506)、TNNSSSYPAEVVQK(SEQ ID NO:508)、TNNQSRYPAEVV QK(SEQ ID NO:510)、TNNQSSYPAEVVQK(SEQ ID NO:510) NO:512)、TNNAGAYPAEVVQK(SEQ ID NO:513)、TNNIGSYPAEVVQK(SEQ ID NO:514)、TNNQASYPAEVVQK(SEQ ID NO:517)、TNT ASSYPAEVVQK(SEQ ID NO:520)、TNNLGSYPAEVVQK(SEQ ID NO:523)、TNNQSTNKAEVVQK(SEQ ID NO:524)、TNNHSS YPAEVVQK(SEQ ID NO:525)、TNNSSSYTAEVVQK(SEQ IDNO:526), ​​TNNQSKYPAEVEQK(SEQ ID NO:529), TNNTSLYP AEEVQK(SEQ ID NO:530), TNTASSYQAEVVQK(SEQ ID NO:531), TNNQSSYTPSLVQK(SEQ ID NO:533), TNNQSRYPAEE VQK(SEQ ID NO:534), TNNQSSYPPSLEQK(SEQ ID NO:535), TNNQSSYPPSLVKK(SEQ ID NO:536), TNNLSSYQAEVVQ K(SEQ ID NO:539), TNNSSSYPAEVVKK(SEQ ID NO:540), TNNQSKYPAEVVHK(SEQ ID NO:542), INNQSSYPAEVVQK(SEQ ID NO:543), TNNHSSYPAAVVQK(SEQ ID NO:545), TNS QSSNPAEVVQK(SEQ ID NO:548), TNNSSSYPAEVVQQ(SEQ ID NO:549) NO:551)、NNNQSRYPAEVVQK(SEQ ID NO:552)、TNNQSS YTAEVVQK(SEQ ID NO:553)、TNNTSLCPAEVVQK(SEQ ID NO:554)、TNSTSLYPAEVVQK(SEQ ID NO:556)、TNNQRSYT AEVVQK(SEQ ID NO:554)NO:557), TNNQSSYTAEVVKK (SEQ ID NO:558), TNNHSSYPAEVLQK (SEQ ID NO:560), TNNQSSYQAEE VQK (SEQ ID NO:562) or TNKQASYPAEVVQK (SEQ ID NO:563);

[0182] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 amino acids, such as consecutive amino acids);

[0183] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0184] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0185] 33. AAV capsid variants as described in embodiment 3 or 32, wherein [N0]-[N1]-[N2]-[N3] is or contains TNNQSSYPAEVVQK (SEQ ID NO:500).

[0186] 34. AAV capsid variants as described in embodiment 3 or 32, wherein [N0]-[N1]-[N2]-[N3] are or include TNNAGAYPAEVVQK (SEQ ID NO:513), TNNTSL YPAEVVQK (SEQ ID NO:506), TNNQSKYPAEVVQK (SEQ ID NO:503), TNNQSSYTPSLVQK (SEQ ID NO:533), TNNQSSYPP SLVQK (SEQ ID NO:512), TNNQSRYPAEVVQK (SEQ ID NO:510), TNNQSSYPPSLEQK (SEQ ID NO:535), TNNQSSYPPSLVK K (SEQ ID NO:536), or INNQSSYPAEVVQK (SEQ ID NO:543).

[0187] 35. An AAV capsid variant of any of embodiments 1-34, further comprising [N4], wherein [N4] comprises position X G and X H ,in:

[0188] (a) Location X GIt is T, P, or N; and

[0189] (b) Location X H It is A; and

[0190] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (a) or (b).

[0191] 36. AAV capsid variant as described in embodiment 35, wherein [N4] is or contains TA, PA, or NA.

[0192] 37. AAV capsid variants as described in any of embodiments 3, 35, or 36, wherein [N3]-[N4] are or comprise:

[0193] (i) VQKTA (SEQ ID NO:564), EQKTA (SEQ ID NO:565), VKKTA (SEQ ID NO:566), VQKPA (SEQ ID NO:567), VHKTA (SEQ ID NO:568), VQQTA (SEQ ID NO:569), VQKNA (SEQ ID NO:570) or LQKTA (SEQ ID NO:571);

[0194] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, or 4 amino acids, such as consecutive amino acids);

[0195] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0196] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0197] 38. AAV capsid variants as described in embodiment 3 or any of 35-37, wherein [N0]-[N1]-[N2]-[N3]-[N4] are or comprise:

[0198] (i)TNNQSSYPAEVVQKTA(SEQ ID NO:1533)、TNNQSKYP AEVVQKTA(SEQ ID NO:1538)、TNNTSLYPAEVVQKTA(SEQ ID NO:1232)、TNNSSSYPAEVVQKTA(SEQ ID NO:1539)、TNNQSRYPAEVVQKTA(SEQ ID NO:1327)、TNNQSSYPPSLVQKT A(SEQ ID NO:1300)、TNNAGAYPAEVVQKTA(SEQ ID NO:1021)、TNNIGSYPAEVVQKTA(SEQ ID NO:1112)、TNNQASYPAEVVQKTA(SEQ ID NO:1194)、TNTASSYPAEVVQKTA(SEQ ID NO:1575)、TNNLGSYPAEVVQKTA(SEQID NO:1027)、TNN QSTNKAEVVQKTA(SEQ ID NO:1578)、TNNHSSYPAEVVQKTA(SEQ ID NO:1310)、TNNQSKYPAEVVQKTA(SEQ ID NO:1538)、TNNSSSYTAEVVQKTA(SEQ ID NO:1214)、TNNQSKYPAE VEQKTA(SEQ ID NO:1254)、TNNSSLYPAEEVQKTA(SEQ ID NO:1583)、TNTASSYQAEVVQKTA(SEQ ID NO:1584)、TNNQS SYTPSLVQKTA(SEQ ID NO:1585), TNNQSRYPAEEVQKTA(SEQ ID NO:1342), TNNQSSYPPSLEQKTA(SEQ ID NO:1590), TNNQSSYPPSLVKKTA(SEQ ID NO:1591), TNNLSSYQAEVVQKTA(SEQ ID NO:1592), TNNQSSYPPSLVQKPA(SEQ ID NO:1593), TNNSSSYPAEVVKKTA(SEQ ID NO:1331), TNNQSKYPAEVVHKTA(SEQ ID NO:1453), TNNSSSYPAEVVQKPA(SEQ ID NO:1142), INNQSSYPAEVVQKTA(SEQID NO:1024)、TNN HSSYPAAVVQKTA(SEQ ID NO:1598)、TNSQSSNPAEVVQKTA(SEQ IDNO:1599), TNNSSSYPAEVVQQTA (SEQ ID NO:1419), NNNQSRYPAEVVQKTA (SEQ ID NO:1601), TNNQSSYTAE VVQKNA (SEQ ID NO:1602), TNNTSLCPAEVVQKTA (SEQ ID NO:1603), TNSTSLYPAEVVQKTA (SEQ ID NO:1602) NO:1605), TNNQR SYTAEVVQKTA (SEQ ID NO:1604), TNNQSSYTAEVVKKTA (SEQ ID NO:1606), TNNHSSYPAEVLQKTA (SEQ ID NO:1607), TNNQSSYQAEEVQKTA (SEQ ID NO:1608), TNKQASYPAEVVQ KTA (SEQ ID NO:1587);

[0199] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids, such as consecutive amino acids);

[0200] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0201] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0202] 39. AAV capsid variants as described in embodiment 3 or 35-38, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or contains TNNQSSYPAEVVQKTA (SEQ ID NO:1533).

[0203] 40. AAV capsid variants as described in embodiment 3 or 35-38, wherein [N0]-[N1]-[N2]-[N3]-[N4] are or include TNNAGAYPAEVVQKTA (SEQ ID NO:1021), TNNTSLYPAEVVQKTA (SEQ ID NO:1232), TNNQSKYPAE VVQKTA (SEQ ID NO:1538), TNNQSSYTPSLVQKTA (SEQ ID NO:1585), TNNQSSYPPSLVQKTA (SEQ ID NO:1300), TNNQS RYPAEVVQKTA (SEQ ID NO:1327), TNNQSSYPPSLEQKTA (SEQ ID NO:1590), TNNQSSYPPSLVKKTA (SEQ ID NO:1591), or INNQSSYPAEVVQKTA (SEQ ID NO:1024).

[0204] 41. An AAV capsid variant (e.g., an AAV5 capsid variant), said AAV capsid variant comprising an amino sequence comprising the following formula: [B]-[C], wherein

[0205] (i)[B] contains positions X1, X2, and X3, where:

[0206] (a) Position X1 is Q, T, S, A, I, L or H;

[0207] (b) Position X2 is S, G, or A; and

[0208] (c) Position X3 is S, K, L, R, or A; and

[0209] (ii) [C] Contains the amino acid sequence of YPAEVVQK (SEQ ID NO: 943); and

[0210] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (i) and / or (ii).

[0211] 42. An AAV capsid variant (e.g., an AAV5 capsid variant), said AAV capsid variant comprising one, two, three, four, or all of the following:

[0212] (i)[A], where [A] contains the amino acid sequence of TNN, TNT, INN, NNN, TNS or TNK;

[0213] (ii)[B], wherein [B] contains the amino acid sequence of QSS, TSL, SSS, QSR, QSK, AGA, IGS, QAS, ASS, LGS or HSS;

[0214] (iii) [C], wherein [C] contains the amino acid sequence of YPAEVVQK (SEQ ID NO: 943); and

[0215] (iv)[D], where [D] contains the amino acid sequence of TA or PA; and

[0216] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conserved substitution) of any of the above-mentioned amino acids in (i)-(v); and

[0217] Further optionally, wherein [C] replaces position 577 of the reference sequence relative to the amino acid sequence number according to SEQ ID NO:138.

[0218] 43. AAV capsid variant as described in embodiment 41, wherein:

[0219] (a) Position X1 is Q, T, S, A or H;

[0220] (b) Position X2 is S or G; and

[0221] (c) Position X3 is S, K, L or R.

[0222] 44. AAV capsid variants as described in implementation scheme 41 or 43, wherein [B] comprises QS, TS, SS, AG, IG, QA, AS, LG, HS, SK, SL, SR, GA, or GS.

[0223] 45. AAV capsid variants as described in any of embodiments 41-44, wherein [B] is or includes QSS, TSL, SSS, QSR, QSK, AGA, IGS, QAS, ASS, LGS, or HSS.

[0224] 46. ​​AAV capsid variants as described in any of embodiments 41 or 43-45, wherein [B]-[C] comprises:

[0225] (i) SSYPAEVVQK (SEQ ID NO: 572), SKYPAEVVQK (SEQ ID NO: 573), SLYPAEVVQK (SEQ ID NO: 574), SRYPAEVVQK (SEQ ID NO: 575), GAYPAEVVQK (SEQ ID NO: 576), GSYPAEVVQK (SEQ ID NO:580) or ASYPAEVVQK (SEQ ID NO:582);

[0226] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8 or 9 amino acids, such as consecutive amino acids);

[0227] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0228] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0229] 47. AAV capsid variants of any of embodiments 41-46, wherein [B]-[C] are or include:

[0230] (i) QSSYPAEVVQK (SEQ ID NO: 150), QSKYPAEVVQK (SEQ ID NO: 151), TSLYPAEVVQK (SEQ ID NO: 152), SSSYPAEVVQK (SEQ ID NO: 153), QSRYPAEVVQK (SEQ ID NO: 154), AGAYPAEVVQK (SEQ ID NO:156), IGSYPAEVVQK (SEQ ID NO:157), QASYPAEVVQK (SEQ ID NO:158), ASSYPAEVVQK (SEQ ID NO:159), LGSYPAEVVQK (SEQ ID NO:160) or HSSYPAEVVQK (SEQ ID NO:162);

[0231] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, such as consecutive amino acids);

[0232] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0233] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0234] 48. AAV capsid variants of any of embodiments 41-47, wherein [B]-[C] is or contains QSSYPAEVVQK (SEQ ID NO:150).

[0235] 49. AAV capsid variants of any of embodiments 41-47, wherein [B]-[C] are or include AGAYPAEVVQK (SEQ ID NO:156), TSLYPAEVVQK (SEQ ID NO:152), QSKYPAEVVQK (SEQ ID NO:151) or QSRYPAEVVQK (SEQ ID NO:154).

[0236] 50. An AAV capsid variant of any of embodiments 1-49, further comprising one or both of the following: a non-T amino acid (e.g., I or N) at position 571 relative to a reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982, and / or a non-N amino acid (e.g., T, S or K) at position 573.

[0237] 51. AAV capsid variants of any of embodiments 1-49, further comprising:

[0238] (i) T at position 571, N at position 572 and / or N at position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0239] (ii) T at position 571, N at position 572 and / or T at position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0240] (iii) I at position 571, N at position 572 and / or N at position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0241] (iv) T at position 571, N at position 572 and / or S at position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0242] (v) N at position 571, N at position 572, and / or N at position 573 relative to the reference sequence numbered according to SEQ ID NO: 138 or 982; or

[0243] (vi) T at position 571, N at position 572 and / or K at position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138 or 982.

[0244] 52. AAV capsid variants as described in any of embodiments 41-51, further comprising [A], wherein [A] comprises position X A X B and X C ,in:

[0245] (a) Location X A For T, I, or N;

[0246] (b) Location X B Let N be N; and

[0247] (c) Position X C It is N, T, S or K; and

[0248] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (a)-(c).

[0249] 53. AAV capsid variant as described in embodiment 52, wherein [A] comprises TN, IN, NN, NT, NS, or NK.

[0250] 54. AAV capsid variant of any of embodiments 42, 52 or 53, wherein [A] is or includes TNN, TNT, INN, NNN, TNS or TNK.

[0251] 55. AAV capsid variants as described in any of embodiments 42 or 52-54, wherein [A]-[B] are or comprise:

[0252] (i) TNNQSS (SEQ ID NO: 183), TNNQSK (SEQ ID NO: 184), TNNTSL (SEQ ID NO: 185), TNNSSS (SEQ ID NO: 186), TNNQSR (SEQ ID NO: 187), TNNAGA (SEQ ID NO: 188), TNNIGS (SEQ ID NO: 189), TNNQAS (SEQ ID NO:190), TNTASS (SEQ ID NO:191), TNNLGS (SEQ ID NO:192), TNNHSS (SEQ ID NO:194), INNQSS (SEQ ID NO:196), NNNQSR (SEQ ID NO:198), TNSTSL (SEQ ID NO:199) or TNKQAS (SEQ ID NO:201);

[0253] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4 or 5 amino acids, such as consecutive amino acids);

[0254] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0255] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0256] 56. AAV capsid variants as described in any of embodiments 42 or 52-55, wherein [A]-[B]-[C] are or comprise:

[0257] (i) TNNQSSYPAEVVQK (SEQ ID NO: 500), TNNQSKYPAE VVQK (SEQ ID NO: 503), TNNTSLYPAEVVQK (SEQ ID NO: 506), TNNSSSYPAEVVQK (SEQ ID NO: 508), TNNQSRYPAEVV QK (SEQ ID NO:510), TNNAGAYPAEVVQK (SEQ ID NO:513), TNNIGSYPAEVVQK (SEQ ID NO:514), TNNQASYPAEVVQK (SEQ ID NO:517), TNTASSYPAEVVQK (SEQ ID NO:520), TNNLGSYPAEVVQK (SEQ ID NO:523), TNNHSSYPAEVVQK (SEQ ID NO:525), INNQSSYPAEVVQK (SEQ ID NO:543), NNN QSRYPAEVVQK (SEQ ID NO:552), TNSTSLYPAEVVQK (SEQ ID NO:556) or TNKQASYPAEVVQK (SEQ ID NO:563);

[0258] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 amino acids, such as consecutive amino acids);

[0259] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0260] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0261] 57. An AAV capsid variant of any of embodiments 42 or 52-54, wherein [A]-[B]-[C] is or contains TNNQSSYPAEVVQK (SEQ ID NO:500).

[0262] 58. AAV capsid variants as described in any of embodiments 42 or 52-54, wherein [A]-[B]-[C] are or include TNNAGAYPAEVVQK (SEQ ID NO:513), TNNTSLYPAEVVQK (SEQ ID NO:506), TNNQSKYPAEVVQK (SEQ ID NO:503), TNNQSRYPAEVVQK (SEQ ID NO:510), or INNQSSYPAEVVQK (SEQ ID NO:543).

[0263] 59. AAV capsid variants of any of embodiments 1-58, further comprising:

[0264] (i) The non-T amino acid (e.g., P or N) at position 578 relative to the reference sequence numbered according to SEQ ID NO: 138; or

[0265] (ii) A non-T amino acid (e.g., P or N) at position 585 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:982.

[0266] 60. AAV capsid variants of any of embodiments 1-58, further comprising:

[0267] (i) T at position 578 and / or A at position 579 relative to the reference sequence numbered according to SEQ ID NO: 138; or T at position 585 and / or A at position 586 relative to the reference sequence numbered according to SEQ ID NO: 982;

[0268] (ii) P at position 578 and / or A at position 579 relative to the reference sequence numbered according to SEQ ID NO: 138; or P at position 585 and / or A at position 586 relative to the reference sequence numbered according to SEQ ID NO: 982; or

[0269] (iii) N at position 578 and / or A at position 579 relative to the reference sequence numbered according to SEQ ID NO:138; or N at position 585 and / or A at position 586 relative to the reference sequence numbered according to SEQ ID NO:982.

[0270] 61. A variant of the AAV capsid as described in any of embodiments 41-60, further comprising [D], wherein [D] comprises positions X4 and X5, wherein:

[0271] (a) Position X4 is T or N; and

[0272] (b) Position X5 is A; and

[0273] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (a) or (b).

[0274] 62. AAV capsid variants as described in implementation 42 or 61, wherein [D] is or contains TA or PA.

[0275] 63. AAV capsid variants of any of embodiments 42, 61, or 62, wherein [C]-[D] are or comprise:

[0276] (i) YPAEVVQKTA (SEQ ID NO:584) or YPAEVVQKPA (SEQ ID NO:586);

[0277] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8 or 9 amino acids, such as consecutive amino acids);

[0278] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0279] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0280] 64. AAV capsid variants as described in any of embodiments 42 or 61-63, wherein [A]-[B]-[C]-[D] are or include:

[0281] (i) TNNQSSYPAEVVQKTA (SEQ ID NO: 1533), TNNQSKYP AEVVQKTA (SEQ ID NO: 1538), TNNTSLYPAEVVQKTA (SEQ ID NO: 1232), TNNSSSYPAEVVQKTA (SEQ ID NO: 1539), TNNQSRYPAEVVQKTA (SEQ ID NO:1327), TNNAGAYPAEVVQKTA (SEQ ID NO:1021), TNNIGSYPAEVVQKTA (SEQ ID NO:1112), TNNQASYPAEVVQKTA (SEQ ID NO:1194), TNTASSYPAEVVQKTA (SEQ ID NO:1575), TNNLGSYPAEVVQKTA (SEQ ID NO:1027), TNNHSSYPAEVVQKTA (SEQ ID NO:1310), TNN SSSYPAEVVQKPA (SEQ ID NO:1142), INNQSSYPAEVVQKTA (SEQ ID NO:1024), NNNQSRYPAEVVQKTA (SEQ ID NO:1601), TNSTSLYPAEVVQKTA (SEQ ID NO:1605) or TNKQASYPAE VVQKTA (SEQ ID NO:1587);

[0282] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids, such as consecutive amino acids);

[0283] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0284] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0285] 65. An AAV capsid variant of any of embodiments 42 or 61-64, wherein [A]-[B]-[C]-[D] is or contains TNNQSSYPAEVVQKTA (SEQ ID NO:1533).

[0286] 66. AAV capsid variants as described in any of embodiments 42 or 61-64, wherein [A]-[B]-[C]-[D] are or include TNNAGAYPAEVVQKTA (SEQ ID NO:1021), TNNTSLYPAEVVQKTA (SEQ ID NO:1232), TNNQSKYPAE VVQKTA (SEQ ID NO:1538), TNNQSRYPAEVVQKTA (SEQ ID NO:1327), or INNQSSYPAEVVQKTA (SEQ ID NO:1024).

[0287] 67. An AAV capsid variant (e.g., an AAV5 capsid variant), said AAV capsid variant comprising an amino sequence comprising the following formula:

[0288] [N2]-[N3], where:

[0289] (i)[N2] contains positions X1, X2, X3, X4, and X5, where:

[0290] (a) Position X1 is either Y or T;

[0291] (b) Position X2 is Q, T, P, or E;

[0292] (c) Position X3 is A;

[0293] (d) Position X4 is either E or D; and

[0294] (e) Position X5 is V or E; and

[0295] (ii) [N3] An amino acid sequence containing VQK or VQN; or

[0296] The AAV capsid variants described herein include amino acid modifications (e.g., conservative substitutions) of any of the above-mentioned amino acids in (i) and / or (ii).

[0297] 68. An AAV capsid variant (e.g., an AAV5 capsid variant), said AAV capsid variant comprising one, two, three, four, or all of the following:

[0298] (i)[N0] contains TNN, TNS, TNT, or TNK;

[0299] (ii)[N1] includes QSS, SLS, SLY, SAT or QTS;

[0300] (iii)[N2] includes YPAEV (SEQ ID NO:1), YQAEV (SEQ ID NO:6), YTAEV (SEQ ID NO:4), YPAEE (SEQ ID NO:5), TEAEV (SEQ ID NO:12) or YPADV (SEQ ID NO:13);

[0301] (iv)[N3] contains VQK or VQN; and

[0302] (v)[N4] includes TA, PA, TD, NA, or PA; and

[0303] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (i)-(v).

[0304] 69. AAV capsid variants as described in embodiment 1 or 67, wherein [N2] comprises YP, YQ, YT, TE, QA, TA, PA, EA, EV, EE, DV, AE, or AD.

[0305] 70. AAV capsid variants as described in any of embodiments 1, 67, or 69, wherein [N2] comprises YPA, YQA, YTA, TEA, QAE, TAE, PAE, EAE, PAD, AEV, AEE, or ADV.

[0306] 71. An AAV capsid variant of any one of embodiments 1, 67, 69 or 70, wherein [N2] comprises YPAE (SEQ ID NO:21), YQAE (SEQ ID NO:25), YTAE (SEQ ID NO:24), TEAE (SEQ ID NO:587), YPAD (SEQ ID NO:588), QAEV (SEQ ID NO:15), TAEV (SEQ ID NO:16), PAEV (SEQ ID NO:17), PAEE (SEQ ID NO:18), EAEV (SEQ ID NO:590) or PADV (SEQ ID NO:19).

[0307] 72. An AAV capsid variant as described in embodiment 1 or any of 67-71, wherein [N2] is or includes YPAEV (SEQ ID NO:1), YQAEV (SEQ ID NO:6), YTAEV (SEQ ID NO:4), YPAEE (SEQ ID NO:5), TEAEV (SEQ ID NO:12), or YPADV (SEQ ID NO:13).

[0308] 73. An AAV capsid variant as described in embodiment 1 or any of 67-72, wherein [N3] comprises the amino acid sequence of VQK.

[0309] 74. AAV capsid variants as described in any of embodiments 1, 67, or 69-73, wherein [N2]-[N3] comprises:

[0310] (i) AEVVQK (SEQ ID NO:36), AEEVQK (SEQ ID NO:39), AEVVQN (SEQ ID NO:591) or ADVVQK (SEQ ID NO:593);

[0311] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4 or 5 amino acids, such as consecutive amino acids);

[0312] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0313] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0314] 75. AAV capsid variants as described in any of embodiments 1, 67, or 69-74, wherein [N2]-[N3] comprises:

[0315] (i) PAEVVQN (SEQ ID NO:594), QAEVVQK (SEQ ID NO:52), TAEVVQK (SEQ ID NO:49), PAEVVQK (SEQ ID NO:20), PAEEVQK (SEQ ID NO:51), EAEVVQK (SEQ ID NO:595) or PADVVQK (SEQ ID NO:596);

[0316] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5 or 6 amino acids, such as consecutive amino acids);

[0317] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0318] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0319] 76. An AAV capsid variant as described in embodiment 1 or any of 57-75, wherein [N2]-[N3] are or comprise:

[0320] (i) YPAEVVQK (SEQ ID NO:943), YQAEVVQK (SEQ ID NO:951), YTAEVVQK (SEQ ID NO:948), YPAEEVQK (SEQ ID NO:950), YPAEVVQN (SEQ ID NO:964), TEAEVVQK (SEQ ID NO:965) or YPADVVQK (SEQ ID NO:966);

[0321] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6 or 7 amino acids, such as consecutive amino acids);

[0322] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0323] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0324] 77. An AAV capsid variant as described in embodiment 1 or any of 67-76, wherein [N2]-[N3] is or contains YPAEVVQK (SEQ ID NO:943).

[0325] 78. An AAV capsid variant of any of embodiments 1-77, wherein the [N2]-[N3] substitution is located at position 577 of the reference sequence relative to the amino acid sequence number according to SEQ ID NO:138.

[0326] 79. An AAV capsid variant as described in embodiment 1 or any of 67-78, further comprising one, two, three, or all of the following: a non-Q amino acid at position 574 (e.g., S), a non-S amino acid at position 575 (e.g., L, A, or T), and / or a non-S amino acid at position 576 (e.g., Y or T), relative to a reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982.

[0327] 80. AAV capsid variants as described in embodiment 1 or any of 67-78, further comprising:

[0328] (i) Q at position 574, S at position 575 and / or S at position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0329] (ii) S at position 574, L at position 575 and / or S at position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0330] (iii) S at position 574, L at position 575 and / or Y at position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982;

[0331] (iv) S at position 574, A at position 575, and / or T at position 576 relative to the reference sequence numbered according to SEQ ID NO: 138 or 982; or

[0332] (v) Q at position 574, T at position 575 and / or S at position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138 or 982.

[0333] 81. AAV capsid variants as described in embodiment 1 or any of 67-80, further comprising [N1], wherein [N1] contains position X D X E and X F ,in:

[0334] (a) Location X D For Q or S;

[0335] (b) Location X E It can be S, L, A, or T; and

[0336] (c) Position X F It is S, Y, or T; and

[0337] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (a)-(c).

[0338] 82. AAV capsid variants as described in embodiment 81, wherein [N1] comprises QS, SL, SA, QT, LS, LY, AT, TS, or SS.

[0339] 83. AAV capsid variants as described in any of embodiments 68, 81, and 82, wherein [N1] is or includes QSS, SLS, SLY, SAT, or QTS.

[0340] 84. AAV capsid variants of any of embodiments 81-83, wherein [N1]-[N2] comprise:

[0341] (i) SSYPA (SEQ ID NO: 63), LSYQA (SEQ ID NO: 597), LSYTA (SEQ ID NO: 598), LYYPA (SEQ ID NO: 600), ATYPA (SEQ ID NO: 601), LSYPA (SEQ ID NO: 603) or TSTEA (SEQ ID NO: 605);

[0342] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, or 4 amino acids, such as consecutive amino acids);

[0343] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0344] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0345] 85. AAV capsid variants of any of embodiments 81-84, wherein [N1]-[N2] comprise:

[0346] (i) SSYPAE (SEQ ID NO:79), LSYQAE (SEQ ID NO:607), LSYTAE (SEQ ID NO:610), LYYPAE (SEQ ID NO:611), ATYPAE (SEQ ID NO:613), LSYPAE (SEQ ID NO:616), TSTEAE (SEQ ID NO:619) or LSYPAD (SEQ ID NO:621);

[0347] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4 or 5 amino acids, such as consecutive amino acids);

[0348] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0349] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0350] 86. AAV capsid variants as described in any of embodiments 68 or 81-85, wherein [N1]-[N2] are or comprise:

[0351] (i) QSSYPAEV (SEQ ID NO: 96), SLSYQAEV (SEQ ID NO: 622), SLSYTAEV (SEQ ID NO: 623), SLYYPAEV (SEQ ID NO: 624), SATYPAEV (SEQ ID NO: 625), SLSYPAEV (SEQ ID NO: 629), SLSYPAEE (SEQ ID NO: 632), QTSTEAEV (SEQ ID NO:633) or SLSYPADV (SEQ ID NO:634);

[0352] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6 or 7 amino acids, such as consecutive amino acids);

[0353] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0354] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0355] 87. AAV capsid variants as described in any of embodiments 68 or 81-86, wherein [N1]-[N2]-[N3] are or comprise:

[0356] (i) QSSYPAEVVQK (SEQ ID NO: 150), SLSYQAEVVQK (SEQ ID NO: 635), SLSYTAEVVQK (SEQ ID NO: 637), SLYYPAEVVQK (SEQ ID NO: 639), SATYPAEVVQK (SEQ ID NO: 641), SLSYPAEVVQK (SEQ ID NO:642), SLSYPAEEVQK (SEQ ID NO:643), SLSYPAEVVQN (SEQ ID NO:644), QTSTEAEVVQK (SEQ ID NO:645) or SLSYPADVVQK (SEQ ID NO:646);

[0357] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acids, such as consecutive amino acids);

[0358] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0359] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0360] 88. AAV capsid variants as described in any of embodiments 68 or 81-87, wherein [N1]-[N2]-[N3] are or contain QSSYPAEVVQK (SEQ ID NO:150).

[0361] 89. AAV capsid variants as described in embodiment 1 or any of 67-88, further comprising [N0], wherein [N0] comprises position X A X B and X C ,in:

[0362] (a) Location X A Let T be the value of T.

[0363] (b) Location X B Let N be N; and

[0364] (c) Position X C It is N, T, S or K; and

[0365] Optionally, the AAV capsid comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (a)-(c).

[0366] 90. AAV capsid variant as described in embodiment 89, wherein [N0]:

[0367] (i) Includes TN, NS, NT, NN, or NK; and / or

[0368] (ii) is or contains TNS, TNT, TNN or TNK.

[0369] 91. AAV capsid variants as described in any of embodiments 68, 89, or 90, wherein [N0]-[N1] are or comprise:

[0370] (i) TNNQSS (SEQ ID NO: 183), TNSSLS (SEQ ID NO: 647), TNSSLY (SEQ ID NO: 648), TNTSAT (SEQ ID NO: 649), TNNQTS (SEQ ID NO: 650) or TNKSAT (SEQ ID NO: 651);

[0371] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4 or 5 amino acids, such as consecutive amino acids);

[0372] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0373] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0374] 92. AAV capsid variants as described in any of embodiments 68 or 89-91, wherein [N0]-[N1]-[N2]-[N3] are or comprise:

[0375] (i) TNNQSSYPAEVVQK (SEQ ID NO: 500), TNSSLSYQAEV VQK (SEQ ID NO: 652), TNSSLSYTAEVVQK (SEQ ID NO: 654), TNSSLYYPAEVVQK (SEQ ID NO: 655), TNTSATYPAEVVQ K (SEQ ID NO: 656), TNSSLSYPAEVVQK (SEQ ID NO:657), TNSSLSYPAEEVQK (SEQ ID NO:658), TNSSLSYPAEVVQN (SE Q ID NO:660), TNNQTSTEAEVVQK (SEQ ID NO:662), TNKS ATYPAEVVQK (SEQ ID NO:663) or TNSSLSYPADVVQK (SEQ ID NO:665);

[0376] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 amino acids, such as consecutive amino acids);

[0377] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0378] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0379] 93. An AAV capsid variant of any of embodiments 68 or 89-92, wherein [N0]-[N1]-[N2]-[N3] is or contains TNNQSSYPAEVVQK (SEQ ID NO:500).

[0380] 94. AAV capsid variants as described in embodiment 1 or any of 67-93, further comprising [N4], wherein [N4] contains position X G and X H ,in:

[0381] (a) Location X G It is T, P, or N; and

[0382] (b) Location X H It is either A or D; and

[0383] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (a) or (b).

[0384] 95. AAV capsid variant as described in embodiment 94, wherein [N4] is or includes TA, TD, PA, or NA.

[0385] 96. AAV capsid variants as described in embodiments 68, 94, or 95, wherein [N3]-[N4] are or comprise:

[0386] (i) VQKTA (SEQ ID NO:564), EQKTA (SEQ ID NO:565), VKKTA (SEQ ID NO:566), VQKPA (SEQ ID NO:567), VHKTA (SEQ ID NO:568), VQQTA (SEQ ID NO:569), VQKNA (SEQ ID NO:570) or LQKTA (SEQ ID NO:570) NO:571);

[0387] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, or 4 amino acids, such as consecutive amino acids);

[0388] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0389] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0390] 97. AAV capsid variants as described in any of embodiments 68 or 94-96, wherein [N0]-[N1]-[N2]-[N3]-[N4] are or comprise:

[0391] (i) TNNQSSYPAEVVQKTA (SEQ ID NO: 1533), TNSSLSYQ AEVVQKTA (SEQ ID NO: 2064), TNSSLSYTAEVVQKTA (SEQ ID NO: 2065), TNSSLYYPAEVVQKTA (SEQ ID NO: 2066), TNTSATYPAEVVQKTA (SEQ ID NO:2067), TNSSLSYPAEVVQKTA (SEQ ID NO:2068), TNSSLSYPAEEVQKTA (SEQ ID NO:2069), TNSSLSYPAEVVQKTD (SEQ ID NO:2070), TNSSLSYPAEVVQN TA (SEQ ID NO:2071), TNSSLSYPAEVVQKNA (SEQ ID NO:2072), TNSSLSYPAEVVQKPA (SEQ ID NO:2073), TNNQTSTEA EVVQKTA (SEQ ID NO:2074), TNKSATYPAEVVQKTA (SEQ ID NO:2075) or TNSSLSYPADVVQKTA (SEQ ID NO:2076);

[0392] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids, such as consecutive amino acids);

[0393] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0394] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0395] 98. An AAV capsid variant of any of embodiments 68 or 94-97, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or contains TNNQSSYPAEVVQKTA (SEQ ID NO:1533).

[0396] 99. An AAV capsid variant (e.g., an AAV5 capsid variant), said AAV capsid variant comprising the formula [K1]-[K2], wherein:

[0397] (i)[K1] contains either LSY or LYY; and

[0398] (ii) [K2] contains positions X1, X2, X3, and X4, where:

[0399] (a) Position X1 is Q, T or P;

[0400] (b) Position X2 is A;

[0401] (c) Position X3 is either E or D; and

[0402] (d) Position X4 is V or E; and

[0403] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (i) and / or (ii).

[0404] 100. An AAV capsid variant (e.g., an AAV5 capsid variant), said AAV capsid variant comprising one, two, three, four, or all of the following:

[0405] (i)[K0], which contains TNNS (SEQ ID NO:14);

[0406] (ii)[K1], which contains LSY or LYY;

[0407] (iii) [K2], which includes QAEV (SEQ ID NO:15), TAEV (SEQ ID NO:16), PAEV (SEQ ID NO:17), PAEE (SEQ ID NO:18) or PADV (SEQ ID NO:19);

[0408] (iv)[K3], which contains VQK or VQN; and

[0409] (v)[K4], which includes TA, TD, NA or PA; and

[0410] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (i)-(v).

[0411] 101. AAV capsid variants as described in implementation scheme 99 or 100, wherein [K1] contains LSY.

[0412] 102. AAV capsid variants as described in embodiment 99 or 101, wherein [K2] comprises QA, TA, PA, EV, EE, DV, AE, or AD.

[0413] 103. AAV capsid variants as described in any of embodiments 99, 101 or 102, wherein [K2] comprises QAE, TAE, PAE, PAD, AEV, AEE or ADV.

[0414] 104. AAV capsid variants of any of embodiments 99-103, wherein [K2] is or includes QAEV (SEQ ID NO:15), TAEV (SEQ ID NO:16), PAEV (SEQ ID NO:17), PAEE (SEQ ID NO:18), or PADV (SEQ ID NO:19).

[0415] 105. AAV capsid variants as described in any of embodiments 99 or 101-104, wherein [K1]-[K2] comprise LSYQA (SEQ ID NO:597), LSYTA (SEQ ID NO:598), LYYPA (SEQ ID NO:600), or LSYPA (SEQ ID NO:603).

[0416] 106. AAV capsid variants as described in any of embodiments 99 or 101-105, wherein [K1]-[K2] comprises:

[0417] (i) LSYQAE (SEQ ID NO:607), LSYTAE (SEQ ID NO:610), LYYPAE (SEQ ID NO:611), LSYPAE (SEQ ID NO:616) or LSYPAD (SEQ ID NO:621);

[0418] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4 or 5 amino acids, such as consecutive amino acids);

[0419] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0420] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0421] 107. AAV capsid variants as described in any of embodiments 99-106, wherein [K1]-[K2] are or include:

[0422] (i) LSYQAEV (SEQ ID NO:667), LSYTAEV (SEQ ID NO:668), LYYPAEV (SEQ ID NO:669), LSYPAEV (SEQ ID NO:671), LSYPAEE (SEQ ID NO:673) or LSYPADV (SEQ ID NO:674);

[0423] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5 or 6 amino acids, such as consecutive amino acids);

[0424] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0425] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0426] 108. An AAV capsid variant of any of embodiments 99-107, wherein the AAV capsid variant further comprises a non-Q amino acid (e.g., S) at position 574 relative to a reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138.

[0427] 109. An AAV capsid variant of any of embodiments 99-108, wherein the AAV capsid variant further comprises S at position 574 relative to a reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0428] 110. An AAV capsid variant of any of embodiments 99-109, further comprising [K0], wherein [K0] is or comprises TNNS (SEQ ID NO:14); an amino acid sequence comprising any portion of an amino acid sequence (e.g., any 2 or 3 amino acids, such as consecutive amino acids); an amino acid sequence comprising one, two, or three but not more than four modifications (e.g., substitutions (e.g., conservative substitutions), insertions, or deletions) relative to the amino acid sequence of TNNS (SEQ ID NO:14); or an amino acid sequence comprising one, two, or three but not more than four different amino acids relative to the amino acid sequence of TNNS (SEQ ID NO:14).

[0429] 111. AAV capsid variant of embodiment 110, wherein [K0]-[K1] comprises:

[0430] (i) TNSSLS (SEQ ID NO:647) or TNSSLY (SEQ ID NO:648);

[0431] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4 or 5 amino acids, such as consecutive amino acids);

[0432] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0433] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0434] 112. AAV capsid variants as described in any of embodiments 100, 110, or 111, wherein [K0]-[K1] are or include:

[0435] (i) TNSSLSY (SEQ ID NO: 676) or TNSSLYY (SEQ ID NO: 678);

[0436] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5 or 6 amino acids, such as consecutive amino acids);

[0437] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0438] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0439] 113. AAV capsid variants as described in any of embodiments 110-112, wherein [K0]-[K1]-[K2] comprise:

[0440] (i) TNSSLSYQA (SEQ ID NO: 679), TNSSLSYTA (SEQ ID NO: 681), TNSSLYYPA (SEQ ID NO: 682) or TNSSLSYPA (SEQ ID NO: 683);

[0441] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7 or 8 amino acids, such as consecutive amino acids);

[0442] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0443] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0444] 114. AAV capsid variants as described in any of embodiments 110-113, wherein [K0]-[K1]-[K2] comprise:

[0445] (i) TNSSLSYQAE (SEQ ID NO: 684), TNSSLSYTAE (SEQ ID NO: 685), TNSSLYYPAE (SEQ ID NO: 686), TNSSLSYPAE (SEQ ID NO: 687) or TNSSLSYPAD (SEQ ID NO: 689);

[0446] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8 or 9 amino acids, such as consecutive amino acids);

[0447] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0448] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0449] 115. AAV capsid variants as described in any of embodiments 100 or 110-114, wherein [K0]-[K1]-[K2] are or include:

[0450] (i) TNSSLSYQAEV (SEQ ID NO:692), TNSSLSYTAEV (SEQ ID NO:693), TNSSLYPAEV (SEQ ID NO:696), TNSSLSYPAEV (SEQ ID NO:697), TNSSLSYPAEE (SEQ ID NO:698) or TNSSLSYPADV (SEQ ID NO:699);

[0451] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, such as consecutive amino acids);

[0452] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0453] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0454] 116. A variant of the AAV capsid as described in any of embodiments 99-115, further comprising [K3], wherein [K3] contains position X A X B and X C ,in:

[0455] (a) Location X A V;

[0456] (b) Location X B Let Q be Q; and

[0457] (c) Position X C It is K or N; and

[0458] Optionally, the AAV capsid comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (a)-(c).

[0459] 117. An AAV capsid variant as described in embodiment 116, wherein [K3]:

[0460] (i) Includes VQ, QK, or QN;

[0461] (ii) is or contains VQK or VQN.

[0462] 118. AAV capsid variants as described in embodiments 100, 116, or 117, wherein [K2]-[K3] are or include:

[0463] (i)QAEVVQK (SEQ ID NO:52), TAEVVQK (SEQ ID NO:49), PAEVVQK (SEQ ID NO:20), PAEEVQK (SEQ ID NO:51), PAEVVQN (SEQ ID NO:594) or PADVVQK (SEQ ID NO:596);

[0464] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5 or 6 amino acids, such as consecutive amino acids);

[0465] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0466] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0467] 119. AAV capsid variants as described in embodiments 100 or 116-118, wherein [K1]-[K2]-[K3] are or include:

[0468] (i) LSYQAEVVQK (SEQ ID NO:700), LSYTAEVVQK (SEQ ID NO:701), LYYPAEVVQK (SEQ ID NO:702), LSYPAEVVQK (SEQ ID NO:703), LSYPAEEVQK (SEQ ID NO:704), LSYPAEVVQN (SEQID NO:706) or LSYPADVVQK (SEQ ID NO:708);

[0469] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8 or 9 amino acids, such as consecutive amino acids);

[0470] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0471] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0472] 120. AAV capsid variants as described in embodiments 100 or 116-119, wherein [K0]-[K1]-[K2]-[K3] are or include:

[0473] (i) TNSSLSYQAEVVQK (SEQ ID NO: 652), TNSSLSYTAEV VQK (SEQ ID NO: 654), TNSSLSYPAEVVQK (SEQ ID NO: 655), TNSSLSYPAEVVQK (SEQ ID NO: 657), TNSSLSYPAEEVQK (SEQ ID NO: 658), TNSSLSYPAEVVQN (SEQ ID NO:660) or TNSSLSYPADVVQK (SEQ ID NO:665);

[0474] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 amino acids, such as consecutive amino acids);

[0475] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0476] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0477] 121. A variant of the AAV capsid as described in any of embodiments 99-120, further comprising [K4], wherein [K4] contains position X D and X E ,in:

[0478] (a) Location X D It is T, P, or N; and

[0479] (b) Location X E It is either A or D; and

[0480] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (a) or (b).

[0481] 122. AAV capsid variants as described in implementation 100 or 121, wherein [K4] is or contains TA, TD, PA, or NA.

[0482] 123. AAV capsid variants as described in any of embodiments 100, 121, or 122, wherein [K3]-[K4] are or include:

[0483] (i) VQKTA (SEQ ID NO:564), VQKTD (SEQ ID NO:714), VQNTA (SEQ ID NO:715), VQKNA (SEQ ID NO:570) or VQKPA (SEQ ID NO:567);

[0484] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, or 4 amino acids, such as consecutive amino acids);

[0485] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0486] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0487] 124. AAV capsid variants as described in any of embodiments 100 or 121-123, wherein [K0]-[K1]-[K2]-[K3]-[K4] are or comprise:

[0488] (i) TNSSLSYQAEVVQKTA (SEQ ID NO: 2064), TNSSLSYT AEVVQKTA (SEQ ID NO: 2065), TNSSLSYPAEVVQKTA (SEQ ID NO: 2066), TNSSLSYPAEVVQKTA (SEQ ID NO: 2068), TNSSLSYPAEEVQKTA (SEQ ID NO:2069), TNSSLSYPAEVVQKTD (SEQ ID NO:2070), TNSSLSYPAEVVQNTA (SEQ ID NO:2071), TNSSLSYPAEVVQKNA (SEQ ID NO:2072), TNSSLSYPAEVVQK PA (SEQ ID NO:2073) or TNSSLSYPADVVQKTA (SEQ ID NO:2076);

[0489] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids, such as consecutive amino acids);

[0490] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0491] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0492] 125. An AAV capsid variant (e.g., an AAV5 capsid variant) comprising [B]-[C], wherein:

[0493] (i)[B] contains positions X1, X2, and X3, where:

[0494] (a) Position X1 is either Q or S;

[0495] (b) Position X2 is S, L, or A; and

[0496] (c) Position X3 is S, Y, or T; and

[0497] (ii) [C] Contains the amino acid sequence of YPAEVVQK (SEQ ID NO: 943); and

[0498] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (i) and / or (ii).

[0499] 126. An AAV capsid variant (e.g., an AAV5 capsid variant), said AAV capsid variant comprising one, two, three, four, or all of the following:

[0500] (i)[A] contains TNN, TNS, TNT, or TNK;

[0501] (ii)[B] contains QSS, SLY, SAT, or SLS;

[0502] (iii)[C] contains YPAEVVQK (SEQ ID NO:943); and

[0503] (iv)[D] includes TA, TD, NA, or PA; and

[0504] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conserved substitution) of any of the above-mentioned amino acids in (i)-(v), and

[0505] Further optionally, wherein [C] replaces position 577 of the reference sequence relative to the amino acid sequence number according to SEQ ID NO:138.

[0506] 127. AAV capsid variants as described in embodiment 125, wherein [B] contains QS, SL, SA, LY, AT, LS or SS.

[0507] 128. AAV capsid variants of any of embodiments 125-127, wherein [B] is or contains QSS, SLY, SAT or SLS.

[0508] 129. AAV capsid variants of any of embodiments 125, 127, or 128, wherein [B]-[C] comprises:

[0509] (i) SSYPAEVVQK (SEQ ID NO: 572), LYYPAEVVQK (SEQ ID NO: 702), ATYPAEVVQK (SEQ ID NO: 718) or LSYPAEVVQK (SEQ ID NO: 703);

[0510] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8 or 9 amino acids, such as consecutive amino acids);

[0511] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0512] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0513] 130. AAV capsid variants as described in any of embodiments 125-129, wherein [B]-[C] are or include:

[0514] (i) QSSYPAEVVQK (SEQ ID NO: 150), SLYYPAEVVQK (SEQ ID NO: 639), SATYPAEVVQK (SEQ ID NO: 641) or SLSYPAEVVQK (SEQ ID NO: 642);

[0515] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, such as consecutive amino acids);

[0516] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0517] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0518] 131. AAV capsid variants as described in embodiments 126 or 130, wherein [B]-[C] is or contains QSSYPAEVVQK (SEQ ID NO:150).

[0519] 132. An AAV capsid variant of any of embodiments 67-98 or 125-131, wherein the AAV capsid variant further comprises a non-N amino acid (e.g., T, S, or K) at position 573 relative to a reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138.

[0520] 133. AAV capsid variants as described in any of embodiments 67-98 or 125-131, further comprising:

[0521] (i) T at position 571, N at position 572 and / or N at position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138;

[0522] (ii) T at position 571, N at position 572 and / or T at position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138;

[0523] (iii) T at position 571, N at position 572, and / or S at position 573, relative to the reference sequence numbered according to SEQ ID NO: 138; or

[0524] (iv) T at position 571, N at position 572 and / or K at position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0525] 134. AAV capsid variants as described in any of embodiments 125-133, further comprising [A], wherein [A] contains position X A X B and X C ,in:

[0526] (a) Location X A Let T be the value of T.

[0527] (b) Location X B Let N be N; and

[0528] (c) Position X C It is N, T, S or K; and

[0529] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (a)-(c).

[0530] 135. AAV capsid variants as described in embodiments 126 or 134, wherein [A]:

[0531] (i) Includes TN, NS, NT, NK, or NN;

[0532] (ii) is or contains TNN, TNS, TNT or TNK.

[0533] 136. AAV capsid variants as described in any of embodiments 126, 134, or 135, wherein [A]-[B] are or comprise:

[0534] (i) TNNQSS (SEQ ID NO: 183), TNSSLY (SEQ ID NO: 648), TNTSAT (SEQ ID NO: 649), TNSSLS (SEQ ID NO: 647) or TNKSAT (SEQ ID NO: 651);

[0535] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4 or 5 amino acids, such as consecutive amino acids);

[0536] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0537] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0538] 137. AAV capsid variants as described in any of embodiments 126 or 134-136, wherein [A]-[B]-[C] are or comprise:

[0539] (i) TNNQSSYPAEVVQK (SEQ ID NO: 500), TNSSLYYPAEV VQK (SEQ ID NO: 655), TNTSATYPAEVVQK (SEQ ID NO: 656), TNSSLSYPAEVVQK (SEQ ID NO: 657) or TNKSATYPAEVVQ K (SEQ ID NO: 663);

[0540] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 amino acids, such as consecutive amino acids);

[0541] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0542] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0543] 138. An AAV capsid variant of any of embodiments 126 or 134-137, wherein [A]-[B]-[C] is or contains TNNQSSYPAEVVQK (SEQ ID NO:500).

[0544] 139. An AAV capsid variant of any of embodiments 67-98 or 125-138, further comprising one or both of the following: a non-T amino acid (e.g., P or N) at position 578 and / or a non-A amino acid (e.g., D) at position 579 relative to a reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138.

[0545] 140. AAV capsid variants as described in any of embodiments 67-98 or 125-138, further comprising:

[0546] (i) T at position 578 and / or A at position 579 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138;

[0547] (ii) T at position 578 and / or D at position 579 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138;

[0548] (iii) P at position 578 and / or A at position 579 relative to the reference sequence numbered according to SEQ ID NO: 138; or

[0549] (iv) N at position 578 and / or A at position 579 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0550] 141. An AAV capsid variant of any of embodiments 125-140, further comprising [D], wherein [D] comprises positions X4 and X5, wherein:

[0551] (a) Position X4 is T, N, or P; and

[0552] (b) Position X5 is either A or D; and

[0553] Optionally, the AAV capsid variant comprises an amino acid modification (e.g., a conservative substitution) of any of the above-mentioned amino acids in (a) or (b).

[0554] 142. AAV capsid variants as described in embodiment 141, wherein [D] is or includes TA, TD, NA or PA.

[0555] 143. AAV capsid variants as described in embodiments 126, 141, or 142, wherein [C]-[D] are or comprise:

[0556] (i) YPAEVVQKTA (SEQ ID NO: 584), YPAEVVQKTD (SEQ ID NO: 719), YPAEVVQKNA (SEQ ID NO: 724) or YPAEVVQKPA (SEQ ID NO: 586);

[0557] (ii) An amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8 or 9 amino acids, such as consecutive amino acids);

[0558] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0559] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0560] 144. AAV capsid variants as described in any of embodiments 126 or 141-143, wherein [A]-[B]-[C]-[D] are or include:

[0561] (i) TNNQSSYPAEVVQKTA (SEQ ID NO: 1533), TNSSLYYP AEVVQKTA (SEQ ID NO: 2066), TNTSATYPAEVVQKTA (SEQ ID NO: 2067), TNSSLSYPAEVVQKTA (SEQ ID NO: 2068), TNSSLSYPAEVVQKTD (SEQ ID NO:2070), TNSSLSYPAEVVQKNA (SEQ ID NO:2072), TNSSLSYPAEVVQKPA (SEQ ID NO:2073) or TNKSATYPAEVVQKTA (SEQ ID NO:2075);

[0562] (ii) The amino acid sequence that includes any part of the amino acid sequence in (i) (e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids, such as consecutive amino acids);

[0563] (iii) A sequence containing one, two, or three, but no more than four, modified (e.g., substitution (e.g., conserved substitution), insertion, or deletion) amino acid sequences relative to any amino acid sequence in (i); or

[0564] (iv) An amino acid sequence containing one, two, or three, but no more than four different amino acids, relative to any amino acid sequence in (i).

[0565] 145. An AAV capsid variant of any of embodiments 126 or 141-144, wherein [A]-[B]-[C]-[D] is or contains TNNQSSYPAEVVQKTA (SEQ ID NO:1533).

[0566] 146. An AAV capsid variant of any one of embodiments 1-40, 59, 60, 67-98, 139 or 140, wherein [N2]-[N3] are present in ring VIII, optionally wherein ring VIII comprises positions 571-592 (e.g., amino acid TNNQSSTTAPATGTYNLQEIVP (SEQ ID NO:736)), these positions being numbered according to SEQ ID NO:138; or positions 571-599, these positions being numbered according to SEQ ID NO:982.

[0567] 147. An AAV capsid variant of any one of embodiments 2, 15-40, 59, 60, 68, 79-98, 139, 137 or 146, wherein [N0], [N1] and / or [N4] are present in ring VIII, optionally wherein ring VIII comprises positions 571-592 (e.g., amino acid TNNQSSTTAPATGTYNLQEIVP (SEQ ID NO:736)), which are numbered according to SEQ ID NO:138; or positions 571-599, which are numbered according to SEQ ID NO:982.

[0568] 148. An AAV capsid variant of any one of embodiments 2, 15-40, 59, 60, 68, 79-98, 139, 140, 146 or 147, wherein [N0]-[N1]-[N2]-[N3]-[N4] are present in ring VIII, optionally wherein ring VIII comprises positions 571-592 (e.g., amino acid TNNQSSTTAPATGTYNLQEIVP (SEQ ID NO: 736)), these positions being numbered according to SEQ ID NO: 138; or positions 571-599, these positions being numbered according to SEQ ID NO: 982.

[0569] 149. An AAV capsid variant of any of embodiments 1-40, 59, 60, 67-98, 139, 140 or 146-148, wherein [N2] is present immediately after position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982.

[0570] 150. An AAV capsid variant of any of embodiments 1-40, 59, 60, 67-98, 139, 140 or 146-149, wherein the [N2] substitution position is 577 (e.g., T577) relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138.

[0571] 151. An AAV capsid variant of any of embodiments 1-40, 59, 60, 67-98, 139, 140 or 146-150, wherein [N2] is present immediately after position 576 relative to the reference sequence numbered according to SEQ ID NO:138, and wherein [N2] replaces position 577 (e.g., T577).

[0572] 152. AAV capsid variants such as 1-40, 59, 60, 67-98, 139, 140 or 146-151, wherein [N2] corresponds to position 577-581 of SEQ ID NO:982 (e.g., Y577, P578, A579, E580, V581).

[0573] 153. An AAV capsid variant of any of embodiments 1-152, wherein the AAV capsid variant comprises a non-T amino acid at position 577 relative to a reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0574] 154. An AAV capsid variant of any of embodiments 1-153, wherein the AAV capsid variant contains a Y at position 577 relative to a reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982.

[0575] 155. An AAV capsid variant of any of embodiments 1-40, 59, 60, 67-98, 139, 140 or 146-154, wherein X1 of [N2] is present at position 577 (e.g., T577) relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982, and positions X2-X5 of [N2] are present immediately after position 577.

[0576] 156. An AAV capsid variant of any one of embodiments 1-40, 59, 60, 67-98, 139, 140 or 146-155, wherein X1 of [N2] corresponds to position 577 (e.g., Y577), X2 of [N2] corresponds to position 578 (e.g., P588), X3 of [N2] corresponds to position 579 (e.g., A579), X4 of [N2] corresponds to position 580 (e.g., E580), and X5 of [N2] corresponds to position 581 of SEQ ID NO:982 (e.g., V581).

[0577] 157. An AAV capsid variant of any of embodiments 1-40, 59, 60, 67-98, 139, 140 or 146-156, wherein [N2]-[N3] are present immediately after position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982.

[0578] 158. An AAV capsid variant of any of embodiments 1-40, 59, 60, 67-98, 139, 140 or 146-157, wherein position 577 is replaced by [N2]-[N3] relative to the reference sequence numbered according to SEQ ID NO:138.

[0579] 159. An AAV capsid variant of any of embodiments 1-40, 59, 60, 67-98, 139, 140 or 146-158, wherein [N2]-[N3] is present immediately after position 576 relative to the reference sequence numbered according to SEQ ID NO:138, and wherein [N2]-[N3] replaces position 577 (e.g., T577).

[0580] 160. AAV capsid variants of any of embodiments 1-40, 59, 60, 67-98, 139, 140 or 146-159, wherein [N2]-[N3] correspond to positions 577-584 of SEQ ID NO:982 (e.g., Y577, P578, A579, E580, V581, V582, Q583, K584).

[0581] 161. An AAV capsid variant of any of embodiments 1-40, 59, 60, 67-98, 139, 140 or 146-160, wherein [N2]-[N3]-[N4] are present immediately after position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982.

[0582] 162. An AAV capsid variant of any of embodiments 1-40, 59, 60, 67-98, 139, 140 or 146-161, wherein [N2]-[N3]-[N4] substitution positions 577-579 (e.g., T577, T578 and A579) are relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0583] 163. An AAV capsid variant of any of embodiments 1-40, 59, 60, 67-98, 139, 140 or 146-162, wherein [N2]-[N3]-[N4] is present immediately after position 576 relative to the reference sequence numbered according to SEQ ID NO:138, and wherein [N2]-[N3]-[N4] replaces positions 577-579 (e.g., T577, T578 and A579).

[0584] 164. AAV capsid variants of any of embodiments 1-40, 59, 60, 67-98, 139, 140 or 146-163, wherein [N2]-[N3]-[N4] correspond to positions 577-586 of SEQ ID NO:982 (e.g., Y577, P578, A579, E580, V581, V582, Q583, K584, T585, A586).

[0585] 165. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140 or 146-164, wherein [N1] is present immediately after position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982.

[0586] 166. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140, or 146-165, wherein the [N1] substitution positions are 574-576 (e.g., Q574, S575, and S576) relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138.

[0587] 167. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140, or 146-166, wherein [N1] is present immediately after position 573 relative to the reference sequence numbered according to SEQ ID NO: 138, and wherein [N1] replaces positions 574-576 (e.g., Q574, S575, and S576).

[0588] 168. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140, or 146-167, wherein the [N1] substitution positions are 574-576 (e.g., Q574, S575, and S576) relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 982.

[0589] 169. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140, or 146-168, wherein [N1] is present immediately after position 573 relative to the reference sequence numbered according to SEQ ID NO: 982, and wherein [N1] replaces positions 574-576 (e.g., Q574, S575, and S576).

[0590] 170. AAV capsid variants of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140 or 146-169, wherein [N1] corresponds to positions 574-576 of SEQ ID NO:982 (e.g., Q574, S575 and S576).

[0591] 171. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140, or 146-170, wherein [N1]-[N2]-[N3]-[N4] immediately follows position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982.

[0592] 172. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140, or 146-171, wherein the [N1]-[N2]-[N3]-[N4] substitution positions 574-579 (e.g., Q574, S575, S576, T577, T578, and A579) are relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138.

[0593] 173. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140, or 146-171, wherein [N1]-[N2]-[N3]-[N4] is present immediately after position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138, and wherein [N1]-[N2]-[N3]-[N4] replaces positions 574-579 (e.g., Q574, S575, S576, T577, T578, and A579).

[0594] 174. AAV capsid variants of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140 or 146-173, wherein [N1]-[N2]-[N3]-[N4] correspond to positions 574-586 of SEQ ID NO:982 (e.g., Q574, S575, S576, Y577, P578, A579, E580, V581, V582, Q583, K584, T585, A586).

[0595] 175. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140 or 146-174, wherein [N0] is present immediately after position 570 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0596] 176. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140, or 146-175, wherein [N0] substitution positions 571-573 (e.g., T571, N572, and N573) are relative to the reference sequence according to the amino acid sequence number of SEQ ID NO: 138.

[0597] 177. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140, or 146-176, wherein [N0] is present immediately after position 570 relative to the reference sequence numbered according to SEQ ID NO: 138, and wherein [N0] replaces positions 571-573 (e.g., T571, N572, and N573).

[0598] 178. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140 or 146-177, wherein [N0] is present immediately after position 570 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 982.

[0599] 179. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140, or 146-178, wherein [N0] substitution positions 571-573 (e.g., T571, N572, and N573) are relative to the reference sequence according to the amino acid sequence number of SEQ ID NO: 982.

[0600] 180. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140, or 146-179, wherein [N0] is present immediately after position 570 relative to the reference sequence numbered according to SEQ ID NO: 982, and wherein [N0] replaces positions 571-573 (e.g., T571, N572, and N573).

[0601] 181. AAV capsid variants of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140 or 146-181, wherein [N0] corresponds to positions 571-573 of SEQ ID NO:982 (e.g., T571, N572 and N573).

[0602] 182. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140, or 146-181, wherein [N0]-[N1]-[N2]-[N3]-[N4] immediately follows position 570 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982.

[0603] 183. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140, or 146-182, wherein the [N0]-[N1]-[N2]-[N3]-[N4] substitution positions 571-579 (e.g., T571, N572, N573, Q574, S575, S576, T577, T578, and A579) are used relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138.

[0604] 184. An AAV capsid variant of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140, or 146-183, wherein [N0]-[N1]-[N2]-[N3]-[N4] is present immediately after position 570 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138, and wherein [N0]-[N1]-[N2]-[N3]-[N4] replaces positions 571-579 (e.g., T571, N572, N573, Q574, S575, S576, T577, T578, and A579).

[0605] 185. AAV capsid variants of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140 or 146-184, wherein [N0]-[N1]-[N2]-[N3]-[N4] correspond to positions 571-586 of SEQ ID NO:982 (e.g., T571, N572, N573, Q574, S575, S576, Y577, P578, A579, E580, V581, V582, Q583, K584, T585, A586).

[0606] 186. AAV capsid variants of any of embodiments 3, 31-40, 68, 94-98, 139, 140 or 146-185, wherein [N4] is present immediately after position 584 according to SEQ ID NO:982.

[0607] 187. AAV capsid variants of any of embodiments 3, 31-40, 68, 94-98, 139, 140 or 146-186, wherein [N4] substitution positions 578 and 579, which are numbered according to SEQ ID NO:138; or positions 585 and 586, which are numbered according to SEQ ID NO:982.

[0608] 188. AAV capsid variants of any of embodiments 3, 31-40, 68, 94-98, 139, 140 or 146-187, wherein [N4] is present immediately after position 584 and replaces positions 585 and 586, which are numbered according to SEQ ID NO:982.

[0609] 189. AAV capsid variants as described in any of embodiments 3, 31-40, 68, 94-98, 139, 140, or 146-188, wherein:

[0610] (i)X of [N0] A X exists at position 571, [N0] B X exists at position 572 and [N0] C It exists at location 573, which are numbered according to SEQ ID NO:982;

[0611] (ii) X of [N1] D X exists at position 574, [N1] E X exists at position 575 and [N1] F It exists at location 576, which are numbered according to SEQ ID NO:982;

[0612] (iii) X1 of [N2] is located at position 577, X2 of [N2] is located at position 578, X3 of [N2] is located at position 579, X4 of [N2] is located at position 580, and X5 of [N2] is located at position 581, these positions are numbered according to SEQ ID NO: 982;

[0613] (iv)[N3] is present at positions 582-584, which are numbered according to SEQ ID NO:982; and / or

[0614] (v)[N4] of X G X exists at position 585 and [N4]. H It exists at position 586, which are numbered according to SEQ ID NO: 982.

[0615] 190. AAV capsid variants as described in any of embodiments 3, 31-40, 68, 94-98, 139, 140, or 146-189, wherein:

[0616] (i)[N0] exists at positions 571-573, which are numbered according to SEQ ID NO:982;

[0617] (ii)[N1] exists at positions 574-576, which are numbered according to SEQ ID NO:982;

[0618] (iii)[N2] exists at positions 577-581, which are numbered according to SEQ ID NO:982;

[0619] (iv)[N3] is present at positions 582-584, which are numbered according to SEQ ID NO:982;

[0620] (v)[N4] is present at positions 585-586, which are numbered according to SEQ ID NO:982;

[0621] (vi)[N2]-[N3] are present at positions 577-584, which are numbered according to SEQ ID NO:982; and / or

[0622] (vii)[N0]-[N1]-[N2]-[N3]-[N4] are present at positions 571-586, which are numbered according to SEQ ID NO:982.

[0623] 191. AAV capsid variants of any of embodiments 1-40, 59, 60, 67-98, 139, 140 or 146-190, wherein [N3] is present immediately following [N2].

[0624] 192. AAV capsid variants of any of embodiments 3, 31-40, 68, 94-98, 139, 140 or 146-191, wherein [N4] is present immediately following [N3].

[0625] 193. AAV capsid variants of any of embodiments 1-40, 59, 60, 67-98, 139, 140 or 146-192, which contain [N2]-[N3] from the N-terminus to the C-terminus.

[0626] 194. AAV capsid variants of any of embodiments 1-40, 59, 60, 67-98, 139, 140 or 146-193, which contain [N1]-[N2]-[N3] from the N-terminus to the C-terminus.

[0627] 195. AAV capsid variants of any of embodiments 3, 18, 19, 28-40, 59, 60, 68, 89-98, 139, 140 or 146-194, which contain [N0]-[N1]-[N2]-[N3] from the N-terminus to the C-terminus.

[0628] 196. AAV capsid variants of any of embodiments 3, 18-40, 59, 60, 68, 79-98, 139, 140 or 146-195, which contain [N1]-[N2]-[N3]-[N4] from the N-terminus to the C-terminus.

[0629] 197. AAV capsid variants of any of embodiments 3, 18, 19, 28-40, 59, 60, 68, 89-98, 139, 140 or 146-196, which contain [N0]-[N1]-[N2]-[N3]-[N4] from the N-terminus to the C-terminus.

[0630] 198. An AAV capsid variant of any of embodiments 41-66 or 125-145, wherein [B]-[C] are present in ring VIII, optionally wherein ring VIII comprises positions 571-592 (e.g., amino acid TNNQSSTTAPATGTYNLQEIVP (SEQ ID NO:736)), which are numbered according to SEQ ID NO:138; or positions 571-599, which are numbered according to SEQ ID NO:982.

[0631] 199. An AAV capsid variant of any one of embodiments 42, 52-66, 126, 134-145 or 198, wherein [A] and / or [D] are present in ring VIII, optionally wherein ring VIII comprises positions 571-592 (e.g., amino acid TNNQSSTTAPATGTYNLQEIVP (SEQ ID NO:736)), which are numbered according to SEQ ID NO:138; or positions 571-599, which are numbered according to SEQ ID NO:982.

[0632] 200. An AAV capsid variant of any one of embodiments 42, 52-66, 126, 134-145, 198 or 199, wherein [A]-[B]-[C]-[D] are present in ring VIII, optionally wherein ring VIII comprises positions 571-592 (e.g., amino acid TNNQSSTTAPATGTYNLQEIVP (SEQ ID NO:736)), these positions being numbered according to SEQ ID NO:138; or positions 571-599, these positions being numbered according to SEQ ID NO:982.

[0633] 201. An AAV capsid variant of any of embodiments 41-66, 125-145 or 198-200, wherein [B] is present immediately after position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0634] 202. An AAV capsid variant of any of embodiments 41-66, 125-145 or 198-201, wherein [B] substitution positions 574-576 (e.g., Q574, S575 and S576) are relative to the reference sequence with the amino acid sequence number according to SEQ ID NO:138.

[0635] 203. An AAV capsid variant of any of embodiments 41-66, 125-145 or 198-202, wherein [B] is present immediately after position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138, and wherein [B] replaces positions 574-576 (e.g., Q574, S575 and S576).

[0636] 204. An AAV capsid variant of any of embodiments 41-66, 125-145 or 198-203, wherein [B] is present immediately after position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:982.

[0637] 205. An AAV capsid variant of any of embodiments 41-66, 125-145 or 198-204, wherein [B] substitution positions 574-576 (e.g., Q574, S575 and S576) are relative to the reference sequence with the amino acid sequence number according to SEQ ID NO:982.

[0638] 206. An AAV capsid variant of any of embodiments 41-66, 125-145 or 198-205, wherein [B] is present immediately after position 573 relative to the reference sequence numbered according to SEQ ID NO:982, and wherein [B] replaces positions 574-576 (e.g., Q574, S575 and S576).

[0639] 207. AAV capsid variants of any of embodiments 41-66, 125-145 or 198-206, wherein [B] corresponds to positions 574-576 of SEQ ID NO:982 (e.g., Q574, S575 and S576).

[0640] 208. An AAV capsid variant of any of embodiments 41-66, 125-145 or 198-207, wherein [B]-[C] are present immediately after position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982.

[0641] 209. An AAV capsid variant of any of embodiments 41-66, 125-145 or 198-208, wherein the [B]-[C] substitution positions are 574-577 (e.g., Q574, S575, S576 and T577) relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0642] 210. An AAV capsid variant of any of embodiments 41-66, 125-145 or 198-209, wherein [B]-[C] is present immediately after position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138, and wherein [B]-[C] replaces positions 574-577 (e.g., Q574, S575, S576 and T577).

[0643] 211. AAV capsid variants of any of embodiments 41-66, 125-145 or 198-210, wherein [B]-[C] correspond to positions 574-584 of SEQ ID NO:982 (e.g., Q574, S575, S576, Y577, P578, A579, E580, V581, V582, Q583, K584).

[0644] 212. An AAV capsid variant of any of embodiments 41-66, 125-145 or 198-211, wherein [B]-[C]-[D] are present immediately after position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982.

[0645] 213. An AAV capsid variant of any of embodiments 41-66, 125-145 or 198-212, wherein [B]-[C]-[D] substitution positions 574-579 (e.g., Q574, S575, S576, T577, T578 and A579) are relative to the reference sequence according to the amino acid sequence number of SEQ ID NO:138.

[0646] 214. An AAV capsid variant of any of embodiments 41-66, 125-145 or 198-213, wherein [B]-[C]-[D] is present immediately after position 573 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138, and wherein [B]-[C]-[D] replaces positions 574-579 (e.g., Q574, S575, S576, T577, T578 and A579).

[0647] 215. AAV capsid variants of any of embodiments 41-66, 125-145 or 198-214, wherein [B]-[C]-[D] correspond to positions 574-586 of SEQ ID NO:982 (e.g., Q574, S575, S576, Y577, P578, A579, E580, V581, V582, Q583, K584, T585, A586).

[0648] 216. An AAV capsid variant of any of embodiments 41-66, 125-145 or 198-215, wherein [C] is present immediately after position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0649] 217. An AAV capsid variant of any of embodiments 41-66, 125-145 or 198-216, wherein [C] replaces position 577 (e.g., T577) relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0650] 218. An AAV capsid variant of any of embodiments 41-66, 125-145 or 198-217, wherein [C] is present immediately after position 576 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138, and wherein [C] replaces 577 (e.g., T577).

[0651] 219. AAV capsid variants of any of embodiments 41-66, 125-145 or 198-218, wherein [C] corresponds to position 577-584 of SEQ ID NO:982 (e.g., Y577, P578, A579, E580, V581, V582, Q583, K584).

[0652] 220. An AAV capsid variant of any of embodiments 42, 52-66, 126, 134-145 or 198-219, wherein [A] is present immediately after position 570 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0653] 221. An AAV capsid variant of any of embodiments 42, 52-66, 126, 134-145 or 198-220, wherein the [A] substitution positions are 571-573 (e.g., T571, N572 and N573) relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0654] 222. An AAV capsid variant of any of embodiments 42, 52-66, 126, 134-145 or 198-221, wherein [A] is present immediately after position 570 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138, and wherein [A] replaces positions 571-573 (e.g., T571, N572 and N573).

[0655] 223. An AAV capsid variant of any of embodiments 42, 52-66, 126, 134-145 or 198-222, wherein [A] is present immediately after position 570 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:982.

[0656] 224. An AAV capsid variant of any of embodiments 42, 52-66, 126, 134-145 or 198-223, wherein the [A] substitution positions are 571-573 (e.g., T571, N572 and N573) relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:982.

[0657] 225. An AAV capsid variant of any of embodiments 42, 52-66, 126, 134-145 or 198-224, wherein [A] is present immediately after position 570 relative to the reference sequence numbered according to SEQ ID NO:982, and wherein [A] replaces positions 571-573 (e.g., T571, N572 and N573).

[0658] 226. AAV capsid variants of any of embodiments 42, 52-66, 126, 134-145 or 198-225, wherein [A] corresponds to positions 571-573 of SEQ ID NO:982 (e.g., T571, N572 and N573).

[0659] 227. AAV capsid variants of any of embodiments 42, 52-66, 126, 134-145 or 198-226, wherein [D] is present immediately following position 584 according to SEQ ID NO:982.

[0660] 228. AAV capsid variants of any of embodiments 42, 52-66, 126, 134-145 or 198-227, wherein [D] substitution positions 578 and 579, which are numbered according to SEQ ID NO:138; or positions 585 and 586, which are numbered according to SEQ ID NO:982.

[0661] 229. AAV capsid variants of any of embodiments 42, 52-66, 126, 134-145 or 198-228, wherein [D] is present immediately after position 584 and replaces positions 585 and 586, which are numbered according to SEQ ID NO:982.

[0662] 230. An AAV capsid variant of any of embodiments 42, 52-66, 126, 134-145 or 198-229, wherein [A]-[B]-[C]-[D] are present immediately after position 570 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138 or 982.

[0663] 231. An AAV capsid variant of any of embodiments 42, 52-66, 126, 134-145 or 198-230, wherein [A]-[B]-[C]-[D] substitution positions 571-579 (e.g., T571, N572, N573, Q574, S575, S576, T577, T578 and A579) are used relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0664] 232. An AAV capsid variant of any of embodiments 42, 52-66, 126, 134-145 or 198-231, wherein [A]-[B]-[C]-[D] is present immediately after position 570 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138, and wherein [A]-[B]-[C]-[D] replaces positions 571-579 (e.g., T571, N572, N573, Q574, S575, S576, T577, T578 and A579).

[0665] 233. AAV capsid variants of any of embodiments 42, 52-66, 126, 134-145 or 198-232, wherein [A]-[B]-[C]-[D] correspond to positions 571-586 of SEQ ID NO:982 (e.g., T571, N572, N573, Q574, S575, S576, Y577, P578, A579, E580, V581, V582, Q583, K584, T585, A586).

[0666] 234. AAV capsid variants as described in any of embodiments 42, 52-66, 126, 134-145 or 198-233, wherein:

[0667] (i)X of [A] A X exists at position 571, [A] B It exists at position 572, and [A]'s X C It exists at location 573, which are numbered according to SEQ ID NO:982;

[0668] (ii) X1 of [B] is located at position 574, X2 of [B] is located at position 575, and X3 of [B] is located at position 576, these positions being numbered according to SEQ ID NO:982;

[0669] (iii)[C] exists at locations 577-584, which are numbered according to SEQ ID NO:982; and / or

[0670] (iv) X4 of [D] is present at position 585 and X5 of [D] is present at position 586, these positions are numbered according to SEQ ID NO:982.

[0671] 235. AAV capsid variants as described in any of embodiments 42, 52-66, 126, 134-145 or 198-234, wherein:

[0672] (i)[A] exists at positions 571-573, which are numbered according to SEQ ID NO:982;

[0673] (ii)[B] exists at positions 574-576, which are numbered according to SEQ ID NO:982;

[0674] (iii)[C] exists at positions 577-584, which are numbered according to SEQ ID NO:982;

[0675] (iv)[D] exists at positions 585-586, which are numbered according to SEQ ID NO:982; and / or

[0676] (v)[A]-[B]-[C]-[D] exists at positions 571-586, which are numbered according to SEQ ID NO:982.

[0677] 236. AAV capsid variants as described in any of embodiments 41-66, 125-145 or 198-235, wherein [C] is present immediately following [B].

[0678] 237. AAV capsid variants as described in any of embodiments 42, 61-66, 126, 141-145 or 198-236, wherein [D] is present immediately following [C].

[0679] 238. AAV capsid variants of any of embodiments 41-66, 125-145 or 198-237, which contain [B]-[C] from the N-terminus to the C-terminus.

[0680] 239. AAV capsid variants of any of embodiments 42, 52-66, 126, 134-145 or 198-238, which contain [A]-[B]-[C] from the N-terminus to the C-terminus.

[0681] 240. AAV capsid variants of any of embodiments 42, 61-66, 126, 141-145 or 198-239, which contain [B]-[C]-[D] from the N-terminus to the C-terminus.

[0682] 241. AAV capsid variants of any of embodiments 42, 61-66, 126, 141-145 or 198-240, which contain [A]-[B]-[C]-[D] from the N-terminus to the C-terminus.

[0683] 242. AAV capsid variants as described in any of embodiments 99-124, wherein [K1]-[K2] are present in ring VIII.

[0684] 243. An AAV capsid variant of any of embodiments 100, 92-124 or 242, wherein [K0], [K3] and / or [K4] are present in ring VIII, optionally wherein ring VIII comprises positions 571-592 (e.g., amino acid TNNQSSTTAPATGTYNLQEIVP (SEQ ID NO:736)), which are numbered according to SEQ ID NO:138; or positions 571-599, which are numbered according to SEQ ID NO:982.

[0685] 244. An AAV capsid variant as described in any of embodiments 100, 92-124, 242 or 243, wherein [K0]-[K1]-[K2]-[K3]-[K4] are present in ring VIII, optionally wherein ring VIII comprises positions 571-592 (e.g., amino acid TNNQSSTTAPATGTYNLQ EIVP (SEQ ID NO:736)), these positions being numbered according to SEQ ID NO:138; or positions 571-599, these positions being numbered according to SEQ ID NO:982.

[0686] 245. An AAV capsid variant of any of embodiments 99-124 or 242-244, wherein [K1] is present immediately after position 574 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0687] 246. An AAV capsid variant of any of embodiments 99-124 or 242-245, wherein the [K1] substitution positions are 575-577 (e.g., S575, S576, and T577) relative to the reference sequence with the amino acid sequence number according to SEQ ID NO:138.

[0688] 247. An AAV capsid variant of any of embodiments 99-124 or 242-246, wherein [K1] is present immediately after position 574 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138, and wherein [K1] replaces positions 575-577 (e.g., S575, S576 and T577).

[0689] 248. An AAV capsid variant of any of embodiments 100, 116-124 or 242-247, wherein [K1]-[K2]-[K3] are present immediately after position 574 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0690] 249. An AAV capsid variant of any of embodiments 100, 116-124 or 242-248, wherein the [K1]-[K2]-[K3] substitution positions 575-577 (e.g., S575, S576 and T577) are relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0691] 250. An AAV capsid variant of any of embodiments 100, 116-124 or 242-249, wherein [K1]-[K2]-[K3] is present immediately after position 574 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138, and wherein [K1]-[K2]-[K3] replaces positions 575-577 (e.g., S575, S576 and T577).

[0692] 251. An AAV capsid variant of any of embodiments 100, 121-124 or 242-250, wherein [K1]-[K2]-[K3]-[K4] immediately follows position 574 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0693] 252. An AAV capsid variant of any of embodiments 100, 121-124 or 242-251, wherein the [K1]-[K2]-[K3]-[K4] substitution positions 575-579 (e.g., S575, S576, T577, T578 and A579) are relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0694] 253. An AAV capsid variant as described in any of embodiments 100, 121-124, or 242-252, wherein [K1]-[K2]-[K3]-[K4] is present immediately after position 574 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138, and wherein [K1]-[K2]-[K3]-[K4] replaces positions 575-579 (e.g., S575, S576, T577, T578, and A579).

[0695] 254. An AAV capsid variant of any of embodiments 100, 110-124 or 242-253, wherein [K0] is present immediately after position 570 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0696] 255. An AAV capsid variant of any of embodiments 100, 110-124 or 242-254, wherein [K0] substitution positions 571 to 574 (e.g., T571, N572, N573 and Q574) are relative to the reference sequence according to the amino acid sequence number of SEQ ID NO:138.

[0697] 256. An AAV capsid variant as described in any of embodiments 100, 110-124 or 242-255, wherein [K0] is present immediately after position 570 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138, and wherein [K0] replaces positions 571 to 574 (e.g., T571, N572, N573 and Q574).

[0698] 257. An AAV capsid variant of any of embodiments 100, 121-124 or 242-256, wherein [K0]-[K1]-[K2]-[K3]-[K4] immediately follows position 570 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0699] 258. An AAV capsid variant of any of embodiments 100, 121-124 or 242-257, wherein [K0]-[K1]-[K2]-[K3]-[K4] substitution positions 571-579 (e.g., T571, N572, N573, Q574, S575, S576, T577, T578 and A579) are used relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0700] 259. An AAV capsid variant as described in any of embodiments 100, 121-124, or 242-258, wherein [K0]-[K1]-[K2]-[K3]-[K4] is present immediately after position 570 relative to the reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138, and wherein [K0]-[K1]-[K2]-[K3]-[K4] replaces positions 571-579 (e.g., T571, N572, N573, Q574, S575, S576, T577, T578, and A579).

[0701] 260. AAV capsid variants as described in any of embodiments 100, 116-124 or 242-259, wherein [K3] is present immediately following [K2].

[0702] 261. A variant of the AAV capsid as described in any of embodiments 100, 121-124 or 242-260, wherein [K4] is present immediately following [K3].

[0703] 262. AAV capsid variants of any of embodiments 100, 121-124 or 242-261, which contain [K1]-[K2] from the N-terminus to the C-terminus.

[0704] 263. AAV capsid variants of any of embodiments 100, 116-124 or 242-262, which contain [K1]-[K2]-[K3] from the N-terminus to the C-terminus.

[0705] 264. AAV capsid variants of any of embodiments 100, 116-124 or 242-263, which contain [K0]-[K1]-[K2]-[K3] from the N-terminus to the C-terminus.

[0706] 265. An AAV capsid variant of any of embodiments 100, 121-124 or 242-264, comprising [K1]-[K2]-[K3]-[K4] from the N-terminus to the C-terminus.

[0707] 266. An AAV capsid variant of any of embodiments 100, 121-124 or 242-265, comprising [K0]-[K1]-[K2]-[K3]-[K4] from the N-terminus to the C-terminus.

[0708] 267. An AAV capsid variant (e.g., an AAV5 capsid variant), said AAV capsid variant comprising:

[0709] (a) The amino acid sequence of any of the sequences provided in Tables 1, 2A, 2B, 9 or 15-20;

[0710] (b) An amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive amino acids from any of the sequences provided in Tables 1, 2A, 2B, 9 or 15-20;

[0711] (c) An amino acid sequence containing one, two, or three, but not more than four distinct amino acids, relative to any of the amino acid sequences provided in Tables 1, 2A, 2B, 9, or 15-20; or

[0712] (d) An amino acid sequence relative to any of the amino acid sequences provided in Tables 1, 2A, 2B, 9 or 15-20, containing one, two or three but no more than four modified (e.g., substitution (e.g., conservative substitution), insertion or deletion) amino sequences.

[0713] 268. An AAV capsid variant (e.g., an AAV5 capsid variant), said AAV capsid variant comprising:

[0714] (a) The amino acid sequence of any one of SEQ ID NO: 943, 1021, 1024, 1027, 1112, 1142, 1214, 1232, 1254, 1300, 1310, 1327, 1331, 1342, 1419, 1453, 1533, 1538, 1539, 1575, 1578, 1583-1587, 1590, 1591-1593, 1598-1608 or 1610-1624;

[0715] (b) An amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive amino acids from any one of SEQ ID NO: 943, 1021, 1024, 1027, 1112, 1142, 1214, 1232, 1254, 1300, 1310, 1327, 1331, 1342, 1419, 1453, 1533, 1538, 1539, 1575, 1578, 1583-1587, 1590, 1591-1593, 1598-1608 or 1610-1624;

[0716] (c) An amino acid sequence containing one, two, or three but not more than four distinct amino acids relative to any one of SEQ ID NO: 943, 1021, 1024, 1027, 1112, 1142, 1214, 1232, 1254, 1300, 1310, 1327, 1331, 1342, 1419, 1453, 1533, 1538, 1539, 1575, 1578, 1583-1587, 1590, 1591-1593, 1598-1608, or 1610-1624; or

[0717] (d) An amino acid sequence relative to any one of SEQ ID NO: 943, 1021, 1024, 1027, 1112, 1142, 1214, 1232, 1254, 1300, 1310, 1327, 1331, 1342, 1419, 1453, 1533, 1538, 1539, 1575, 1578, 1583-1587, 1590, 1591-1593, 1598-1608 or 1610-1624, containing one, two or three but no more than four modified (e.g., substitution (e.g., conservative substitution), insertion or deletion) amino sequences.

[0718] 269. An AAV capsid variant (e.g., an AAV5 capsid variant), said AAV capsid variant comprising:

[0719] (a) The amino acid sequence of any one of SEQ ID NO: 943 or 2064-2080;

[0720] (b) An amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive amino acids from any one of SEQ ID NO: 943 or 2064-2080;

[0721] (c) An amino acid sequence comprising one, two, or three, but not more than four, distinct amino acids relative to any one of SEQ ID NO: 943 or 2064-2080; or

[0722] (d) The amino acid sequence relative to any one of SEQ ID NO:943 or 2064-2080 contains one, two, or three but no more than four modified (e.g., substitution (e.g., conservative substitution), insertion, or deletion) amino sequences.

[0723] 270. An AAV capsid variant (e.g., an AAV5 capsid variant), said AAV capsid variant comprising:

[0724] (a) The amino acid sequence of any one of SEQ ID NO: 1021, 1024, 1232, 1300, 1327, 1533, 1538, 1585, 1590 or 1591;

[0725] (b) An amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive amino acids from any one of SEQ ID NO: 1021, 1024, 1232, 1300, 1327, 1533, 1538, 1585, 1590 or 1591;

[0726] (c) An amino acid sequence containing one, two, or three but not more than four distinct amino acids relative to any one of SEQ ID NO: 1021, 1024, 1232, 1300, 1327, 1533, 1538, 1585, 1590, or 1591; or

[0727] (d) The amino acid sequence relative to any one of SEQ ID NO: 1021, 1024, 1232, 1300, 1327, 1533, 1538, 1585, 1590 or 1591 contains one, two or three but no more than four modified (e.g., substitution (e.g., conservative substitution), insertion or deletion) amino sequences.

[0728] 271. An AAV capsid variant of any of embodiments 267-270, comprising at least 3, 4, 5, 6 or 7 consecutive amino acids from any of SEQ ID NO: 943 or 946-966.

[0729] 272. AAV capsid variants as described in embodiments 267-271, wherein the three consecutive amino acids comprise YPA.

[0730] 273. AAV capsid variants of embodiments 267-272, wherein the four consecutive amino acids comprise YPAE (SEQ ID NO: 21).

[0731] 274. The AAV capsid variant of embodiments 267-273, wherein the five consecutive amino acids comprise YPAEV (SEQ ID NO:1).

[0732] 275. An AAV capsid variant of embodiments 267-274, wherein the six consecutive amino acids comprise YPAEVV (SEQ ID NO: 725).

[0733] 276. An AAV capsid variant of embodiments 267-275, wherein the seven consecutive amino acids comprise YPAEVVQ (SEQ ID NO:726).

[0734] 277. An AAV capsid variant of embodiments 267-276, wherein the amino acid sequence comprises YPAEVVQK (SEQ ID NO: 943).

[0735] 278. AAV capsid variants as described in any of embodiments 267, 268, or 270, wherein:

[0736] (i) Three consecutive amino acids contain YTP;

[0737] (ii) The four consecutive amino acids contain YTPS (SEQ ID NO:26);

[0738] (iii) The five consecutive amino acids contain YTPSL (SEQ ID NO:7);

[0739] (iv) The six consecutive amino acids contain YTPSLV (SEQ ID NO:727);

[0740] (v) The seven consecutive amino acids contain YTPSLVQ (SEQ ID NO:728); and / or

[0741] (vi) The amino acid sequence contains YTPSLVQK (SEQ ID NO:952).

[0742] 279. AAV capsid variants as described in any of embodiments 267, 268, or 270, wherein:

[0743] (i) Three consecutive amino acids contain YPP;

[0744] (ii) The four consecutive amino acids contain YPPS (SEQ ID NO:22);

[0745] (iii) The five consecutive amino acids contain YPPSL (SEQ ID NO:2);

[0746] (iv) The six consecutive amino acids contain YPPSLV (SEQ ID NO:729);

[0747] (v) The seven consecutive amino acids contain YPPSLVQ (SEQ ID NO:732); and / or

[0748] (vi) The amino acid sequence contains YPPSLVQK (SEQ ID NO:946).

[0749] 280. AAV capsid variants as described in any of embodiments 267, 268, or 270, wherein:

[0750] (i) Three consecutive amino acids contain YPP;

[0751] (ii) The four consecutive amino acids contain YPPS (SEQ ID NO:22);

[0752] (iii) The five consecutive amino acids contain YPPSL (SEQ ID NO:2);

[0753] (iv) The six consecutive amino acids contain YPPSLE (SEQ ID NO:733);

[0754] (v) Seven consecutive amino acids contain YPPSLEQ (SEQ ID NO:734); and / or

[0755] (vi) The amino acid sequence contains YPPSLEQK (SEQ ID NO:953).

[0756] 281. AAV capsid variants as described in any of embodiments 267, 268, or 270, wherein:

[0757] (i) Three consecutive amino acids contain YPP;

[0758] (ii) The four consecutive amino acids contain YPPS (SEQ ID NO:22);

[0759] (iii) The five consecutive amino acids contain YPPSL (SEQ ID NO:2);

[0760] (iv) The six consecutive amino acids contain YPPSLV (SEQ ID NO:729);

[0761] (v) The seven consecutive amino acids contain YPPSLVK (SEQ ID NO:735); and / or

[0762] (vi) The amino acid sequence contains YPPSLVKK (SEQ ID NO:954).

[0763] 282. An AAV capsid variant of any of embodiments 267-277, comprising an amino acid sequence relative to YPAEVVQK (SEQ ID NO: 943), comprising one, two, or three but not more than four different amino acids.

[0764] 283. An AAV capsid variant of any of embodiments 267, 268, 270 or 278-281, comprising an amino acid sequence relative to any of SEQ ID NO: 1021, 1024, 1232, 1300, 1327, 1533, 1538, 1585, 1590 or 1591, comprising one, two or three but no more than four different amino acid sequences.

[0765] 284. An AAV capsid variant of any of embodiments 267, 268, 270 or 378-281, comprising an amino acid sequence relative to any of SEQ ID NO: 946, 952, 953 or 954, comprising one, two or three but no more than four different amino acid sequences.

[0766] 285. An AAV capsid variant of any of embodiments 267-277 or 282, comprising an amino acid sequence relative to YPAEVVQK (SEQ ID NO: 943) and comprising one, two, or three but no more than four modified (e.g., substitution (e.g., conservative substitution), insertion, or deletion) amino acid sequences.

[0767] 286. An AAV capsid variant of any of embodiments 267, 268, 270, 278-281 or 283, comprising an amino acid sequence relative to any of SEQ ID NO: 1021, 1024, 1232, 1300, 1327, 1533, 1538, 1585, 1590 or 1591, comprising one, two or three but no more than four modified (e.g., substitution (e.g., conservative substitution), insertion or deletion) amino acid sequences.

[0768] 287. An AAV capsid variant of any one of embodiments 267, 268, 270, 278-281 or 284, comprising an amino acid sequence relative to any one of SEQ ID NO: 946, 952, 953 or 954, comprising one, two or three but no more than four modified (e.g., substitution (e.g., conservative substitution), insertion or deletion) amino acid sequences.

[0769] 288. An AAV capsid variant of any of embodiments 267-277, 282, or 285, comprising an amino acid sequence encoded by:

[0770] (i) a nucleotide sequence containing at least one, two, three, four, five, six, or seven modifications (e.g., substitutions) but no more than ten modifications (e.g., substitutions) relative to the nucleotide sequence of SEQ ID NO:944; or

[0771] (ii) A nucleotide sequence containing at least one, two, three, four, five, six or seven but not more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO:944.

[0772] 289. An AAV capsid variant of any of embodiments 267-277, 282, 285, or 289, wherein the nucleotide sequence encoding the amino acid sequence comprises:

[0773] (i) a nucleotide sequence containing at least one, two, three, four, five, six, or seven modifications (e.g., substitutions) but no more than ten modifications (e.g., substitutions) relative to the nucleotide sequence of SEQ ID NO:944; or

[0774] (ii) A nucleotide sequence containing at least one, two, three, four, five, six or seven but not more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO:944.

[0775] 290. AAV capsid variant of embodiment 267, comprising:

[0776] (a) The amino acid sequence of any one of SEQ ID NO: 2024-2063;

[0777] (b) An amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive amino acids from any one of SEQ ID NO:2024-2063;

[0778] (c) An amino acid sequence comprising one, two, or three, but not more than four, distinct amino acids relative to any one of SEQ ID NO: 2024-2063; or

[0779] (d) The amino acid sequence relative to any one of SEQ ID NO:2024-2063 contains one, two, or three but no more than four modified (e.g., substitution (e.g., conservative substitution), insertion, or deletion) amino sequences.

[0780] 291. AAV capsid variants as described in embodiments 267 or 290, wherein the amino acid sequence relative to any one of SEQ ID NO: 2024-2063 comprises one, two, or three but no more than four different amino acids present at one or more of the following locations:

[0781] (i) Position 1, where different amino acids are T or L;

[0782] (ii) Position 2, wherein the different amino acids are N, L, K, A, T or P;

[0783] (iii) Position 3, wherein the different amino acids are N, K, L, A, Y or S;

[0784] (iv) Position 4, wherein the different amino acids are Q, L, T, S, F, Y, K or A;

[0785] (v) Position 5, where the different amino acids are S, H, A, M, Q, T, V or F;

[0786] (vi) Position 6, where the different amino acids are S, P, V, A, Q, L, T, N or M;

[0787] (vii) Position 7, where the different amino acids are Y, H, S, V, A, L or T;

[0788] (viii) Position 8, wherein the different amino acids are D, P, A, Q, F, L, S, H or M;

[0789] (ix) Position 9, where the different amino acids are F, A, L, D or Q;

[0790] (x) Position 10, where the different amino acids are T, E, I or S;

[0791] (xi) Position 11, where different amino acids are V, A, N or S;

[0792] (xii) Position 12, where different amino acids are V, L or P;

[0793] (xiii) Position 13, where the different amino acids are Q, E or P;

[0794] (xiv) position 14, where the different amino acids are K, N, S or L;

[0795] (xv) position 15, where the different amino acids are T, V, M or L; and / or

[0796] (xvi) position 16, where different amino acids are A, G or R.

[0797] 292. AAV capsid variant of embodiment 267, comprising:

[0798] (a) The amino acid sequence of any one of SEQ ID NO:1632-2023;

[0799] (b) An amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive amino acids from any one of SEQ ID NO:1632-2023;

[0800] (c) An amino acid sequence comprising one, two, or three, but not more than four, distinct amino acids relative to any one of SEQ ID NO:1632-2023; or

[0801] (d) The amino acid sequence relative to any one of SEQ ID NO:1632-2023 contains one, two, or three but no more than four modified (e.g., substitution (e.g., conservative substitution), insertion, or deletion) amino sequences.

[0802] 293. AAV capsid variants as described in embodiments 268 or 292, wherein the amino acid sequence relative to any one of SEQ ID NO:1632-2023 comprises one, two, or three but no more than four different amino acids present at one or more of the following locations:

[0803] (i) Position 1, wherein the different amino acids are T, G, N, S, E, L, Y, V or I;

[0804] (ii) Position 2, wherein the different amino acids are D, N, K, E, V, G, R, L, H, F, P, T, A, S, I or Y;

[0805] (iii) Position 3, wherein the different amino acids are Y, N, K, T, W, Q, M, V, C, A, L, F, H, G, R, S or P;

[0806] (iv) Position 4, wherein the different amino acids are H, Q, P, E, R, K, A, S, V, L, T, D, I, G, M or N;

[0807] (v) Position 5, wherein the different amino acids are R, S, K, N, H, G, W, A, P, V, Q, Y, L or F;

[0808] (vi) Position 6, wherein the different amino acids are G, S, F, R, W, H, I, C, M, A, Y, K, N, Q, V, P, E, D, T or L;

[0809] (vii) Position 7, wherein the different amino acids are D, Y, S, I, H, F, P, K, R, G, L, Q, A, M, T, N, V, W, C or E;

[0810] (viii) Position 8, wherein the different amino acids are P, L, Q, T, W, V, G, K, I, Y, N, H, R, D, S, M, A, F or E;

[0811] (ix) Position 9, where the different amino acids are A, R, T, Q, S, M, L, E, K, V, G, D, N, H, F, P or I;

[0812] (x) Position 10, where the different amino acids are K, E, Q, H, V, G, R, S, P, I, N, M, A, L, D or T;

[0813] (xi) Position 11, where the different amino acids are V, A, E, N, R, L, M, T, Q, S, K, C, G, D, Y, P, H, F or I;

[0814] (xii) Position 12, where the different amino acids are V, P, L, S, T, N, A, G, K, R, I, H, E, Q or M;

[0815] (xiii) Position 13, wherein the different amino acids are Q, K, N, A, H, R, T, V, E, I, P, G, S or L;

[0816] (xiv) position 14, where the different amino acids are K, E, I, Y, Q, R, G, D, L, N or S;

[0817] (xv) Position 15, wherein the different amino acids are S, T, N, Q, I, P, E, G, K, M, or H; and / or

[0818] (xvi) position 16, where the different amino acids are A, D, L, Y, Q or T.

[0819] 294. An AAV capsid variant of any of embodiments 267-293, wherein the amino acid sequence is present in ring VIII.

[0820] 295. An AAV capsid variant of any of embodiments 267-294, wherein the amino acid sequence is present immediately following position 570, 571, 572, 573, 574, 575, or 576 relative to a reference sequence numbered according to SEQ ID NO: 138 or 982.

[0821] 296. An AAV capsid variant of any of embodiments 267-295, wherein, relative to a reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138, the amino acid sequence replaces one, two, three, four, five, or all of positions 571, 572, 573, 574, 575, and / or 576 (e.g., positions T571, N572, N573, Q574, S575, S576, T577, T578, and / or A579).

[0822] 297. An AAV capsid variant of any of embodiments 267-296, wherein the amino acid sequence is present immediately after position 576 relative to a reference sequence numbered according to SEQ ID NO: 138 or 982.

[0823] 298. An AAV capsid variant of any of embodiments 267-297, wherein the AAV capsid variant comprises a non-T amino acid residue at position 577 relative to a reference sequence numbered according to the amino acid sequence number of SEQ ID NO:138.

[0824] 299. An AAV capsid variant of any of embodiments 267-298, wherein the AAV capsid variant comprises amino acid Y at position 577 relative to a reference sequence numbered according to amino acid sequence number SEQ ID NO: 138 or 982.

[0825] 300. An AAV capsid variant of any of embodiments 267-299, comprising the substituted T577Y according to SEQ ID NO:138.

[0826] 301. An AAV capsid variant as described in embodiment 298 or 299, wherein the amino acid sequence is or contains YPAEVVQK (SEQ ID NO: 943) and begins at position 577 relative to a reference sequence numbered according to amino acid sequence number SEQ ID NO: 138 or 982.

[0827] 302. An AAV capsid variant of any of embodiments 267-277, 282, 285, 288, 289 or 294-301, comprising a non-T amino acid at position 577, and further comprising the amino acid sequence PAEVVQK (SEQ ID NO:20), said amino acid sequence being present immediately after position 577 relative to the number SEQ ID NO:138.

[0828] 303. An AAV capsid variant of any of embodiments 267-277, 282, 285, 288, 289 or 294-302, comprising amino acid Y at position 577, and further comprising the amino acid sequence PAEVVQK (SEQ ID NO: 20), said amino acid sequence being present immediately after position 577 relative to the number SEQ ID NO: 138.

[0829] 304. An AAV capsid variant of any of embodiments 267-277, 282, 285, 288, 289 or 294-303, comprising amino acid Y at position 577, and further comprising the amino acid sequence PAEVVQK (SEQ ID NO: 20), said amino acid sequence being present immediately after position 577 relative to SEQ ID NO: 982 (e.g., positions 578-584).

[0830] 305. An AAV capsid variant of any one of embodiments 267-277, 282, 285, 288, 289 or 294-304, comprising the amino acid sequence YPAEVVQK (SEQ ID NO: 943), wherein the amino acid sequence is replaced at position 577 (e.g., T577) relative to a reference sequence numbered according to the amino acid sequence number of SEQ ID NO: 138.

[0831] 306. An AAV capsid variant of any one of embodiments 267-277, 282, 285, 288, 289 or 294-305, comprising the amino acid sequence YPAEVVQK (SEQ ID NO: 943), wherein the amino acid sequence is:

[0832] (i) It exists immediately following position 576; and

[0833] (ii) Replace position 577 (e.g., T577),

[0834] In (i) and (ii), the numbers are relative to SEQ ID NO:138.

[0835] 307. An AAV capsid variant of any of embodiments 267-277, 282, 285, 288, 289 or 294-306, further comprising a non-T amino acid (e.g., I) at position 571 relative to the number SEQ ID NO:138 or SEQ ID NO:982.

[0836] 308. An AAV capsid variant of any of embodiments 267-277, 272, 275, 278, 289 or 294-307, further comprising I at position 571 relative to the number SEQ ID NO:138 or SEQ ID NO:982.

[0837] 309. An AAV capsid variant of any of embodiments 267-277, 282, 285, 288, 289 or 294-308, further comprising one, two or all of the following: a non-Q amino acid at position 574 (e.g., A or T), a non-S amino acid at position 575 (e.g., G), and / or a non-S amino acid at position 576 (e.g., A, L, K or R), these positions being relative to SEQ ID NO:138 or SEQ ID NO:982.

[0838] 310. AAV capsid variants of any of embodiments 267-277, 282, 285, 288, 289 or 294-309, further comprising:

[0839] (i) A at position 574, G at position 575, and A at position 576, these positions relative to SEQ ID NO: 138 or 982; or

[0840] (ii) T at position 574 and L at position 576, which are relative to SEQ ID NO: 138 or 982.

[0841] 311. AAV capsid variants of any of embodiments 267-277, 282, 285, 288, 289 or 294-309, further comprising:

[0842] (i) K at position 576 relative to SEQ ID NO: 138 or 982; or

[0843] (ii) R at position 576 relative to SEQ ID NO:138 or 982.

[0844] 312. AAV capsid variants as described in any of embodiments 267-277, 282, 285, 288, 289 or 294-310, comprising:

[0845] (i) A at position 574, G at position 575, A at position 576, and Y at position 577, these positions relative to SEQ ID NO: 138 or 982; and

[0846] (ii) The amino acid sequence of PAEVVQK (SEQ ID NO:20), which is present immediately after position 577 relative to SEQ ID NO:138 or 982.

[0847] 313. An AAV capsid variant of any of embodiments 267-277, 282, 285, 288, 289 or 294-310, comprising:

[0848] (i) T at position 574, L at position 576, and Y at position 577, these positions relative to SEQ ID NO: 138 or 982; and

[0849] (ii) The amino acid sequence of PAEVVQK (SEQ ID NO:20), which is present immediately after position 577 relative to SEQ ID NO:138 or 982.

[0850] 314. AAV capsid variants as described in any of embodiments 267-277, 282, 285, 288, 289, 294-309, or 311, comprising:

[0851] (i) K at position 576 and Y at position 577, these positions being relative to SEQ ID NO: 138 or 982; and

[0852] (ii) The amino acid sequence of PAEVVQK (SEQ ID NO:20), which is present immediately after position 577 relative to SEQ ID NO:138 or 982.

[0853] 315. AAV capsid variants as described in any of embodiments 267-277, 282, 285, 288, 289, 295-309, or 311, comprising:

[0854] (i) R at position 576 and Y at position 577, these positions being relative to SEQ ID NO: 138 or 982; and

[0855] (ii) The amino acid sequence of PAEVVQK (SEQ ID NO:20), which is present immediately after position 577 relative to SEQ ID NO:138 or 982.

[0856] 316. An AAV capsid variant of any of embodiments 267-277, 282, 285, 288, 289, 294-308, comprising:

[0857] (i) I at position 571 and Y at position 577, these positions being relative to SEQ ID NO: 138 or 982; and

[0858] (ii) The amino acid sequence of PAEVVQK (SEQ ID NO:20), which is present immediately after position 577 relative to SEQ ID NO:138 or 982.

[0859] 317. An AAV capsid variant of any one of embodiments 267, 268, 270, 278, 283, 284, 286 or 287, comprising Y at position 577 and the amino acid sequence TPSLVQK (SEQ ID NO: 53), the amino acid sequence being present immediately following position 577, all of which are numbered according to SEQ ID NO: 138 or 982.

[0860] 318. An AAV capsid variant of any one of embodiments 267, 268, 270, 279, 283, 284, 286 or 287, comprising Y at position 577 and the amino acid sequence PPSLVQK (SEQ ID NO: 47), the amino acid sequence being present immediately following position 577, all of which are numbered according to SEQ ID NO: 138 or 982.

[0861] 319. An AAV capsid variant of any one of embodiments 267, 268, 270, 280, 283, 284, 286 or 287, comprising Y at position 577 and the amino acid sequence PPSLEQK (SEQ ID NO: 54), the amino acid sequence being present immediately following position 577, all of which are numbered according to SEQ ID NO: 138 or 982.

[0862] 320. An AAV capsid variant of any one of embodiments 267, 268, 270, 281, 283, 284, 286 or 287, comprising Y at position 577 and the amino acid sequence PPSLVKK (SEQ ID NO: 55), the amino acid sequence being present immediately following position 577, all of which are numbered according to SEQ ID NO: 138 or 982.

[0863] 321. AAV capsid variants as described in any of the foregoing embodiments, further comprising modifications (e.g., insertions, substitutions (e.g., conservative substitutions) and / or deletions) in rings I, II, IV and / or VI).

[0864] 322. An AAV capsid variant of any of the foregoing embodiments, comprising an amino acid sequence relative to SEQ ID NO:138, comprising at least one, two, or three modified (e.g., substitution (e.g., conservative substitution), insertion, or deletion) amino acid sequences, but not exceeding 30, 20, or 10 modified (e.g., substitution (e.g., conservative substitution), insertion, or deletion) amino acid sequences.

[0865] 323. An AAV capsid variant of any of the foregoing embodiments, comprising an amino acid sequence relative to SEQ ID NO:138, comprising at least one, two, or three, but not exceeding 30, 20, or 10 different amino acids.

[0866] 324. An AAV capsid variant as described in any of the foregoing embodiments, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO:138, or an amino acid sequence having at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity with it.

[0867] 325. An AAV capsid variant of any of the foregoing embodiments, comprising the amino acid sequence of SEQ ID NO:138.

[0868] 326. An AAV capsid variant as described in any of the foregoing embodiments, wherein the AAV capsid variant comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 137, or a sequence having at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity with it.

[0869] 327. An AAV capsid variant as described in any of the foregoing embodiments, wherein the nucleotide sequence encoding the capsid variant comprises the nucleotide sequence of SEQ ID NO:137, or a sequence having at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity with it.

[0870] 328. An AAV capsid variant of any of the foregoing embodiments, comprising VP1 protein, VP2 protein, VP3 protein, or a combination thereof.

[0871] 329. An AAV capsid variant of any one of embodiments 1-98, 125-242, 267-277, 282, 285, 288, 289, 294-306 or 321-328, wherein the AAV capsid variant comprises an amino acid sequence corresponding to positions 137-731 (e.g., VP2) of SEQ ID NO:982, or a sequence having at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98 or 99%) sequence identity with it.

[0872] 330. An AAV capsid variant as described in any of embodiments 1-98, 125-242, 267-277, 282, 285, 288, 289, 294-306 or 321-329, said AAV capsid variant comprising an amino acid sequence corresponding to positions 193-731 (e.g., VP3) of SEQ ID NO:982, or a sequence having at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98 or 99%) sequence identity with it.

[0873] 331. An AAV capsid variant of any one of embodiments 1-321, said AAV capsid variant comprising an amino acid sequence corresponding to positions 137-724 (e.g., VP2) of SEQ ID NO:138, or a sequence having at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98 or 99%) sequence identity with it.

[0874] 332. An AAV capsid variant of any one of embodiments 1-321, said AAV capsid variant comprising an amino acid sequence corresponding to positions 193-724 (e.g., VP3) of SEQ ID NO:138, or a sequence having at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity with it.

[0875] 333. An AAV capsid variant of any one of embodiments 267-277, 282, 285, 288, 289, 294-306, or 321-328, comprising an amino acid sequence comprising at least 3, 4, 5, or 6 consecutive amino acids comprising an amino acid sequence from YPAEVVQK (SEQ ID NO: 943), wherein:

[0876] (i) Three consecutive amino acids contain YPA;

[0877] (ii) The four consecutive amino acids contain YPAE (SEQ ID NO:21);

[0878] (iii) The five consecutive amino acids contain YPAEV (SEQ ID NO:1);

[0879] (iv) The six consecutive amino acids contain YPAEVV (SEQ ID NO:725);

[0880] (v) The seven consecutive amino acids contain YPAEVVQ (SEQ ID NO:726);

[0881] The AAV capsid variant contains the amino acid sequence of SEQ ID NO:739, or an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:739.

[0882] 334. An AAV capsid variant of any one of embodiments 267-277, 282, 285, 288, 289, 294-306, 321-328, or 333, comprising an amino acid sequence comprising at least 3, 4, 5, or 6 consecutive amino acids comprising an amino acid sequence from YPAEVVQK (SEQ ID NO: 943), wherein:

[0883] (i) Three consecutive amino acids contain YPA;

[0884] (ii) The four consecutive amino acids contain YPAE (SEQ ID NO:21);

[0885] (iii) The five consecutive amino acids contain YPAEV (SEQ ID NO:1);

[0886] (iv) The six consecutive amino acids contain YPAEVV (SEQ ID NO:725);

[0887] (v) The seven consecutive amino acids contain YPAEVVQ (SEQ ID NO:726);

[0888] The AAV capsid variants comprise: (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO:138 or SEQ ID NO:982; (b) a VP2 protein comprising the amino acid sequence of positions 137-724 of SEQ ID NO:138 or positions 137-731 of SEQ ID NO:982; (c) a VP3 protein comprising the amino acid sequence of positions 193-724 of SEQ ID NO:138 or positions 193-731 of SEQ ID NO:982; or (d) an amino acid sequence having at least 90% (e.g., at least about 95, 96, 97, 98, or 99%) sequence identity with any of the amino acid sequences in (a)-(c).

[0889] 335. An AAV capsid variant of any one of embodiments 267-277, 282, 285, 288, 289, 294-306, 321-328, or 334, comprising, relative to the amino acid sequence of YPAEVVQK (SEQ ID NO: 943), one, two, or three, but not more than four, distinct amino acids, wherein the AAV capsid variant comprises:

[0890] (a) VP1 protein containing the amino acid sequence of SEQ ID NO:138 or SEQ ID NO:982;

[0891] (b) The VP2 protein containing the amino acid sequence at positions 137-724 of SEQ ID NO:138 or positions 137-731 of SEQ ID NO:982;

[0892] (c) A VP3 protein containing the amino acid sequence of SEQ ID NO:138 positions 193-724 or SEQ ID NO:982 positions 193-731; or

[0893] (d) An amino acid sequence that has at least 90% (e.g., at least about 95, 96, 97, 98 or 99%) sequence identity with any amino acid sequence in (a)-(c).

[0894] 336. An AAV capsid variant of any one of embodiments 267-277, 282, 285, 288, 289, 294-306, 321-328 or 333-335, wherein, relative to the amino acid sequence of YPAEVVQK (SEQ ID NO: 943), the AAV capsid variant comprises one, two or three but no more than four different amino acids, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 739; or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence of SEQ ID NO: 739.

[0895] 337. An AAV capsid variant of any one of embodiments 267-277, 282, 285, 288, 289, 294-306, 321-328 or 333-336, relative to the amino acid sequence of YPAEVVQK (SEQ ID NO: 943), wherein the AAV capsid variant comprises one or two but no more than three substitutions, wherein the AAV capsid variant comprises an amino acid sequence that is at least 90% (e.g., at least about 95, 96, 97, 98 or 99%) identical to the amino acid sequence of SEQ ID NO: 982.

[0896] 338. An AAV capsid variant of any one of embodiments 1-98, 125-241, 267-277, 282, 285, 288, 289, 294-306, 321-328 or 333-337, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO:982, or an amino acid sequence having at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98 or 99%) sequence identity with it.

[0897] 339. An AAV capsid variant of any one of embodiments 1-98, 125-241, 267-277, 282, 285, 288, 289, 294-306, 321-328 or 333-338, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO:982, or an amino acid sequence having at least 95% identity with it.

[0898] 340. An AAV capsid variant of any one of embodiments 1-98, 125-241, 267-277, 282, 285, 288, 289, 294-306, 321-328 or 333-339, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO:982, or an amino acid sequence having at least 98% identity with it.

[0899] 341. An AAV capsid variant of any one of embodiments 1-98, 125-241, 267-277, 282, 285, 288, 289, 294-306, 321-328 or 333-340, comprising an amino acid sequence relative to SEQ ID NO:982, comprising at least one, two or three modified (e.g., substitution (e.g., conservative substitution), insertion or deletion) but not more than 30, 20 or 10 modified (e.g., substitution (e.g., conservative substitution), insertion or deletion) amino acid sequences.

[0900] 342. An AAV capsid variant of any one of embodiments 1-98, 125-241, 267-277, 282, 285, 288, 289, 294-306, 321-328 or 333-341, comprising an amino acid sequence relative to SEQ ID NO:982, comprising at least one, two or three but not more than 30, 20 or 10 different amino acids.

[0901] 343. An AAV capsid variant of any one of the aforementioned embodiments 1-98, 125-241, 267-277, 282, 285, 288, 289, 294-306, 321-328 or 333-342, wherein the nucleotide sequence encoding the capsid variant comprises the nucleotide sequence of SEQ ID NO: 984, or a nucleotide sequence having at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98 or 99%) sequence identity with it.

[0902] 344. An AAV capsid variant as described in any of the foregoing embodiments, wherein the nucleotide sequence encoding the capsid variant is codon-optimized.

[0903] 345. An AAV capsid variant (e.g., an AAV5 capsid variant) comprising an amino acid sequence as described in any one of embodiments 267-277, 282, 285, 288, 289, 294-306, 321-328, or 333-342, and further comprising an amino acid sequence that is at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) identical to SEQ ID NO:982.

[0904] 346. An AAV capsid variant (e.g., an AAV5 capsid variant) comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 739, wherein the AAV capsid variant comprises the amino acid sequence of YPAEVVQK (SEQ ID NO: 943).

[0905] 347. An AAV capsid variant as described in embodiment 346, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO:739.

[0906] 348. An AAV capsid variant (e.g., an AAV5 capsid variant) comprising the amino acid sequence of SEQ ID NO:982.

[0907] 349. An AAV capsid variant (e.g., an AAV5 capsid variant) comprising an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:984, or a nucleotide sequence that is at least 95% identical thereto.

[0908] 350. An AAV capsid variant of any one of embodiments 1-66, 139, 140, 146-241, 267, 268, 270-289 or 294-349, having an increased tropism for CNS cells or tissues (e.g., brain cells, brain tissue, spinal cord cells or spinal cord tissue) relative to a reference sequence containing the amino acid sequence of SEQ ID NO: 138.

[0909] 351. An AAV capsid variant of any one of embodiments 1-66, 139, 140, 146-241, 267, 268, 270-289 or 294-350, wherein the AAV capsid variant exhibits increased tropism toward CNS cells or tissues (e.g., brain cells, brain tissue, spinal cord cells or spinal cord tissue) relative to a reference sequence containing the amino acid sequence of SEQ ID NO: 982.

[0910] 352. An AAV capsid variant of any one of embodiments 1-66, 139, 140, 146-241, 267, 268, 270-289 or 294-351, having an increased tropism for CNS cells or tissues (e.g., brain cells, brain tissue, spinal cord cells or spinal cord tissue) relative to a reference sequence containing the amino acid sequence of SEQ ID NO: 139.

[0911] 353. AAV capsid variants of any of embodiments 1-66, 139, 140, 146-241, 267, 268, 270-289, or 294-352, whose transduction brain regions, such as the temporal lobe cortex, perinatal cortex, globus pallidus, putamen, caudate nucleus, thalamus, hippocampus, geniculate nucleus, Purkinje layer, deep cerebellar nuclei, and / or cerebellum, optionally wherein such transduction regions are associated with SEQ ID NO. Compared to the reference sequence of NO:139, the transduction level is at least 1.5, 2.2, 2.4, 2.5, 2.6, 2.7, 3.0, 3.2, 3.5, 3.7, 4.0, 4.2, 4.5, 4.7, 4.9, 5, 10, 15, 20, 25, 30, or 35 times larger, for example, when measured by assays such as immunohistochemistry or qPCR, as described in Example 2.

[0912] 354. An AAV capsid variant of any one of embodiments 1-66, 139, 140, 146-241, 267, 268, 270-289 or 294-353, wherein the AAV capsid variant is enriched in the brain by at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 25, 30, 35, 40, 45, 50, 55, 60 or 65 times, for example, when measured by a determination as described in Example 1.

[0913] 355. An AAV capsid variant of any one of embodiments 1-66, 139, 140, 146-241, 267, 268, 270-289 or 294-354, wherein the AAV capsid variant is enriched in the brain by at least about 10, 12, 15, 17, 20, 25, 30, 35, 40, 45, 50, 55, 60, 61, 62, 63, 64 or 65 times compared with the reference sequence of SEQ ID NO:138, for example when measured by a determination as described in Example 1.

[0914] 356. An AAV capsid variant of any one of embodiments 1-66, 139, 140, 146-241, 267, 268, 270-289 or 294-355, which is enriched in the brains of at least two to three species (e.g., non-human primates and rodents (e.g., rats and / or mice)), for example, as compared with the reference sequence of SEQ ID NO:138.

[0915] 357. An AAV capsid variant of any one of embodiments 1-66, 139, 140, 146-241, 267, 268, 270-289 or 294-356, which, compared with the reference sequence of SEQ ID NO:138, is enriched at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 25, 30, 35, 40, 45 times in the brains of at least two to three species (e.g., non-human primates and rodents (e.g., rats and / or mice)), for example when measured by a assay as described in Examples 1, 2, 4 and 5.

[0916] 358. AAV capsid variants as described in embodiments 356 or 357, wherein the at least two to three species are cynomolgus monkeys, West African green monkeys, common marmosets, rats and / or mice (e.g., BALB / c mice).

[0917] 359. An AAV capsid variant of any one of embodiments 1-66, 139, 140, 146-241, 267, 268, 270-289 or 294-358, which, compared with the reference sequence of SEQ ID NO:982, is enriched in the brain by at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 125, 150, 175, 200 or 225 times, for example, when measured by a determination as described in Example 4.

[0918] 360. An AAV capsid variant of any one of embodiments 1-66, 139, 140, 146-241, 267, 268, 270-289 or 294-359, which delivers an increased level of payload to a brain region, optionally wherein the level of payload is increased by at least 20, 25, 30, or 35 times compared to the reference sequence of SEQ ID NO: 139, for example when measured by an assay such as qRT-PCR or qPCR (e.g., as described in Example 2).

[0919] 361. An AAV capsid variant of any one of embodiments 1-66, 139, 140, 146-241, 267, 268, 270-289 or 294-360, which delivers elevated levels of viral genome to brain regions, optionally wherein the level of viral genome is increased by at least 1.5, 2.2, 2.4, 2.5, 2.6, 2.7, 3.0, 3.2, 3.5, 3.7, 4.0, 4.2, 4.5, 4.7, 4.9 or 5 times compared to the reference sequence of SEQ ID NO:139, for example when measured by an assay such as qRT-PCR or qPCR (e.g., as described in Example 2).

[0920] 362. AAV capsid variants as described in any of embodiments 350-361, wherein the brain region is the temporal lobe cortex, pernasal cortex, globus pallidus, putamen, caudate nucleus, thalamus, hippocampus, geniculate nucleus, Purkinje layer, deep cerebellar nuclei, cerebellum, or a combination thereof.

[0921] 363. An AAV capsid variant of any one of embodiments 1-66, 139, 140, 146-241, 267, 268, 270-289 or 294-362, wherein the AAV capsid variant is enriched in the spinal cord region by at least about 3, 3.5, 4.0, 4.5, 5, 5.0, 6.0 or 6.5 times, compared with the reference sequence of SEQ ID NO:139, for example when measured by a determination as described in Example 2.

[0922] 364. AAV capsid variant of any of embodiments 363, wherein the spinal cord region is the cervical region, lumbar region, thoracic region, or a combination thereof.

[0923] 365. The AAV capsid variant of any of the foregoing embodiments exhibits preferential transduction in the brain region relative to transduction in the dorsal root ganglion (DRG).

[0924] 366. AAV capsid variants of any of embodiments 1-66, 139, 140, 146-241, 267, 268, 270-289 or 294-365 that are capable of transducing neuronal cells.

[0925] 367. AAV capsid variants of any of embodiments 1-66, 139, 140, 146-241, 267, 268, 270-289 or 294-366, which are capable of transducing non-neuronal cells, such as glial cells (e.g., oligodendrocytes).

[0926] 368. An AAV capsid variant of any of embodiments 1-66, 139, 140, 146-241, 267, 268, 270-289 or 294-367, wherein the AAV capsid variant exhibits preferential transduction in a brain region relative to transduction in the liver.

[0927] 369. An AAV capsid variant of any one of embodiments 67-267, 269, 271-277, 282, 285, 288, 289, 294-306 or 321-349, having an increased tropism for cardiac cells or cardiac tissue (e.g., ventricles or atria) relative to a reference sequence containing the amino acid sequence of SEQ ID NO: 138.

[0928] 370. An AAV capsid variant of any one of embodiments 67-267, 269, 271-277, 282, 285, 288, 289, 294-306, 321-349 or 369, having an increased tropism for cardiac cells or tissues (e.g., ventricles or atria) relative to a reference sequence containing the amino acid sequence of SEQ ID NO: 139.

[0929] 371. An AAV capsid variant of any one of embodiments 67-267, 269, 271-277, 282, 285, 288, 289, 294-306, 321-349, 369 or 370, which delivers an increased level of payload to the cardiac region, optionally wherein the level of payload is increased by at least 1.5, 2 or 2.5 times compared to the reference sequence of SEQ ID NO:139, for example when measured by an assay such as IHC assay or RT-ddPCR assay (e.g., as described in Example 2).

[0930] 372. An AAV capsid variant of any one of embodiments 67-267, 269, 271-277, 282, 285, 288, 289, 294-306, 321-349 or 369-371, having an increased tropism for cardiac cells or tissues (e.g., ventricles or atria) relative to a reference sequence containing the amino acid sequence of SEQ ID NO: 982.

[0931] 373. An AAV capsid variant of any one of embodiments 67-267, 269, 271-277, 282, 285, 288, 289, 294-306, 321-349 or 369-372, which is enriched in the heart by at least about 4, 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 times compared with the reference sequence of SEQ ID NO:982, for example when measured by a assay as described in Example 4.

[0932] 374. An AAV capsid variant of any one of embodiments 267, 290, 291, 321-328, 331, 332 or 344, having an increased tendency toward muscle cells or tissues relative to a reference sequence containing the amino acid sequence of SEQ ID NO: 982.

[0933] 375. An AAV capsid variant of any one of embodiments 267, 290, 291, 321-328, 331, 332, 344 or 374, which is enriched in muscle by at least about 2, 3, 4, 5, 10, 15, 20, 25, 30 or 35 times compared to the reference sequence of SEQ ID NO: 982, for example when measured by a determination as described in Example 4.

[0934] 376. AAV capsid variants as described in embodiments 374 or 375, wherein the muscle cells or tissue are cardiac muscle (e.g., ventricle or atrium or both), quadriceps femoris or both.

[0935] 377. An AAV capsid variant of any one of embodiments 267, 292, 293, 321-328, 331, 332 or 344, having an increased tropism for hepatocytes or tissues relative to a reference sequence containing the amino acid sequence of SEQ ID NO: 982.

[0936] 378. An AAV capsid variant of any one of embodiments 267, 292, 293, 321-328, 331, 332, 344 or 377, wherein the AAV capsid variant is enriched in the liver by at least about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 115, 120, 130, 140, 150, 160, 170, 180, 185 or 190 times, for example, when measured by a assay as described in Example 4.

[0937] 379. A polynucleotide encoding an AAV capsid variant as described in any one of embodiments 1-378.

[0938] 380. The polynucleotide of embodiment 379, comprising:

[0939] (i) A nucleotide sequence containing at least one, two, three, four, five, six or seven modifications (e.g., substitutions) but no more than ten modifications (e.g., substitutions) relative to the nucleotide sequence of SEQ ID NO:944;

[0940] (ii) A nucleotide sequence containing at least one, two, three, four, five, six, or seven but not more than ten distinct nucleotides relative to the nucleotide sequence of SEQ ID NO:944; or

[0941] (iii) The nucleotide sequence of SEQ ID NO:944, or a nucleotide sequence that is substantially the same as it (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity).

[0942] 381. A polynucleotide as described in embodiments 379 or 380, said polynucleotide comprising the nucleotide sequence of SEQ ID NO: 984, or a nucleotide sequence having at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity with it.

[0943] 382. A polynucleotide encoding an AAV capsid variant (e.g., an AAV5 capsid variant), wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO:984.

[0944] 383. A polynucleotide encoding an AAV capsid variant (e.g., an AAV5 capsid variant), wherein the encoded AAV capsid variant comprises the amino acid sequence of SEQ ID NO:982.

[0945] 384. A polynucleotide encoding an AAV capsid variant (e.g., an AAV5 capsid variant), wherein the encoded AAV capsid variant comprises:

[0946] (a) The amino acid sequence of any of the sequences provided in Tables 1, 2A, 2B, 9 or 15-20;

[0947] (b) An amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive amino acids from any of the sequences provided in Tables 1, 2A, 2B, 9, or 15-20; or

[0948] (c) An amino acid sequence containing one, two, or three, but not more than four distinct amino acids, relative to any of the amino acid sequences provided in Tables 1, 2A, 2B, 9, or 15-20; or

[0949] (d) An amino acid sequence that contains one, two, or three, but no more than four modifications (e.g., substitution (e.g., conservative substitution), insertion, or deletion) relative to any of the amino acid sequences provided in Tables 1, 2A, 2B, 9, or 15-20.

[0950] 385. A polynucleotide encoding an AAV capsid variant (e.g., an AAV5 capsid variant), wherein the encoded AAV capsid variant comprises:

[0951] (i) The amino acid sequence of YPAEVVQK (SEQ ID NO: 943);

[0952] (ii) An amino acid sequence containing one, two, or three but no more than four different amino acids relative to the amino acid sequence of YPAEVVQK (SEQ ID NO: 943);

[0953] (iii) An amino acid sequence containing one, two, or three modifications (e.g., substitutions (e.g., conservative substitutions)) but no more than four modifications (e.g., substitutions (e.g., conservative substitutions)) relative to the amino acid sequence of YPAEVVQK (SEQ ID NO: 943); or

[0954] (iv) At least 3, 4, 5, 6 or 7 consecutive amino acids from the amino acid sequence of YPAEVVQK (SEQ ID NO:943).

[0955] 386. A polynucleotide as described in any of embodiments 384 or 385, comprising:

[0956] (i) The nucleotide sequence of SEQ ID NO:944, or a nucleotide sequence that is substantially the same as it (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity);

[0957] (ii) A nucleotide sequence containing at least one, two, three, four, five, six, or seven but not more than ten distinct nucleotides relative to the nucleotide sequence of SEQ ID NO:944; or

[0958] (iii) A nucleotide sequence containing at least one, two, three, four, five, six or seven modifications (e.g., substitution, insertion or deletion) but no more than ten modifications (e.g., substitution, insertion or deletion) relative to the nucleotide sequence of SEQ ID NO:944.

[0959] 387. A polynucleotide as described in any one of embodiments 384-386, wherein the AAV capsid variant comprises:

[0960] (i) The amino acid sequence of SEQ ID NO:982, or an amino acid sequence having at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98 or 99%) sequence identity with it;

[0961] (ii) An amino acid sequence containing one, two, or three but no more than four different amino acids relative to the amino acid sequence of SEQ ID NO:982; or

[0962] (iii) An amino acid sequence containing one, two, or three modifications (e.g., substitution (e.g., conservative substitution), insertion, or deletion) but not more than 30, 20, or 10 modifications (e.g., substitution (e.g., conservative substitution), insertion, or deletion) relative to the amino acid sequence of SEQ ID NO:982.

[0963] 388. A polynucleotide as described in any one of embodiments 384-387, said polynucleotide comprising the nucleotide sequence of SEQ ID NO:984, or a nucleotide sequence having at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity with it.

[0964] 389. A polynucleotide as described in any of embodiments 384-388, comprising a codon-optimized nucleotide sequence.

[0965] 390. A peptide comprising:

[0966] (a) The amino acid sequence of any of the sequences provided in Tables 1, 2A, 2B, 9 or 15-20;

[0967] (b) An amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive amino acids from any of the sequences provided in Tables 1, 2A, 2B, 9, or 15-20; or

[0968] (c) An amino acid sequence containing one, two, or three, but not more than four distinct amino acids, relative to any of the amino acid sequences provided in Tables 1, 2A, 2B, 9, or 15-20; or

[0969] (d) An amino acid sequence relative to any of the amino acid sequences provided in Tables 1, 2A, 2B, 9 or 15-20, containing one, two or three but no more than four modified (e.g., substitution (e.g., conservative substitution), insertion or deletion) amino sequences.

[0970] 391. A peptide comprising:

[0971] (i) The amino acid sequence of YPAEVVQK (SEQ ID NO: 943);

[0972] (ii) An amino acid sequence containing one, two, or three but no more than four different amino acids relative to the amino acid sequence of YPAEVVQK (SEQ ID NO: 943);

[0973] (iii) An amino acid sequence containing one, two, or three modifications (e.g., substitutions (e.g., conservative substitutions)) but no more than four modifications (e.g., substitutions (e.g., conservative substitutions)) relative to the amino acid sequence of YPAEVVQK (SEQ ID NO: 943); or

[0974] (iv) At least 3, 4, 5, 6 or 7 consecutive amino acids from the amino acid sequence of YPAEVVQK (SEQ ID NO:943).

[0975] 392. A peptide comprising the amino acid sequence YPAEVVQK (SEQ ID NO: 943).

[0976] 393. A peptide encoded by the following:

[0977] (i) the nucleotide sequence of SEQ ID NO:944, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or

[0978] (ii) A nucleotide sequence containing at least one, two, three, four, five, six or seven but not more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO:944;

[0979] (iii) A nucleotide sequence containing at least one, two, three, four, five, six or seven modifications (e.g., substitution, insertion or deletion) but no more than ten modifications (e.g., substitution, insertion or deletion) relative to the nucleotide sequence of SEQ ID NO:944.

[0980] 394. A peptide, wherein the nucleotide sequence encoding said peptide comprises:

[0981] (i) The nucleotide sequence of SEQ ID NO:944, or a nucleotide sequence that is substantially the same as it (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity);

[0982] (ii) A nucleotide sequence containing at least one, two, three, four, five, six, or seven but not more than ten distinct nucleotides relative to the nucleotide sequence of SEQ ID NO:944; or

[0983] (iii) A nucleotide sequence containing at least one, two, three, four, five, six or seven modifications (e.g., substitution, insertion or deletion) but no more than ten modifications (e.g., substitution, insertion or deletion) relative to the nucleotide sequence of SEQ ID NO:944.

[0984] 395. An AAV capsid variant (e.g., an AAV5 capsid variant) comprising a peptide as described in any one of embodiments 390-394.

[0985] 396. An AAV capsid variant (e.g., an AAV5 capsid variant) encoded by a polynucleotide as described in any one of embodiments 382-389.

[0986] 397. An AAV particle comprising an AAV capsid variant as described in any one of embodiments 1-378, 395 or 396.

[0987] 398. An AAV particle as described in embodiment 399, wherein the AAV particle contains a nucleotide sequence encoding a payload.

[0988] 399. An AAV particle as described in embodiment 398, wherein the encoded payload comprises a therapeutic protein or a functional variant thereof; an antibody or antibody fragment; an enzyme; a component of a gene editing system; an RNAi agent (e.g., dsRNA, siRNA, shRNA, precursor miRNA, primary miRNA, miRNA, stRNA, lncRNA, piRNA, or snoRNA); or a combination thereof.

[0989] 400. AAV particles as described in embodiment 399, wherein the therapeutic protein or a functional variant thereof (e.g., a recombinant protein) is associated with (e.g., a neurological or neurodegenerative disease, muscle or neuromuscular disease, or neurotumor disease) (e.g., aberrantly expressed therein).

[0990] 401. The AAV particles of embodiment 399 or 400, wherein the therapeutic protein or a functional variant thereof is selected from apolipoprotein E (APOE) (e.g., ApoE2, ApoE3 and / or ApoE4); human motor neuron survival protein (SMN) 1 or SMN2; glucocerebrosidase (GBA1); aromatic L-amino acid decarboxylase (AADC); aspartate acylase (ASPA); tripeptidyl peptidase I (CLN2); β-galactosidase (GLB1); N-sulfoglucosamine sulfonylhydrolase (SGSH); N-acetyl-α-aminoglucosidase (NAGLU); idose 2-sulfatase (IDS); intracellular cholesterol transporter (NPC1); macroaxon neuron (GAN); or combinations thereof.

[0991] 402. The AAV particle of embodiment 399, wherein the antibody or antibody-binding fragment binds to:

[0992] (i) CNS-related targets, such as antigens associated with neurological or neurodegenerative diseases, such as β-amyloid, APOE, tau, SOD1, TDP-43, huntingtin (HTT) and / or synuclein;

[0993] (ii) Muscle or neuromuscular targets, such as antigens associated with muscle or neuromuscular disorders; or

[0994] (iii) Neuro-oncology-related targets, such as antigens associated with neuro-oncological conditions, such as HER2 or EGFR (e.g., EGFRvIII).

[0995] 403. The AAV particle of embodiment 399, wherein the enzyme comprises a wide range of nucleases, zinc finger nucleases, TALENs, recombinases, integrases, base editors, Cas9, or fragments thereof.

[0996] 404. The AAV particle of embodiment 399, wherein the components of the gene editing system comprise one or more components of the CRISPR-Cas system.

[0997] 405. An AAV particle as described in embodiment 404, wherein one or more components of the CRISPR-Cas system comprise Cas9, such as a Cas9 ortholog or Cpf1, and a single guide RNA (sgRNA), optionally wherein:

[0998] (i) The sgRNA is located upstream (5') of the Cas9 enzyme; or

[0999] (ii) The sgRNA is located downstream of the Cas9 enzyme (3').

[1000] 406. The AAV particle of embodiment 399, wherein the RNAi agent (e.g., dsRNA, siRNA, shRNA, precursor miRNA, primary miRNA, miRNA, stRNA, lncRNA, piRNA, or snoRNA) regulates (e.g., inhibits) the expression of CNS-related genes, mRNAs, and / or proteins.

[1001] 407. The AAV particle of embodiment 406, wherein the CNS-related gene is selected from SOD1, MAPT, APOE, HTT, C9ORF72, TDP-43, APP, BACE, SNCA, ATXN1, ATXN3, ATXN7, SCN1A-SCN5A, SCN8A-SCN11A or a combination thereof.

[1002] 408. An AAV particle as described in any of embodiments 397-407, comprising a viral genome containing a promoter operatively linked to a nucleic acid sequence encoding the payload.

[1003] 409. The AAV particle of embodiment 408, wherein the promoter is selected from human elongation factor 1α-subunit (EF1α), cytomegalovirus (CMV) immediate early enhancer and / or promoter, chicken β-actin (CBA) and its derivative CAG, β-glucuronidase (GUSB) or ubiquitin C (UBC), neuron-specific enolase (NSE), platelet-derived growth factor (PDGF), platelet-derived growth factor B chain (PDGF-β), intercellular adhesion molecule 2 (ICAM-2), synaptic protein (Syn), methyl-CpG binding protein 2 (MeCP2), Ca2+ / calmodulin-dependent protein Leukokinase II (CaMKII), metabolized glutamate receptor 2 (mGluR2), neurofilament light chain (NFL) or neurofilament heavy chain (NFH), β-globulin microgene nβ2, proenkephalinogen (PPE), enkephalin (Enk) and excitatory amino acid transporter 2 (EAAT2), glial fibrillary acidic protein (GFAP), myelin basic protein (MBP), cardiovascular promoters (e.g., αMHC, cTnT and CMV-MLC2k), liver promoters (e.g., hAAT, TBG), skeletal muscle promoters (e.g., desmin, MCK, C512) or functional fragments (e.g., truncated) or functional variants thereof.

[1004] 410. The AAV particle as described in embodiment 408 or 409, wherein the promoter is an EF-1a promoter variant, such as a truncated EF-1a promoter.

[1005] 411. An AAV particle of any of embodiments 408-410, wherein the promoter comprises a nucleotide sequence of any one of SEQ ID NO: 2100, 2101, 2103, 2104, 2108, 2109, 2111-2120, or any one of the following: nucleotide sequences provided in Table 8, comprising at least one, two, three, four, five, six, or seven but not more than ten modified (e.g., substitution, insertion, or deletion) nucleotide sequences relative to the nucleotide sequences of SEQ ID NO: 2100, 2101, 2103, 2104, 2108, 2109, 2111-2120, or any one of the following: nucleotide sequences provided in Table 8, or sequences related to SEQ ID NO: 2100, 2101, 2103, 2104, 2108, 2109, 2111-2120. A nucleotide sequence having at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity among IDNO: 2100, 2101, 2103, 2104, 2108, 2109, 2111-2120, or any of the nucleotide sequences provided in Table 8.

[1006] 412. An AAV particle as described in any of embodiments 408-411, wherein the viral genome further comprises a polyA signal sequence.

[1007] 413. An AAV particle as described in any of embodiments 408-412, wherein the viral genome further comprises an inverted terminal repeat (ITR) sequence.

[1008] 414. An AAV particle as described in any of embodiments 408-413, wherein the viral genome comprises an ITR sequence located at 5' relative to the nucleic acid sequence encoding the payload.

[1009] 415. An AAV particle as described in any of embodiments 408-414, wherein the viral genome comprises an ITR sequence located at 3' relative to the nucleic acid sequence encoding the payload.

[1010] 416. An AAV particle as described in any of embodiments 408-415, wherein the viral genome comprises an ITR sequence located at 5' relative to the payload and an ITR sequence located at 3' relative to the nucleic acid sequence encoding the payload.

[1011] 417. An AAV particle as described in any of embodiments 408-416, wherein the viral genome further comprises enhancers, Kozak sequences, intron regions and / or exon regions.

[1012] 418. An AAV particle as described in any of embodiments 408-417, wherein the viral genome further comprises a nucleotide sequence encoding a miR binding site, the miR binding site for example regulating (e.g., reducing) the expression of miR binding sites in cells or tissues in which the payload encoded by the viral genome expresses the corresponding miRNA.

[1013] 419. An AAV particle as described in embodiment 418, wherein the encoded miRNA binding site is complementary, for example, fully or partially complementary, to a miRNA expressed in cells or tissues of the DRG, liver, heart, hematopoietic, or a combination thereof.

[1014] 420. AAV particles as described in embodiments 418 or 419, wherein the encoded miR binding site regulates (e.g., reduces) the expression of the encoded antibody molecule in cells or tissues of the DRG, liver, heart, hematopoietic lineage, or combinations thereof.

[1015] 421. An AAV particle as described in any of embodiments 408-420, wherein the viral genome contains at least 1 to 5 copies of the encoded miR binding site, for example at least 1, 2, 3, 4 or 5 copies.

[1016] 422. An AAV particle as described in any of embodiments 408-421, wherein the viral genome contains at least three copies of the encoded miR binding site, optionally wherein all three copies contain the same miR binding site, or at least one, two, three or all of these copies contain different miR binding sites.

[1017] 423. The AAV particle of embodiment 422, wherein the three copies of the encoded miR binding site are consecutive (e.g., not separated by spacers).

[1018] 424. An AAV particle as described in embodiment 422, wherein three copies of the encoded miR binding site are separated by spacers, wherein optionally the spacers contain a nucleotide sequence of GATAGTTA, or a nucleotide sequence containing one, two, or three modifications (e.g., substitution, insertion, or deletion) but no more than four modifications (e.g., substitution, insertion, or deletion) relative to GATAGTTA.

[1019] 425. An AAV particle as described in any of embodiments 408-424, wherein the viral genome contains at least four copies of the encoded miR binding site, optionally wherein all four copies contain the same miR binding site, or at least one, two, three or all of these copies contain different miR binding sites.

[1020] 426. An AAV particle as described in embodiment 425, wherein the four copies of the encoded miR binding site are consecutive (e.g., not separated by spacers).

[1021] 427. An AAV particle as described in embodiment 425, wherein four copies of the encoded miR binding site are separated by spacers, wherein optionally the spacers contain a nucleotide sequence of GATAGTTA, or a nucleotide sequence containing one, two, or three modifications (e.g., substitution, insertion, or deletion) but no more than four modifications (e.g., substitution, insertion, or deletion) relative to GATAGTTA.

[1022] 428. An AAV particle as described in any of embodiments 408-427, wherein the encoded miR binding site comprises a miR122 binding site, a miR183 binding site, a miR-1 binding site, a miR-142-3p or a combination thereof, optionally wherein:

[1023] (i) The miR122 binding site encoded contains the nucleotide sequence of SEQ ID NO:4673, or a nucleotide sequence that is substantially the same as it (e.g., has at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or, relative to SEQ ID NO:4673, contains at least one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but no more than ten modifications (e.g., substitution, insertion, or deletion) of the nucleotide sequence.

[1024] (ii) The miR183 binding site encoded contains the nucleotide sequence of SEQ ID NO:4676, or a nucleotide sequence that is substantially the same as it (e.g., has at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or, relative to SEQ ID NO:4676, contains at least one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but no more than ten modifications (e.g., substitution, insertion, or deletion) of the nucleotide sequence.

[1025] (iii) The miR-1 binding site encoded comprises the nucleotide sequence of SEQ ID NO:4679, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or, relative to SEQ ID NO:4679, comprises at least one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but no more than ten modifications (e.g., substitution, insertion, or deletion); and / or

[1026] (iv) The miR-142-3p binding site encoded contains the nucleotide sequence of SEQ ID NO:4675, or a nucleotide sequence that is substantially the same as it (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or, relative to SEQ ID NO:4675, contains at least one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but no more than ten modifications (e.g., substitution, insertion, or deletion) of the nucleotide sequence.

[1027] 429. An AAV particle as described in any of embodiments 408-428, wherein the viral genome contains an encoded miR122 binding site.

[1028] 430. An AAV particle as described in any of embodiments 408-429, wherein the viral genome contains at least 1 to 5 copies, such as 1, 2 or 3 copies, of the miR122 binding site, optionally wherein each copy is consecutive (e.g., not separated by spacers) or each copy is separated by spacers, optionally wherein the spacers contain a nucleotide sequence of GATAGTTA, or a nucleotide sequence containing one, two or three modifications (e.g., substitution, insertion or deletion) but no more than four modifications (e.g., substitution, insertion or deletion) relative to GATAGTTA.

[1029] 431. An AAV particle as described in embodiment 429 or 430, wherein the encoded miR122 binding site comprises the nucleotide sequence of SEQ ID NO:4673, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or, relative to SEQ ID NO:4673, comprises at least one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but no more than ten modifications (e.g., substitution, insertion, or deletion) of the nucleotide sequence.

[1030] 432. An AAV particle as described in any of embodiments 408-431, wherein the viral genome comprises:

[1031] (A)(i) The first miR122 binding site encoded thereof, comprising the nucleotide sequence of SEQ ID NO:4673, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or, relative to SEQ ID NO:4673, comprising at least one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but no more than ten modifications (e.g., substitution, insertion, or deletion) of the nucleotide sequence.

[1032] (ii) a first spacer comprising a nucleotide sequence of GATAGTTA, or a nucleotide sequence comprising, relative to GATAGTTA, one, two, or three modifications (e.g., substitutions (e.g., conserved substitutions)) but no more than four modifications (e.g., substitutions (e.g., conserved substitutions)); and

[1033] (iii) A second miR122 binding site encoded thereof, comprising the nucleotide sequence of SEQ ID NO:4673, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or, relative to SEQ ID NO:4673, comprising at least one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but no more than ten modifications (e.g., substitution, insertion, or deletion); or

[1034] (B)(i) The first miR122 binding site encoded thereof contains the nucleotide sequence of SEQ ID NO:4673, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or, relative to SEQ ID NO:4673, contains at least one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but no more than ten modifications (e.g., substitution, insertion, or deletion) of the nucleotide sequence.

[1035] (ii) A first spacer containing a nucleotide sequence of GATAGTTA, or a nucleotide sequence containing one, two, or three modifications (e.g., substitutions (e.g., conserved substitutions)) but no more than four modifications (e.g., substitutions (e.g., conserved substitutions)) relative to GATAGTTA;

[1036] (iii) The second miR122 binding site encoded thereof contains the nucleotide sequence of SEQ ID NO:4673, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or, relative to SEQ ID NO:4673, contains at least one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but no more than ten modifications (e.g., substitution, insertion, or deletion) of the nucleotide sequence.

[1037] (iv) A second spacer comprising a nucleotide sequence of GATAGTTA, or a nucleotide sequence comprising, relative to GATAGTTA, one, two, or three modifications (e.g., substitutions (e.g., conserved substitutions)) but no more than four modifications (e.g., substitutions (e.g., conserved substitutions)); and

[1038] (v) The third miR122 binding site, comprising the nucleotide sequence of SEQ ID NO:4673, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or, relative to SEQ ID NO:4673, comprising at least one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but no more than ten modifications (e.g., substitution, insertion, or deletion) of the nucleotide sequence.

[1039] 433. An AAV particle as described in any of embodiments 408-432, wherein the viral genome contains an encoded miR183 binding site.

[1040] 434. An AAV particle as described in any of embodiments 408-433, wherein the viral genome contains at least 1 to 5 copies, such as 1, 2 or 3 copies, of the miR183 binding site, optionally wherein each copy is contiguous (e.g., not separated by spacers) or each copy is separated by spacers, optionally wherein the spacers contain a nucleotide sequence of GATAGTTA, or a nucleotide sequence containing one, two or three modifications (e.g., substitution, insertion or deletion) but no more than four modifications (e.g., substitution, insertion or deletion) relative to GATAGTTA.

[1041] 435. An AAV particle as described in embodiment 433 or 434, wherein the encoded miR183 binding site comprises the nucleotide sequence of SEQ ID NO: 4673, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or, relative to SEQ ID NO: 4673, comprises at least one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but no more than ten modifications (e.g., substitution, insertion, or deletion) of the nucleotide sequence.

[1042] 436. An AAV particle as described in any of embodiments 408-435, wherein the viral genome comprises:

[1043] (A)(i) The first miR183 binding site encoded therein, comprising the nucleotide sequence of SEQ ID NO:4676, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or, relative to SEQ ID NO:4676, comprising at least one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but no more than ten modifications (e.g., substitution, insertion, or deletion) of the nucleotide sequence.

[1044] (ii) a first spacer comprising a nucleotide sequence of GATAGTTA, or a nucleotide sequence comprising, relative to GATAGTTA, at least one, two, or three modifications (e.g., substitution, insertion, or deletion) but no more than four modifications (e.g., substitution, insertion, or deletion); and

[1045] (iii) The second miR183 binding site encoded thereof, comprising the nucleotide sequence of SEQ ID NO:4676, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or, relative to SEQ ID NO:4676, comprising at least one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but no more than ten modifications (e.g., substitution, insertion, or deletion); or

[1046] (B)(i) The first miR183 binding site, comprising the nucleotide sequence of SEQ ID NO:4676, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or, relative to SEQ ID NO:4676, comprising at least one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but no more than ten modifications (e.g., substitution, insertion, or deletion) of the nucleotide sequence.

[1047] (ii) A first spacer containing a nucleotide sequence of GATAGTTA, or a nucleotide sequence containing at least one, two, or three modifications (e.g., substitution, insertion, or deletion) but no more than four modifications (e.g., substitution, insertion, or deletion) relative to GATAGTTA.

[1048] (iii) The second miR183 binding site encoded thereof, comprising the nucleotide sequence of SEQ ID NO:4676, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or, relative to SEQ ID NO:4676, comprising at least one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but no more than ten modifications (e.g., substitution, insertion, or deletion) of the nucleotide sequence.

[1049] (iv) A second spacer comprising a nucleotide sequence of GATAGTTA, or a nucleotide sequence comprising, relative to GATAGTTA, at least one, two, or three modifications (e.g., substitution, insertion, or deletion) but no more than four modifications (e.g., substitution, insertion, or deletion); and

[1050] (v) The third miR183 binding site, comprising the nucleotide sequence of SEQ ID NO:4676, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% sequence identity); or, relative to SEQ ID NO:4676, comprising at least one, two, three, four, five, six, or seven modifications (e.g., substitution, insertion, or deletion) but no more than ten modifications (e.g., substitution, insertion, or deletion) of the nucleotide sequence.

[1051] 437. An AAV particle as described in any of embodiments 408-436, wherein the viral genome contains encoded miR122 binding sites and miR-1 binding sites.

[1052] 438. An AAV particle as described in any of embodiments 408-437, wherein the viral genome is single-stranded or self-complementary.

[1053] 439. An AAV particle as described in any of embodiments 408-438, wherein the viral genome further comprises a nucleotide sequence encoding a Rep protein (e.g., a non-structural protein), wherein the Rep protein comprises Rep78 protein, Rep68, Rep52 protein and / or Rep40 protein (e.g., Rep78 and Rep52 proteins).

[1054] 440. An AAV particle as described in any of embodiments 397-439, wherein the AAV particle further comprises a nucleotide sequence encoding a Rep protein (e.g., a non-structural protein), wherein the Rep protein comprises Rep78 protein, Rep68, Rep52 protein and / or Rep40 protein (e.g., Rep78 and Rep52 proteins).

[1055] 441. The AAV particle of embodiment 439 or 440, wherein the Rep78 protein, the Rep68 protein, the Rep52 protein and / or the Rep40 protein are encoded by at least one Rep gene.

[1056] 442. An AAV particle as described in any of embodiments 408-441, wherein the viral genome further comprises a nucleotide sequence encoding an AAV capsid variant as described in any of embodiments 1-364, 381 or 382.

[1057] 443. An AAV particle as described in any of embodiments 397-442, wherein the AAV particle further comprises a nucleotide sequence encoding an AAV capsid variant as described in any of embodiments 1-364, 381 or 382.

[1058] 444. The AAV capsid variant, polynucleotide, peptide, or AAV particle as described in any of the foregoing embodiments, which is isolated, for example, recombinant.

[1059] 445. A vector comprising a polynucleotide encoding an AAV capsid variant as described in any of embodiments 1-378, 395, 396 or 444, a polynucleotide as described in any of embodiments 379-389 or 444, or a polynucleotide encoding a peptide as described in any of embodiments 390-394 or 444.

[1060] 446. A cell, such as a host cell, said cell comprising an AAV capsid variant as in any one of embodiments 1-378, 395, 396 or 444, a polynucleotide as in any one of embodiments 379-389 or 444, a peptide embodiment as in any one of embodiments 390-394 or 444, an AAV particle as in any one of embodiments 397-444, or a vector as in embodiment 445.

[1061] 447. The cell of embodiment 446, wherein the cell is a mammalian cell or an insect cell.

[1062] 448. Cells as described in embodiments 446 or 447, wherein the cells are cells of brain regions or spinal cord regions, optionally cells of the temporal lobe cortex, perinatal cortex, globus pallidus, putamen, caudate nucleus, thalamus, hippocampus, geniculate nucleus, Purkinje layer, deep cerebellar nuclei, cerebellum, cervical spinal cord, thoracic spinal cord, lumbar spinal cord, or combinations thereof.

[1063] 449. A cell as described in any one of embodiments 446-448, wherein the cell is a neuron, sensory neuron, motor neuron, astrocyte, glial cell, oligodendrocyte, or muscle cell (e.g., cells of the heart, diaphragm, or quadriceps femoris muscle).

[1064] 450. A method for preparing AAV particles, comprising:

[1065] (i) Providing a host cell containing the viral genome; and

[1066] (ii) The host cells are cultured under conditions suitable for encapsulating the viral genome into an AAV capsid variant as described in any of embodiments 1-378, 395, 396 or 444 or an AAV capsid variant encoded by a polynucleotide as described in any of embodiments 379-389 or 444.

[1067] The AAV particles are thus prepared.

[1068] 451. The method of embodiment 450, wherein the method further comprises, prior to step (i), introducing a first nucleic acid molecule containing the viral genome into the host cell.

[1069] 452. The method of embodiment 450 or 451, wherein the host cell contains a second nucleic acid encoding the capsid variant.

[1070] 453. The method of embodiment 452, wherein the second nucleic acid molecule is introduced into the host cell before, simultaneously with or after the first nucleic acid molecule.

[1071] 454. A pharmaceutical composition comprising AAV particles as described in any one of embodiments 397-444, AAV particles comprising a capsid variant as described in any one of embodiments 1-378, 395, 396 or 444, or AAV particles comprising a peptide as described in any one of embodiments 390-394 or 444, and a pharmaceutically acceptable excipient.

[1072] 455. A method of delivering a payload to cells or tissues (e.g., CNS cells, CNS tissues, cardiac cells, cardiac tissues, muscle cells, muscle tissues, hepatocytes, or liver tissues), comprising administering an effective amount of a pharmaceutical composition as described in embodiment 454, AAV particles as described in any one of embodiments 397-444, AAV particles containing a capsid variant as described in any one of embodiments 1-378, 395, 396, or 444, or AAV particles containing a peptide as described in any one of embodiments 390-394 or 444.

[1073] 456. The method of embodiment 455, wherein the cells are cells of a brain region or a spinal cord region, optionally cells of the temporal lobe cortex, perinatal cortex, globus pallidus, putamen, caudate nucleus, thalamus, hippocampus, geniculate nucleus, Purkinje layer, deep cerebellar nuclei, cerebellum, cervical spinal cord, thoracic spinal cord, lumbar spinal cord, or combinations thereof.

[1074] 457. The method of embodiment 455, wherein the cells are cells of the heart (e.g., atria or ventricles).

[1075] 458. The method of embodiment 455, wherein the cells are muscle cells (e.g., quadriceps femoris cells) or hepatocytes.

[1076] 459. The method of embodiment 455 or 456, wherein the cell is a neuron, sensory neuron, motor neuron, astrocyte, glial cell, or oligodendrocyte.

[1077] 460. The method of any one of embodiments 455-459, wherein the cells or tissues are within the subject.

[1078] 461. The method of embodiment 460, wherein the subject has, has been diagnosed with, a genetic condition (e.g., a monogenic condition or a polygenic condition), or is at risk of having a genetic condition (e.g., a monogenic condition or a polygenic condition).

[1079] 462. The method of embodiment 460 or 461, wherein the subject has, has been diagnosed with, a neurological (e.g., neurodegenerative) condition, or is at risk of having a neurological (e.g., neurodegenerative) condition.

[1080] 463. The method of embodiment 460 or 461, wherein the subject has, has been diagnosed with, a myopathy or neuromuscular disorder, or is at risk of having a myopathy or neuromuscular disorder.

[1081] 464. The method of embodiment 460 or 461, wherein the subject has, has been diagnosed with, or is at risk of having a neuro-oncological condition.

[1082] 465. A method of treating a subject who has or has been diagnosed with a genetic condition (e.g., a monogenic condition or a polygenic condition), the method comprising administering to the subject an effective amount of a pharmaceutical composition as described in embodiment 454, AAV particles as described in any one of embodiments 397-444, AAV particles containing a capsid variant as described in any one of embodiments 1-378, 395, 396 or 444, or AAV particles containing a peptide as described in any one of embodiments 390-394 or 444.

[1083] 466. A method of treating a subject who has or has been diagnosed with a neurological condition (e.g., neurodegenerative disease), the method comprising administering to the subject an effective amount of a pharmaceutical composition as described in embodiment 454, AAV particles as described in any one of embodiments 397-444, AAV particles containing a capsid variant as described in any one of embodiments 1-378, 395, 396 or 444, or AAV particles containing a peptide as described in any one of embodiments 390-394 or 444.

[1084] 467. A method of treating a subject suffering from or diagnosed with a muscular or neuromuscular disorder, the method comprising administering to the subject an effective amount of a pharmaceutical composition as described in embodiment 454, AAV particles as described in any one of embodiments 397-444, AAV particles containing a capsid variant as described in any one of embodiments 1-378, 395, 396 or 444, or AAV particles containing a peptide as described in any one of embodiments 390-394 or 444.

[1085] 468. A method of treating a subject suffering from or diagnosed with a neuro-oncological condition, the method comprising administering to the subject an effective amount of a pharmaceutical composition as described in embodiment 454, AAV particles as described in any one of embodiments 397-444, AAV particles containing a capsid variant as described in any one of embodiments 1-378, 395, 396 or 444, or AAV particles containing a peptide as described in any one of embodiments 390-394 or 444.

[1086] 469. The method of any one of embodiments 465-468, wherein the genetic condition, neurological condition, neurodegenerative condition, myopathy, neuromuscular condition, or neurotumor is Huntington's disease, amyotrophic lateral sclerosis (ALS), Gaucher disease, Lewy body dementia, Parkinson's disease, spinal muscular atrophy, Alzheimer's disease, leukodystrophy (e.g., Alexander disease, autosomal dominant leukodystrophy with autonomic dysfunction (ADLD), Canavan disease, cerebral tendon xanthomas (CTX), metachromatic leukodystrophy (MLD), Pelizaeus-Merzbacher disease, or Refsum disease) or cancer (e.g., HER2 / neu-positive cancer or glioblastoma).

[1087] 470. The method of any one of embodiments 465-469, wherein the treatment includes preventing the progression of the disease or condition in the subject.

[1088] 471. The method of any one of embodiments 460-470, wherein the subject is a person.

[1089] 472. The method of any one of embodiments 465-471, wherein the AAV particles are administered to the subject intravenously, via intracisional injection (ICM), intracerebral, intrathecal, intraventricular, via intraparenchymal, or intramuscularly.

[1090] 473. The method of any one of embodiments 465-472, wherein the AAV particles are administered to the subject via focused ultrasound (FUS), for example in combination with intravenous administration of microbubbles (FUS-MB), or MRI-guided FUS in combination with intravenous administration.

[1091] 474. The method of any one of embodiments 465-472, wherein the AAV particles are administered intravenously to the subject.

[1092] 475. The method of any one of embodiments 465-475, wherein the application of the AAV particles results in a reduction in the presence, level and / or activity of genes, mRNAs, proteins or combinations thereof.

[1093] 476. The method of any one of embodiments 465-475, wherein the application of the AAV particles results in an increase in the presence, level and / or activity of genes, mRNAs, proteins or combinations thereof.

[1094] 477. A pharmaceutical composition of embodiment 454, AAV particles of any one of embodiments 397-444, AAV particles comprising a capsid variant of any one of embodiments 1-378, 395, 396 or 444, or AAV particles comprising a peptide of any one of embodiments 390-394 or 444, for use in a method of delivering a payload to cells or tissues.

[1095] 478. A pharmaceutical composition of embodiment 454, AAV particles of any one of embodiments 397-444, AAV particles comprising a capsid variant of any one of embodiments 1-378, 395, 396 or 444, or AAV particles comprising a peptide of any one of embodiments 390-394 or 444, for use in the treatment of genetic diseases, neurological diseases, neurodegenerative diseases, myopathy, neuromuscular diseases or neurotumor diseases.

[1096] 479. A pharmaceutical composition of embodiment 454, AAV particles of any one of embodiments 397-444, AAV particles containing a capsid variant of any one of embodiments 1-378, 395, 396 or 444, or AAV particles containing a peptide of any one of embodiments 390-394 or 444, or AAV particles containing a peptide of any one of embodiments 376-380 or 430, for use in the manufacture of a pharmaceutical preparation.

[1097] 480. Use of a pharmaceutical composition of embodiment 454, AAV particles of any one of embodiments 397-444, AAV particles containing a capsid variant of any one of embodiments 1-378, 395, 396 or 444, or AAV particles containing a peptide of any one of embodiments 390-394 or 444 for the manufacture of a pharmaceutical preparation.

[1098] 481. The use of a pharmaceutical composition of embodiment 454, AAV particles of any one of embodiments 397-444, AAV particles containing a capsid variant of any one of embodiments 1-378, 395, 396 or 444, or AAV particles containing a peptide of any one of embodiments 390-394 or 444 for the manufacture of an agent for the treatment of genetic diseases, neurological diseases, neurodegenerative diseases, myopathy, neuromuscular diseases or neurotumor diseases.

[1099] Details of one or more embodiments of this disclosure are set forth in the following accompanying description. Other features, objects, and advantages of the invention will become apparent from this description. In this specification, the singular form also includes the plural form unless the context clearly specifies otherwise. Certain terms are defined in the definitions section and throughout the text. Attached Figure Description

[1100] Figure 1A-1D Immunohistochemical images of various CNS and peripheral tissues isolated from NHP (cynomolgus monkey) 28 days after intravenous administration of AAV particles containing either the TTN-002 capsid variant (top image) or the AAV9 control capsid (bottom image) and a self-complementary genome encoding a payload fused to a heterologous constitutive promoter-driven HA tag. Figure 1A The cerebellum (Purkinje layer), spinal cord (cervical region), cortex (temporal lobe), and brainstem are shown from left to right. Figure 1B From left to right, the globus pallidus, hippocampus, thalamus, putamen, and dentate nucleus are shown. Figure 1C The images are displayed from left to right as the whole brain (H level), the whole brain (K level), and the cerebellum. Figure 1D The spinal cord (chest), DRG (chest), liver, and heart are shown from left to right. Detailed Implementation

[1101] This document describes in particular compositions comprising AAV capsid variants (e.g., the AAV capsid variants described herein), and methods of their preparation and use. Typically, AAV capsid variants have enhanced tropism to cells or tissues, for example, for delivering payloads to such cells or tissues, such as CNS tissue, CNS cells, cardiac cells, cardiac tissue, muscle cells, muscle tissue, hepatocytes, or liver tissue.

[1102] As demonstrated in the following examples herein, certain AAV capsid variants described herein exhibit several advantages over wild-type AAV5 and / or wild-type AAV9, including (i) increased penetration of the blood-brain barrier after intravenous administration, (ii) more extensive distribution to multiple brain regions, such as the frontal cortex, sensory cortex, motor cortex, putamen, thalamus, cerebellar cortex, dentate nucleus, caudate nucleus, and / or hippocampus, (iii) elevated payload expression in multiple brain regions, (iv) more extensive distribution in one or more peripheral tissues (e.g., heart, muscle, and / or liver), and / or (v) elevated payload expression in one or more peripheral tissues. Without wishing to be bound by theory, these advantages are believed to be partly attributable to the propagation of the AAV capsid variants via the cerebrovascular system. In some embodiments, the AAV capsids described herein enhance payload delivery to multiple brain regions, including, for example, the frontal cortex, sensory cortex, motor cortex, putamen, thalamus, cerebellar cortex, dentate nucleus, caudate nucleus, and / or hippocampus. In some implementations, the AAV capsid described herein enhances the delivery of payloads to the heart, muscles, and / or liver.

[1103] In some embodiments, the AAV capsid variants disclosed herein include modifications in ring VIII of AAV5, for example at positions 577, such as between 571 and 579 relative to SEQ ID NO:138. Not wishing to be bound by theory, it is believed that in some embodiments, the aforementioned region of the AAV5 capsid (e.g., positions between 571 and 579, such as at position 577) protrudes more than three times the axis of symmetry, for example, as a surface-exposed location within the AAV5 capsid, as described, for example, in Govindasamy et al., “Structural Insights into Aden o-Associated Virus Serotype 5,” Journal of Virology, 2013, 87(20):11187-11199 (the contents of which are incorporated herein by reference in their entirety). In some embodiments, the ring (e.g., ring VIII) may be used interchangeably herein with the term variable region (e.g., variable region VII I) or VR (e.g., VR-VIII). In some embodiments, ring VIII (e.g., VR-VIII) comprises positions 571-592 according to SEQ ID NO:138 (e.g., amino acid TNNQSSTTAPATGTYNLQEIVP (SEQ ID NO:736)). In some embodiments, ring VIII (e.g., VR-VIII) comprises positions 571-599 according to SEQ ID NO:982 (e.g., amino acid TNNQSSYPAEVVQKTAPATGTYNLQEIVP (SEQ ID NO:756)). In some embodiments, ring VIII or variable VIII (VR-VIII) is as described by Govindasamy et al. (ibid.) (the contents of which are incorporated herein by reference in their entirety).

[1104] Several methods have been used to generate AAV capsids that enhance tropism to cells or tissues (e.g., CNS cells or tissues). One method involves co-infection of cultured cells (Grimm et al., In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 2008, 82(12):5887–5911) or orthotopic animal tissues (Lisowski et al., Selection and evaluation of clinically relevant AAV variants in axenograft liver model. Nature 2014, 506:382-386) with adenovirus to trigger exponential replication of infectious AAV DNA. Another approach involves using cell-specific CRE transgenic mice (Deverman et al., Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol. 2016 Feb 34(2) 204-209; which is incorporated herein by reference) to allow specific viral DNA recombination in astrocytes, followed by recovery of the CRE-recombined capsid variants. Other approaches employ high-throughput DNA synthesis, multiplexing, sequencing technologies, and machine learning to evaluate sequencing readouts of viral DNA in different tissues to design variant capsids. These approaches differ from those disclosed herein.

[1105] There are some limitations to known capsid generation methods in this field. For example, the transgenic CRE system used by Deverman et al. (2016) has limited capabilities in other animal species, and AAV variants selected through directed evolution in mouse tissues have not shown similar characteristics in large animals. The previously described transduction-specific methods are not suitable for large animal studies because: 1) many relevant tissues (e.g., CNS) are not susceptible to adenovirus co-infection; 2) specific adenovirus tropism itself can bias library distribution; and 3) large animals are generally unsuitable for gene transfer or genetic engineering to express CRE recombinases in specified cell types.

[1106] To address these limitations, a widely applicable functional AAV capsid library screening platform has been developed for cell type-specific bioscreening in non-transgenic animals, as described in the accompanying examples. In the TRACER (Taxis-Redirection of AAV via Cell Type-Specific Expression of RNA) platform system, the capsid gene is placed under the control of a cell type-specific promoter to drive capsid mRNA expression in the absence of helper viral co-infection. Without being bound by theory, it is believed that this RNA-driven screening increases the selection pressure favoring the transduction of capsid variants specific to particular cell types. The TRACER platform allows for the generation of AAV capsid libraries, thereby enabling the specific recovery and subcloning of capsid mRNA expressed in transduced cells without the need for transgenic animals or helper viral co-infection. Without being bound by theory, the method disclosed herein, believed to be a marker of complete transduction of mRNA transcription, allows for the identification of fully infectious AAV capsid mutants. In addition to its high stringency, this method also allows for the identification of capsids with high tropism for specific cell types using libraries designed to express CAP mRNA under the control of any cell-specific promoter (such as, but not limited to, synaptoprotein-1 promoter (neurons), GFAP promoter (astrocytes), TBG promoter (liver), CAMK promoter (skeletal muscle), and MYH6 promoter (cardiomyocytes)). This paper describes AAV capsid variants generated using the TRACER method that have demonstrated enhanced tropism in, for example, CNS cells, CNS tissues, muscle cells, or muscle tissues.

[1107] The AAV particles and payloads disclosed herein can be delivered to one or more target cells, tissues, organs, or organisms. In some embodiments, the AAV particles of this disclosure exhibit an enhancing tropism towards target cell types, tissues, or organs. As a non-limiting example, the AAV particles may have an enhancing tropism towards cells and tissues of the central or peripheral nervous system (CNS and PNS, respectively). In some embodiments, the AAV particles of this disclosure may additionally or alternatively have a reducing tropism towards cell types, tissues, or organs.

[1108] In some implementations, AAV particles are used as biological tools due to their relatively simple structure, their ability to infect a variety of cells (including quiescent and dividing cells) without integration into the host genome, their lack of replication, and their relatively benign immunogenicity. The genome of a manipulated virus contains minimal components for assembling functional recombinant viruses or viral particles loaded with or engineered to target specific tissues and express or deliver the desired payload.

[1109] In some embodiments, the AAV particle is a naturally occurring (e.g., wild-type) AAV or recombinant AAV. In some embodiments, the wild-type AAV viral genome is a linear, single-stranded DNA (ssDNA) molecule approximately 5,000 nucleotides (nt) in length. In some embodiments, inverted terminal repeat sequences (ITRs) cap the viral genome at the 5' and 3' ends, thereby providing an origin of replication for the viral genome. In some embodiments, the AAV viral genome typically contains two ITR sequences. These ITRs have a characteristic T-shaped hairpin structure defined by self-complementary regions (145 nt in wild-type AAV) located at the 5' and 3' ends of the ssDNA, forming an energy-stable double-stranded region. The double-stranded hairpin structure has multiple functions, including but not limited to acting as an origin of DNA replication by serving as a primer for the endogenous DNA polymerase complex of the host viral replication cell.

[1110] In some embodiments, the wild-type AAV viral genome further comprises nucleotide sequences of two open reading frames (ORFs): one ORF for four non-structural Rep proteins (Rep78, Rep68, Rep52, Rep40, encoded by the Rep gene) and one ORF for three capsid or structural proteins (VP1, VP2, VP3, encoded by the capsid gene or Cap gene). The Rep proteins are used for replication and packaging, while the capsid proteins are assembled to produce the protein shell of AAV, or AAV capsid polypeptides, such as AAV capsid variants. Alternating splicing and alternating start codons and promoters result in the generation of four distinct Rep proteins from a single ORF and three capsid proteins from a single ORF. Although this varies depending on the AAV serotype, as a non-limiting example, for AAV5 (SEQ ID NO: 138 and 137), VP1 refers to amino acids 1-724, VP2 refers to amino acids 137-724, and VP3 refers to amino acids 193-724. In some embodiments, for the amino acid sequence of SEQ ID NO:982, VP1 contains amino acids 1-731, VP2 contains amino acids 137-731, and VP3 contains amino acids 193-731. In other words, VP1 is the full-length capsid sequence, while VP2 and VP3 are shorter components of the whole. Therefore, sequence variations in the VP3 region are also variations of VP1 and VP2; however, the percentage difference compared to the parental sequence will be the largest for VP3, as it is the shortest of the three. Although the amino acid sequences are described here, the nucleic acid sequences encoding these proteins can be described similarly. The three capsid proteins are assembled together to produce the AAV capsid protein. While not wishing to be bound by theory, the AAV capsid protein typically contains VP1:VP2:VP3 in a molar ratio of 1:1:10.

[1111] The AAV particles of this disclosure are recombinant and can be based on an adeno-associated virus (AAV) reference sequence. In addition to a single-stranded AAV viral genome (e.g., ssAAV), this disclosure also provides self-complementary AAV (scAAVs) viral genomes. The scAAV viral genome contains DNA strands that are annealed together to form double-stranded DNA. By skipping second-strand synthesis, scAAV allows for rapid expression in transduced cells. In some embodiments, the AAV particles of this disclosure are scAAV. In some embodiments, the AAV particles of this disclosure are ssAAV.

[1112] Methods for generating and / or modifying AAV particles, such as pseudo-AAV particles, are disclosed in the art (PCT patent publications WO200028004; WO200123001; WO2004112727; WO2005005610; and WO2005072364, the contents of which are incorporated herein by reference in their entirety).

[1113] As described herein, the AAV particles of this disclosure, which contain an AAV capsid variant and a viral genome, exhibit enhanced tropism for cell types or tissues (e.g., CNS cell types, regions, or tissues).

[1114] peptides

[1115] This document discloses peptides and related AAV particles comprising AAV capsid variants and peptides for enhancing or improving transduction in target tissues (e.g., cells of the CNS or PNS). In some embodiments, the peptide is isolated, such as a recombinant peptide. In some embodiments, the nucleic acid encoding the peptide is isolated, such as a recombinant nucleic acid.

[1116] In some embodiments, the peptide may increase the distribution of AAV particles to cells, regions, or tissues of the CNS. Cells of the CNS may be, but are not limited to, neurons (e.g., excitatory, inhibitory, motor, sensory, autonomic, sympathetic, parasympathetic, Purkinje, Betz, etc.), glial cells (e.g., microglia, astrocytes, oligodendrocytes), and / or supporting cells of the brain, such as immune cells (e.g., T cells). Tissues of the CNS may be, but are not limited to, the cortex (e.g., frontal lobe, parietal lobe, occipital lobe, temporal lobe), thalamus, hypothalamus, striatum, putamen, caudate nucleus, hippocampus, entorhinal cortex, basal ganglia, or deep cerebellar nuclei. In some embodiments, tissues of the CNS include the temporal lobe cortex, pernasal cortex, globus pallidus, putamen, caudate nucleus, thalamus, hippocampus, geniculate nucleus, Purkinje layer, deep cerebellar nuclei, cerebellum, cervical spinal cord, thoracic spinal cord, or lumbar spinal cord.

[1117] In some embodiments, the peptide may increase the distribution of AAV particles to cells, regions, or tissues of the PNS. The cells or tissues of the PNS may be, but are not limited to, the dorsal root ganglion (DRG).

[1118] In some embodiments, the peptide may increase the distribution of AAV particles into the CNS (e.g., the cortex) after intravenous administration. In some embodiments, the peptide may increase the distribution of AAV particles into the CNS (e.g., the cortex) after focused ultrasound (FUS), such as in combination with intravenous administration of microbubbles (FUS-MB), or MRI-guided FUS in combination with intravenous administration.

[1119] In some embodiments, the peptide may increase the distribution of AAV particles to the PNS (e.g., DRG) after intravenous administration. In some embodiments, the peptide may increase the distribution of AAV particles to the PNS (e.g., DRG) after focused ultrasound (FUS), such as in combination with intravenous administration of microbubbles (FUS-MB), or MRI-guided FUS in combination with intravenous administration.

[1120] In some embodiments, the peptide can increase the distribution of AAV particles to cells, regions, or tissues of the heart (e.g., atria or ventricles). In some embodiments, the peptide can increase the distribution of AAV particles to cardiac cells, regions, or tissues after intravenous administration.

[1121] In some embodiments, the peptide can increase the distribution of AAV particles into muscle cells, regions, or tissues. In some embodiments, the muscle is cardiac muscle (e.g., atrium or ventricle) or quadriceps femoris. In some embodiments, the peptide can increase the distribution of AAV particles into muscle cells, regions, or tissues after intravenous administration.

[1122] In some embodiments, the peptide can increase the distribution of AAV particles into liver cells, regions, or tissues. In some embodiments, the peptide can increase the distribution of AAV particles into liver cells, regions, or tissues after intravenous administration.

[1123] The length of the peptide can vary. In some embodiments, the peptide is about 3 to about 20 amino acids long. As a non-limiting example, the peptide may be 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 3-5, 3-8, 3-10, 3-12, 3-15, 3-18, 3-20, 5-10, 5-15, 5-20, 10-12, 10-15, 10-20, 12-20, or 15-20 amino acids long. In some embodiments, the peptide comprises about 6 to 12 amino acids long, for example, about 9 amino acids long. In some embodiments, the peptide comprises about 7 to 11 amino acids long, for example, about 8 amino acids long. In some embodiments, the peptide comprises about 5 to 10 amino acids long, for example, about 7 amino acids long. In some implementations, the peptide comprises a length of about 4 to 9 amino acids, for example, about 6 amino acids.

[1124] In some embodiments, the peptide may comprise sequences as described in Table 1 (e.g., amino acid sequences comprising any one of SEQ ID NO: 1021, 1024, 1027, 1112, 1142, 1214, 1232, 1254, 1300, 1310, 1327, 1331, 1342, 1419, 1453, 1533, 1538, 1539, 1575, 1578, 1583-1587, 1590-1593, 1598-1624, or 2064-2079). In some embodiments, the peptide may comprise sequences as described in Table 2A or 2B. In some embodiments, the peptide may comprise sequences as described in Table 9 or 15-20. In some embodiments, the peptide is isolated, for example, recombinant.

[1125] Table 1. Exemplary peptide sequences

[1126]

[1127]

[1128] Table 2A. Exemplary peptide sequences

[1129]

[1130]

[1131] Table 2B. Exemplary peptide sequences

[1132]

[1133] In some embodiments, the peptide described herein comprises an amino acid sequence having the formula [N2]-[N3], wherein [N2] comprises positions X1, X2, X3, X4, and X5, and [N3] comprises the amino acid sequence VQK, VQN, EQK, VKK, VHK, VQQ, or LQK. In some embodiments, position X1 of [N2] is Y, N, C, or T. In some embodiments, position X2 of [N2] is P, E, K, T, or Q. In some embodiments, position X3 of [N2] is A or P. In some embodiments, position X4 of [N2] is E, S, D, or A. In some embodiments, position X5 of [N2] is V, L, or E. In some embodiments, [N2] comprises Y at position X1. In some embodiments, [N2] comprises P at position X2. In some embodiments, [N2] comprises A at position X3. In some embodiments, [N2] comprises E at position X4. In some embodiments, [N2] contains V at position X5. In some embodiments, the amino acid sequence of [N3] contains VQK. In some embodiments, the amino acid sequence of [N3] consists of VQK.

[1134] In some embodiments, the peptide described herein comprises an amino acid sequence having the formula [N2]-[N3], wherein [N2] comprises positions X1, X2, X3, X4, and X5, and [N3] comprises an amino acid sequence of VQK, EQK, VKK, VHK, VQQ, or LQK. In some embodiments, [N3] comprises an amino acid sequence of VQK, EQK, or VKK. In some embodiments, [N3] comprises the amino acid sequence VQK. In some embodiments, [N3] consists of the amino acid sequence VQK. In some embodiments, position X1 of [N2] is Y, N, or C. In some embodiments, position X1 of [N2] is Y or N. In some embodiments, position X2 of [N2] is P, K, T, or Q. In some embodiments, position X2 of [N2] is P, T, or Q. In some embodiments, position X3 of [N2] is A or P. In some embodiments, position X3 of [N2] is A. In some embodiments, position X4 of [N2] is E, S, or A. In some embodiments, position X5 of [N2] is V, L, or E. In some embodiments, position X5 of [N2] is V or L. In some embodiments, [N2] includes Y at position X1. In some embodiments, [N2] includes P at position X2. In some embodiments, [N2] includes A at position X3. In some embodiments, [N2] includes E at position X4. In some embodiments, [N2] includes V at position X5. In some embodiments, [N2] includes YPA, YPP, NKA, YTA, YQA, YTP, NPA, CPA, THA, PAE, PPS, KAE, TAE, QAE, TPS, PAA, HAS, AEV, PSL, AEE, or AAV. In some implementations, [N2] includes YPAE (SEQ ID NO:21), YPPS (SEQ ID NO:22), NKAE (SEQ ID NO:23), YTAE (SEQ ID NO:24), YQAE (SEQ ID NO:25), YTPS (SEQ ID NO:26), YPAA (SEQ ID NO:27), NPAE (SEQ ID NO:28), CPAE (SEQ ID NO:29), THAS (SEQ ID NO:30), PAEV (SEQ ID NO:17), PPSL (SEQ ID NO:31), KAEV (SEQ ID NO:32), TAEV (SEQ ID NO:16), PAEE (SEQ ID NO:18), QAEV (SEQ ID NO:15), TPSL (SEQ ID NO:33), PAAV (SEQ ID NO:34), or QAEE (SEQ ID NO:35).In some embodiments, [N2] is or comprises YPAEV (SEQ ID NO:1), YPPSL (SEQ ID NO:2), NKAEV (SEQ ID NO:3), YTAEV (SEQ ID NO:4), YPAEE (SEQ ID NO:5), YQAEV (SEQ ID NO:6), YTPSL (SEQ ID NO:7), YPAAV (SEQ ID NO:8), NPAEV (SEQ ID NO:9), CPAEV (SEQ ID NO:10), or YQAEE (SEQ ID NO:11). In some embodiments, [N2] comprises the amino acid sequence of YPAEV (SEQ ID NO:1). In some embodiments, the amino acid sequence of [N2] consists of YPAEV (SEQ ID NO:1). In some embodiments, [N2]-[N3] comprises the amino acid sequence of AEVVQK (SEQ ID NO:36), PSLVQK (SEQ ID NO:37), AEVEQK (SEQ ID NO:38), AEEVQK (SEQ ID NO:39), PSLEQK (SEQ ID NO:40), PSLVKK (SEQ ID NO:41), AEVVKK (SEQ ID NO:42), AEVVHK (SEQ ID NO:43), AAVVQK (SEQ ID NO:44), AEVVQQ (SEQ ID NO:45), or AEVLQK (SEQ ID NO:46). In some embodiments, [N2]-[N3] comprises the amino acid sequences PAEVVQK (SEQ ID NO:20), PPSLVQK (SEQ ID NO:47), KAEVVQK (SEQ ID NO:48), TAEVVQK (SEQ ID NO:49), PAEVEQK (SEQ ID NO:50), PAEEVQK (SEQ ID NO:51), QAEVVQK (SEQ ID NO:52), TPSLVQK (SEQ ID NO:53), PPSSLEQK (SEQ ID NO:54), PPSLVKK (SEQ ID NO:55), PAEVVKK (SEQ ID NO:56), PAEVVHK (SEQ ID NO:57), PAAVVQK (SEQ ID NO:58), PAEVVQQ (SEQ ID NO:59), TAEVVKK (SEQ ID NO:60), PAEVLQK (SEQ ID NO:61), or QAEEVQK (SEQ ID NO:62).In some implementations, [N2]-[N3] are or include YPAEVVQK (SEQ ID NO:943), YPPSLVQK (SEQ ID NO:946), NKAEVVQK (SEQ ID NO:947), YTAEVVQK (SEQ ID NO:948), YPAEVEQK (SEQ ID NO:949), YPAEEVQK (SEQ ID NO:950), YQAEVVQK (SEQ ID NO:951), YTPSLVQK (SEQ ID NO:952), YPPSLEQK (SEQ ID NO:953), YPPSLVKK (SEQ ID NO:954), YPAEVVKK (SEQ ID NO:955), YPAEVVHK (SEQ ID NO:956), YPAAVVQK (SEQ ID NO:957), NPAEVVQK (SEQ ID NO:958), YPAEVVQQ (SEQ ID NO:959), CPAEVVQK (SEQ ID NO:959), YPAEVVQK (SEQ ID NO:959), YPAEVVQK (SEQ ID NO:950), YPA ...0), YPAEVVQK (SEQ ID NO:950), YPAEVVQK (SEQ ID NO:950), YPAEVVQ The amino acid sequences [N2]-[N3] are: YTAEVVKK (SEQ ID NO: 960), YTAEVVKK (SEQ ID NO: 961), YPAEVLQK (SEQ ID NO: 962), or YQAEEVQK (SEQ ID NO: 963); amino acid sequences comprising any portion of any of the above amino acid sequences (e.g., any 2, 3, 4, 5, 6, or 7 amino acids, such as consecutive amino acids); amino acid sequences comprising one, two, or three but no more than four modifications (e.g., substitutions (e.g., conservative substitutions), insertions, or deletions) relative to any of the above amino acid sequences; or amino acid sequences comprising one, two, or three but no more than four different amino acids relative to any of the above amino acid sequences. In some embodiments, [N2]-[N3] is YPAEVVQK (SEQ ID NO: 943). In some embodiments, [N2]-[N3] comprises the amino acid sequence YPAEVVQK (SEQ ID NO: 943).

[1135] In some embodiments, the peptide comprising the amino acid sequence of formula [N2]-[N3] further comprises [N1], which comprises position X. D X E and X F In some implementations, the position of [N1] is X D It can be Q, T, S, A, I, L, or H. In some implementations, the position of [N1] is X. E It can be S, G, A, or R. In some implementations, the position of [N1] is X. F[N1] is S, K, L, R, A, or T. In some embodiments, [N1] comprises SK, SL, SS, SR, GA, GS, AS, ST, RS, QS, TS, AG, IG, QA, LG, HS, LS, or QR. In some embodiments, [N1] is or comprises QSS, QSK, TSL, SSS, QSR, AGA, IGS, QAS, ASS, LGS, QST, HSS, LSS, or QRS. In some embodiments, the amino acid sequence of [N1] is QSS. In some implementations, [N1]-[N2] includes SSYPA (SEQ ID NO:63), SKYPA (SEQ ID NO:64), SLYPA (SEQ ID NO:65), SRYPA (SEQ ID NO:66), SSYPP (SEQ ID NO:67), GAYPA (SEQ ID NO:68), GSYPA (SEQ ID NO:69), ASYPA (SEQ ID NO:70), STNKA (SEQ ID NO:71), SSYTA (SEQ ID NO:72), SSYQA (SEQ ID NO:73), SSYTP (SEQ ID NO:74), SSNPA (SEQ ID NO:75), SLCPA (SEQ ID NO:76), RSYTA (SEQ ID NO:77), or SSTHA (SEQ ID NO:78). In some embodiments, [N1]-[N2] include SSYPAE (SEQ ID NO:79), SKYPAE (SEQ ID NO:80), SLYPAE (SEQ ID NO:81), SRYPAE (SEQ ID NO:82), SSYPPS (SEQ ID NO:83), GAYPAE (SEQ ID NO:84), GSYPAE (SEQ ID NO:85), ASYPAE (SEQ ID NO:86), STNKAE (SEQ ID NO:87), SSYTAE (SEQ ID NO:88), SSYQAE (SEQ ID NO:89), SSYTPS (SEQ ID NO:90), SSYPAA (SEQ ID NO:91), SSNPAE (SEQ ID NO:92), SLCPAE (SEQ ID NO:93), RSYTAE (SEQ ID NO:94), and SSTHAS (SEQ ID NO:95). In some embodiments,[N1]-[N2] is or contains QSSYPAEV(SEQ ID NO:96), QSKYPAEV(SEQ ID NO:97), TSLYPAEV(SEQ ID NO:98), SSSYPAEV(SEQ ID NO:99), QSRYPAEV(SEQ ID NO:100), QSSYPPSL(SEQ ID NO:101), AGAYPAEV(SEQ ID NO:102), IGSYPAEV (SEQ ID NO:103), QASYPAEV (SEQ ID NO:104), ASSYPAEV (SEQ ID NO:105), LGSYPAEV (SEQ ID NO:106), QSTNKAEV (SEQ ID NO:107), HSSYPAEV (SEQ ID NO:108), SSSYTAEV (SEQ ID NO:109), TSLYPAEE (SEQ ID NO:110), ASSYQAEV (SEQ ID NO:111), QSSYTPSL (SEQ ID NO:112), QSRYPAEE (SEQ ID NO:113), LSSYQAEV (SEQ ID NO:114), HSSYPAAV (SEQ ID NO:115), QSSNPAEV (SEQ ID NO:116), QSSYTAEV (SEQ ID NO:117), TSLCPAEV (SEQ ID NO:118), QRSYTAEV (SEQ ID NO:119), or QSSYQAEE (SEQ ID NO:120); an amino acid sequence comprising any part of any of the above amino acid sequences (e.g., any 2, 3, 4, 5, 6, or 7 amino acids, such as consecutive amino acids); an amino acid sequence comprising one, two, or three but no more than four modifications (e.g., substitution (e.g., conservative substitution), insertion, or deletion) relative to any of the above amino acid sequences; or an amino acid sequence comprising one, two, or three but no more than four different amino acids relative to any of the above amino acid sequences. In some embodiments, the amino acid sequence of [N1]-[N2] is QSSYPAEV (SEQ ID NO:96). In some embodiments,[N1]-[N2]-[N3] contains SSYPAEVVQ (SEQ ID NO:121), SKYPAEVVQ (SEQ ID NO:122), SLYPAEVVQ (SEQ ID NO:123), SRYPAEVVQ (SEQ ID NO:124), SSYPPSLVQ (SEQ ID NO:125), GAYPAEVVQ (SEQ ID NO:126), GSYPAEVVQ (SEQ ID NO:127), ASYPAEVVQ (SEQ ID NO:128), STNKAEVVQ (SEQ ID NO:129), SSYTAEVVQ (SEQ ID NO:130), SKYPAEVEQ (SEQ ID NO:131), SLYPAEEVQ (SEQ ID NO:132), SSYQAEVVQ (SEQ ID NO:133), SSYTPSLVQ (SEQ ID NO:134), SRYPAEEVQ (SEQ ID NO:135), SSYPPSLEQ (SEQ ID NO:136), SSYPPSLVK (SEQ ID NO:140), SSYPAEVVK (SEQ ID NO:141), SKYPAEVVH (SEQ ID NO:142), SSYPAAVVQ (SEQ ID NO:143), SSNPAEVVQ (SEQ ID NO:144), SLCPAEVVQ (SEQ ID NO:145), RSYTAEVVQ (SEQ ID NO:146), SSYTAEVVK (SEQ ID NO:147), SSYPAEVLQ (SEQ ID NO:148), or SSYQAEEVQ (SEQ ID NO:149). In some embodiments,[N1]-[N2]-[N3] is or contains QSSYPAEVVQK(SEQ ID NO:150), QSKYPAEVVQK(SEQ ID NO:151), TSLYPAEVVQK(SEQ ID NO:152), SSSYPAEVVQK(SEQ ID NO:153), QSRYPAEVVQK(SEQ ID NO:154), QSSYPPSLVQK (SEQ ID NO:155), AGAYPAEVVQK (SEQ ID NO:156), IGSYPAEVVQK (SEQ ID NO:157), QASYPAEVVQK (SEQ ID NO:158), ASSYPAEVVQK (SEQ ID NO:159), LGSYPAEVVQK (SEQID NO:160), QSTNKAEVVQK (SEQ ID NO:161), HSSYPAEVVQK (SEQ ID NO:162), SSSYTAEVVQK (SEQ ID NO:163), QSKYPAEVEQK (SEQ ID NO:164), TSLYPAEEVQK (SEQ ID NO:165), ASSYQAEVVQK (SEQ ID NO:166), QSSYTPSLVQK (SEQ ID NO:167), QSRYPAEEVQK (SEQ ID NO:168), QSSYPPSLEQK (SEQ ID NO:169), QSSYPPSLVKK (SEQ ID NO:170), LSSYQAEVVQK (SEQ ID NO:171), SSSYPAEVVKK (SEQ ID NO:172), QSKYPAEVVHK (SEQ ID NO:173), HSSYPAAVVQK (SEQ ID NO:174), QSSNPAEVVQK (SEQ ID NO:175), SSSYPAEVVQQ (SEQ ID NO:176), QSSYTAEVVQK (SEQ ID NO:177), TSLCPAEVVQK (SEQ ID NO:178), QRSYTAEVVQK (SEQ ID NO:179), QSSYTAEVVKK (SEQ ID NO:180), HSSYPAEVLQK (SEQ ID NO:181), or QSSYQAEEVQK (SEQ ID NO:182); an amino acid sequence containing any part of any of the above amino acid sequences (e.g., any 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, such as consecutive amino acids); or, relative to any of the above amino acid sequences, containing one, two, or three but no more than four modifications (e.g., ...The amino acid sequence may be a substitution (e.g., a conservative substitution), insertion, or deletion; or an amino acid sequence comprising one, two, or three, but not more than four, different amino acids relative to any of the above-mentioned amino acid sequences. In some embodiments, the amino acid sequence [N1]-[N2]-[N3] is QSSYPAEVVQK (SEQ ID NO:150).

[1136] In some embodiments, the peptide comprising the amino acid sequence of formula [N2]-[N3] further comprises [N0], wherein [N0] comprises position X. A X B and X C In some implementations, the position of [N0] is X. A It can be T, I, or N. In some implementations, the position of [N0] is X. B Let N be the number of nodes. In some implementations, the position of [N0] is X. C[NO] is N, T, S, or K. In some embodiments, [NO] comprises TN, IN, NN, NT, NS, or NK. In some embodiments, [NO] is or comprises TNN, TNT, INN, TNS, NNN, or TNK. In some embodiments, the amino acid sequence of [NO] is TNN. In some implementations, [N0]-[N1] are or include TNNQSS (SEQ ID NO:183), TNNQSK (SEQ ID NO:184), TNNTSL (SEQ ID NO:185), TNNSSS (SEQ ID NO:186), TNNQSR (SEQ ID NO:187), TNNAGA (SEQ ID NO:188), TNNIGS (SEQ ID NO:189), TNNQAS (SEQ ID NO:190), TNTASS (SEQ ID NO:191), TNNLGS (SEQ ID NO:192), TNNQST (SEQ ID NO:193), TNNHSS (SEQ ID NO:194), TNNQSK (SEQ ID NO:184), TNNLSS (SEQ ID NO:195), INNQSS (SEQ ID NO:196), TNSQSS (SEQ ID NO:197), NNNQSR (SEQ ID NO:198), TNSTSL (SEQ ID NO:19 ... TNNQSS (SEQ ID NO:196), TNSQSS (SEQ ID NO:197), NNNQSR (SEQ ID NO:198), TNSTSL (SEQ ID NO:199), TNNQSK (SEQ ID NO:184), TNNQSK (SEQ ID NO:184), NO:199), TNNQRS (SEQ ID NO:200), or TNKQAS (SEQ ID NO:201); an amino acid sequence comprising any portion of any of the above amino acid sequences (e.g., any 2, 3, 4, or 5 amino acids, such as consecutive amino acids); an amino acid sequence comprising one, two, or three but no more than four modifications (e.g., substitutions (e.g., conservative substitutions), insertions, or deletions) relative to any of the above amino acid sequences; or an amino acid sequence comprising one, two, or three but no more than four different amino acids relative to any of the above amino acid sequences. In some embodiments, [N0]-[N1] is TNNQSS (SEQ ID NO:183). In some implementations, [N0]-[N1]-[N2]-[N3] are or include TNNQSSYPAEVVQK (SEQ ID NO:500), TNNQSKYPAEVVQK (SEQ ID NO:503), TNNTSLYPAEVVQK (SEQ ID NO:506), TNNSSSYPAEVVQK (SEQ ID NO:508), TNNQSRYPAEVVQK (SEQ ID NO:510), TNNQSSYPPSLVQK (SEQ ID NO:512), and TNNAGAYPAEVVQK (SEQ ID NO:508).NO:513), TNNIGSYPAEVVQK (SEQ ID NO:514), TNNQASYPAEVVQK (SEQ ID NO:517), TNTASSYPAEVVQK (SEQ ID NO:520), TNNLGSYPAEVVQK (SEQ ID NO:523), TNNQSTNKAEVVQK (SEQ ID NO:524), TNNHSSYPAEVVQK (SEQ ID NO:525), TNNSSSYTAEVVQK (SEQ ID NO:526), TNNQSKYPAEVEQK (SEQ ID NO:529), TNNTSLYPAEEVQK (SEQ ID NO:530), TNTASSYQAEVVQK (SEQ ID NO:531), TNNQSSYTPSLVQK (SEQ ID NO:533), TNNQSRYPAEEVQK (SEQ ID NO:534), TNNQSSYPPSLEQK (SEQ ID NO:535), TNNQSSYPPSLVKK (SEQ ID NO:536), TNNLSSYQAEVVQK (SEQ ID NO:539), TNNSSSYPAEVVKK (SEQ ID NO:540), TNNQSKYPAEVVHK (SEQ ID NO:542), INNQSSYPAEVVQK (SEQ ID NO:543), TNNHSSYPAAVVQK (SEQ ID NO:545), TNSQSSNPAEVVQK (SEQ ID NO:548), TNNSSSYPAEVVQQ (SEQ ID NO:551), NNNQSRYPAEVVQK (SEQ ID NO:552), TNNQSSYTAEVVQK (SEQ ID NO:553), TNNTSLCPAEVVQK (SEQ ID NO:554), TNSTSLYPAEVVQK (SEQ ID NO:556), TNNQRSYTAEVVQK (SEQ ID NO:557), TNNQSSYTAEVVKK (SEQ ID NO:558), TNNHSSYPAEVLQK (SEQ ID NO:560), TNNQSSYQAEEVQK (SEQ ID NO:562) or TNKQASYPAEVVQK (SEQ IDNO:563); an amino acid sequence comprising any portion of any of the above-described amino acid sequences (e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 amino acids, such as consecutive amino acids); an amino acid sequence comprising one, two, or three but no more than four modifications (e.g., substitutions (e.g., conservative substitutions), insertions, or deletions) relative to any of the above-described amino acid sequences; or an amino acid sequence comprising one, two, or three but no more than four different amino acids relative to any of the above-described amino acid sequences. In some embodiments, [N0]-[N1]-[N2]-[N3] is TNNQSSYPAEVVQK (SEQ ID NO:500).

[1137] In some embodiments, the peptide comprising the amino acid sequence of formula [N2]-[N3] further comprises [N4], which comprises position X. G and X H In some implementations, the position X of [N4] is... G It can be T, P, or N. In some implementations, the position of [N4] is X. G For T. In some implementations, the position of [N4] is X. HFor example, [N4] is A. In some embodiments, [N4] is or contains TA, PA, or NA. In some embodiments, [N4] is TA. In some embodiments, [N3]-[N4] is or contains VQKTA (SEQ ID NO:564), EQKTA (SEQ ID NO:565), VKKTA (SEQ ID NO:566), VQKPA (SEQ ID NO:567), VHKTA (SEQ ID NO:568), VQQTA (SEQ ID NO:569), VQKNA (SEQ ID NO:570), or LQKTA (SEQ ID NO:571); an amino acid sequence containing any part of any of the above amino acid sequences (e.g., any 2, 3, or 4 amino acids, such as consecutive amino acids); an amino acid sequence containing one, two, or three but no more than four modifications (e.g., substitutions (e.g., conservative substitutions), insertions, or deletions) relative to any of the above amino acid sequences; or an amino acid sequence containing one, two, or three but no more than four different amino acids relative to any of the above amino acid sequences. In some implementations, [N3]-[N4] is VQKTA (SEQ ID NO:564). In some implementations, [N0]-[N1]-[N2]-[N3]-[N4] are or include TNNQSSYPAEVVQKTA (SEQ ID NO:1533), TNNQSKYPAEVVQKTA (SEQ ID NO:1538), TNNTSLYPAEVVQKTA (SEQ ID NO:1232), TNNSSSYPAEVVQKTA (SEQ ID NO:1539), TNNQSRYPAEVVQKTA (SEQ ID NO:1327), TNNQSSYPPSLVQKTA (SEQ ID NO:1300), TNNNAGAYPAEVVQKTA (SEQ ID NO:1021), TNNIGSYPAEVVQKTA (SEQ ID NO:1112), TNNQASYPAEVVQKTA (SEQ ID NO:1194), TN TASSYPAEVVQKTA (SEQ ID NO:1194), and TN TASSYPAEVVQKTA (SEQ ID NO:1533). NO:1575), TNNLGSYPAEVVQKTA (SEQ ID NO:1027), TNNQSTNKAEVVQKTA (SEQ ID NO:1578), TNNHSSYPAEVVQKTA (SEQ ID NO:1310), TNNQSKYPA EVVQKTA (SEQ ID NO:1538), TNNSSSYTAEVVQKTA (SEQ ID NO:1214), TNNQSKYPAEVEQKTA (SEQ ID NO:1254), TNNTSLYPAEEVQKTA(SEQ ID NO:1583), TNTASSYQAEVVQKTA(SEQ ID NO:1584), TNNQSSYTPSLVQKTA(SEQ ID NO:1585), TNNQSRYPAEEVQKTA(SEQ ID NO:1342), TNNQSSYPPSLEQK TA(SEQ ID NO:1590), TNNQSSYPPSLVKKTA(SEQ ID NO:1591), TNNLSSYQAEVVQKTA(SEQ ID NO:1592), TNNQSSYPPSLVQKPA(SEQ ID NO:1593), TNNSSSYPAEVVKKTA(SEQ ID NO:1331), TNNQSKYPAEVVHKTA(SEQ ID NO:1453), TNNSSSYPAEVVQKPA(SEQ ID NO:1142), INNQSSYPAEVVQKTA(SEQ ID NO:1024), TNNHSSYPAAVVQKTA(SEQ ID NO:1598)、TNSQSSNPAEVVQKTA(SEQ ID NO:1599)、TNNSSSYPAEVVQ QTA(SEQ ID NO:1419)、NNNQSRYPAEVVQKTA(SEQ ID NO:1601)、TNNQSSYTAEVVQKNA(SEQ ID NO:1602)、TNNTSLC PAEVVQKTA(SEQ ID NO:1603)、TNSTSLYPAEVVQKTA(SEQ ID NO.NO:1587); an amino acid sequence comprising any portion of any of the above-described amino acid sequences (e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids, such as consecutive amino acids); an amino acid sequence comprising one, two, or three but no more than four modifications (e.g., substitutions (e.g., conservative substitutions), insertions, or deletions) relative to any of the above-described amino acid sequences; or an amino acid sequence comprising one, two, or three but no more than four different amino acids relative to any of the above-described amino acid sequences. In some embodiments, [N0]-[N1]-[N2]-[N3]-[N4] is TNNQSSYPAEVVQKTA (SEQ ID NO:1533).

[1138] In some embodiments, the peptide described herein comprises the formula [N2]-[N3], wherein [N2] comprises positions X1, X2, X3, X4, and X5, and [N3] comprises the amino acid sequence VQK or VQN. In some embodiments, [N3] comprises the amino acid sequence VQK. In some embodiments, position X1 of [N2] is Y or T. In some embodiments, position X2 of [N2] is Q, T, P, or E. In some embodiments, position X3 of [N2] is A. In some embodiments, position X4 of [N2] is E or D. In some embodiments, position X4 of [N2] is E or D. In some embodiments, position X5 of [N2] is V or E. In some embodiments, [N2] comprises Y at position X1. In some embodiments, [N2] comprises P at position X2. In some embodiments, [N2] comprises A at position X3. In some embodiments, [N2] comprises E at position X4. In some embodiments, [N2] comprises V at position X5. In some embodiments, [N2] comprises YP, YQ, YT, TE, QA, TA, PA, EA, EV, EE, DV, AE, or AD. In some embodiments, [N2] comprises YPA, YQA, YTA, TEA, QAE, TAE, PAE, EAE, PAD, AEV, AEE, or ADV. In some embodiments, [N2] comprises YPAE (SEQ ID NO:21), YQAE (SEQ ID NO:25), YTAE (SEQ ID NO:24), TEAE (SEQ ID NO:587), YPAD (SEQ ID NO:588), QAEV (SEQ ID NO:15), TAEV (SEQ ID NO:16), PAEV (SEQ ID NO:17), PAEE (SEQ ID NO:18), EAEV (SEQ ID NO:590), or PADV (SEQ ID NO:19). In some embodiments, [N2] is or includes YPAEV (SEQ ID NO:1), YQAEV (SEQ ID NO:6), YTAEV (SEQ ID NO:4), YPAEE (SEQ ID NO:5), TEAEV (SEQ ID NO:12), or YPADV (SEQ ID NO:13). In some embodiments, [N2] is YPAEV (SEQ ID NO:1). In some embodiments, [N2]-[N3] includes AEVVQK (SEQ ID NO:36), AEEVQK (SEQ ID NO:39), AEVVQN (SEQ ID NO:591), or ADVVQK (SEQ ID NO:593).In some implementations, [N2]-[N3] includes PAEVVQN (SEQ ID NO:594), QAEVVQK (SEQ ID NO:52), TAEVVQK (SEQ ID NO:49), PAEVVQK (SEQ ID NO:20), PAEEVQK (SEQ ID NO:51), EAEVVQK (SEQ ID NO:595), or PADVVQK (SEQ ID NO:596). In some embodiments, [N2]-[N3] are or comprise YPAEVVQK (SEQ ID NO:943)...

Claims

1. An AAV capsid variant comprising an amino acid sequence having the formula: [N2]-[N3], where: (i) [N2] contains positions X1, X2, X3, X4 and X5, where: (a) Position X1 is Y, N or C; (b) Position X2 is P, K, T or Q; (c) Position X3 is A or P; (d) Position X4 is E, S or A; and (e) Position X5 is V, L or E; and (ii) [N3] comprises the amino acid sequence of VQK, EQK, VKK, VHK, VQQ or LQK; and The AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 739, or an amino acid sequence that is at least 95% identical thereto.

2. The AAV capsid variant of claim 1, wherein: (a) [N2] contains YP, NK, YT, YQ, NP, CP, TH, AE, PS, AA, AS, PA, PP, KA, TA, QA, TP, HA, EV, SL, EE, AV, or SH; (b) [N2] contains YPA, YPP, NKA, YTA, YQA, YTP, NPA, CPA, THA, PAE, PPS, KAE, TAE, QAE, TPS, PAA, HAS, AEV, PSL, AEE, or AAV; (c) [N2] comprises YPAE (SEQ ID NO:21), YPPS (SEQ ID NO:22), NKAE (SEQ ID NO:23), YTAE (SEQ ID NO:24), YQAE (SEQ ID NO:25), YTPS (SEQ ID NO:26), YPAA (SEQ ID NO:27), NPAE (SEQ ID NO:28), CPAE (SEQ ID NO:29), THAS (SEQ ID NO:30), PAEV (SEQ ID NO:17), PPSL (SEQ ID NO:31), KAEV (SEQ ID NO:32), TAEV (SEQ ID NO:16), PAEE (SEQ ID NO:18), QAEV (SEQ ID NO:15), TPSL (SEQ ID NO:33), PAAV (SEQ ID NO:34) or QAEE (SEQ ID NO:35); and / or (d) [N2] includes YPAEV (SEQ ID NO:1), YPPSL (SEQ ID NO:2), NKAEV (SEQ ID NO:3), YTAEV (SEQ ID NO:4), YPAEE (SEQ ID NO:5), YQAEV (SEQ ID NO:6), YTPSL (SEQ ID NO:7), YPAAV (SEQ ID NO:8), NPAEV (SEQ ID NO:8) NO:9), CPAEV (SEQ ID NO:10) or YQAEE (SEQ ID NO:11).

3. The AAV capsid variant of claim 1 or 2, wherein [N2]-[N3] comprises: (i) the amino acid sequence of AEVVQK (SEQ ID NO:36), PSLVQK (SEQ ID NO:37), AEVEQK (SEQ ID NO:38), AEEVQK (SEQ ID NO:39), PSLEQK (SEQ ID NO:40), PSLVKK (SEQ ID NO:41), AEVVKK (SEQ ID NO:42), AEVVHK (SEQ ID NO:43), AAVVQK (SEQ ID NO:44), AEVVQQ (SEQ ID NO:45), or AEVLQK (SEQ ID NO:46) (ii) the amino acid sequence of PAEVVQK (SEQ ID NO:20), PPSLVQK (SEQ ID NO:47), KAEVVQK (SEQ ID NO:48), TAEVVQK (SEQ ID NO:49), PAEVEQK (SEQ ID NO:50), PAEEVQK (SEQ ID NO:51), QAEVVQK (SEQ ID NO:52), TPSLVQK (SEQ ID NO:53), PPSLEQK (SEQ ID NO:54), PPSLVKK (SEQ ID NO:55), PAEVVKK (SEQ ID NO:56), PAEVVHK (SEQ ID NO:57), PAAVVQK (SEQ ID NO:58), PAEVVQQ (SEQ ID NO:59), TAEVVKK (SEQ ID NO:60), PAEVLQK (SEQ ID NO:61) or QAEEVQK (SEQ ID NO:62).

4. The AAV capsid variant of any one of claims 1 to 3, wherein [N2]-[N3] comprises YPAEVVQK (SEQ ID NO:943), YPPSLVQK (SEQ ID NO:946), NKAEVVQK (SEQ ID NO:947), YTAEVVQK (SEQ ID NO:948), YPAEVEQK (SEQ ID NO:949), YPAEEVQK (SEQ ID NO:950), YQAEVVQK (SEQ ID NO:951), YTPSLVQK (SEQ ID NO:952), YPPSLEQK (SEQ ID NO:953), YPPSLVKK (SEQ ID NO:954), YPAEVVKK (SEQ ID NO:955), YPAEVVHK (SEQ ID NO:956), YPAAVVQK (SEQ ID NO:957), NPAEVVQK (SEQ ID NO:958), YPAEVVQQ (SEQ ID NO:959), YPAEVVQK (SEQ ID NO:960), YQAEVVQK (SEQ ID NO:961), YTPSLVQK (SEQ ID NO:962), YPPSLEQK (SEQ ID NO:963), YPPSLVKK (SEQ ID NO:964), YPAEVVKK (SEQ ID NO:965), YPAEVVHK (SEQ ID NO:966), YPAAVVQK (SEQ ID NO:967), NPAEVVQK (SEQ ID NO:968), YPAEVVQQ (SEQ ID NO:969), NO:959), CPAEVVQK (SEQ ID NO:960), YTAEVVKK (SEQ ID NO:961), YPAEVLQK (SEQ ID NO:962) or YQAEEVQK (SEQ ID NO:963).

5. The AAV capsid variant of any one of claims 1 to 4, further comprising [N1], wherein [N1] comprises position X D , X E and X F ,in: (a) Position X D is Q, T, S, A, I, L or H; (b) Position X E is S, G, A or R; and (c) Position X F It is S, K, L, R, A or T.

6. The AAV capsid variant of claim 5, wherein [N1]: (a) contains SK, SL, SS, SR, GA, GS, AS, ST, RS, QS, TS, AG, IG, QA, LG, HS, LS or QR; and / or (b) Contains QSS, QSK, TSL, SSS, QSR, AGA, IGS, QAS, ASS, LGS, QST, HSS, LSS or QRS.

7. The AAV capsid variant of claim 5 or 6, wherein [N1]-[N2] comprises QSSYPAEV (SEQ ID NO:96), QSKYPAEV (SEQ ID NO:97), TSLYPAEV (SEQ ID NO:98), SSSYPAEV (SEQ ID NO:99), QSRYPAEV (SEQ ID NO:100), QSSYPPSL (SEQ ID NO:101), AGAYPAEV (SEQ ID NO:102), IGSYPAEV (SEQ ID NO:103), QASYPAEV (SEQ ID NO:104), ASSYPAEV (SEQ ID NO:105), LGSYPAEV (SEQ ID NO:106), QSTNKAEV (SEQ ID NO:107), HSSYPAEV (SEQ ID NO:108), SSSYTAEV (SEQ ID NO:109), TSLYPAEE (SEQ ID NO:110), ASSYQAEV (SEQ ID NO:111), QSSYTPSL (SEQ ID NO:112), NO:112), QSRYPAEE (SEQ ID NO:113), LSSYQAEV (SEQ ID NO:114), HSSYPAAV (SEQ ID NO:115), QSSNPAEV (SEQ ID NO:116), QSSYTAEV (SEQ ID NO:117), TSLCPAEV (SEQ ID NO:118), QRSYTAEV (SEQ ID NO:119) or QSSYQAEE (SEQ ID NO:120).

8. The AAV capsid variant of any one of claims 5 to 7, wherein: (a) [N1]-[N2]-[N3] contains SSYPAEVVQ (SEQ ID NO:121), SKYPAEVVQ (SEQ ID NO:122), SLYPAEVVQ (SEQ ID NO:123), SRYPAEVVQ (SEQ ID NO:124), SSYPPSLVQ (SEQ ID NO:125), GAYPAEVVQ (SEQ ID NO:126), GSYPAEVVQ (SEQ ID NO:127), ASYPAEVVQ (SEQ ID NO:128), STNKAEVVQ (SEQ ID NO:129), SSYTAEVVQ (SEQ ID NO:130), SKYPAEVEQ (SEQ ID NO:131), SLYPAEEVQ (SEQ ID NO:132), SSYQAEVVQ (SEQ ID NO:133), SSYTPSLVQ (SEQ ID NO:134), SRYPAEEVQ (SEQ ID NO:135), SSYPPSLEQ (SEQ ID NO:136), SSYPPSLVK (SEQ ID NO:140), SSYPAEVVK (SEQ ID NO:141), SKYPAEVVH (SEQ ID NO:142), SSYPAAVVQ (SEQ ID NO:143), SSNPAEVVQ (SEQ ID NO:144), SLCPAEVVQ (SEQ ID NO:145), RSYTAEVVQ (SEQ ID NO:146), SSYTAEVVK (SEQ ID NO:147), SSYPAEVLQ (SEQ ID NO:148) or SSYQAEEVQ (SEQ ID NO:149); or (b)[N1]-[N2]-[N3] include QSSYPAEVVQK(SEQ ID NO:150), QSKYPAEVVQK(SEQ ID NO:151), TSLYPAEVVQK(SEQ ID NO:152), SSSYPAEVVQK(SEQ ID NO:153), QSRYPAEVVQK(SEQ ID NO:154), QSSYPPSLVQK (SEQ ID NO:155), AGAYPAEVVQK (SEQ ID NO:156), IGSYPAEVVQK (SEQ ID NO:157), QASYPAEVVQK (SEQ ID NO:158), ASSYPAEVVQK (SEQ ID NO:159), LGSYPAEVVQK (SEQ ID NO:160), QSTNKAEVVQK (SEQ ID NO:161), HSSYPAEVVQK (SEQ ID NO:162), SSSYTAEVVQK (SEQ ID NO:163), QSKYPAEVEQK (SEQ ID NO:164), TSLYPAEEVQK (SEQ ID NO:165), ASSYQAEVVQK (SEQ ID NO:166), QSSYTPSLVQK (SEQ ID NO:167), QSRYPAEEVQK (SEQ ID NO:168), QSSYPPSLEQK (SEQ ID NO:169), QSSYPPSLVKK (SEQ ID NO:170), LSSYQAEVVQK (SEQ ID NO:171), SSSYPAEVVKK (SEQ ID NO:172), QSKYPAEVVHK (SEQ ID NO:173), HSSYPAAVVQK (SEQ ID NO:174), QSSNPAEVVQK (SEQ ID NO:175), SSSYPAEVVQQ (SEQ ID NO:176), QSSYTAEVVQK (SEQ ID NO:177), TSLCPAEVVQK (SEQ ID NO:178), QRSYTAEVVQK (SEQ ID NO:179), QSSYTAEVVKK (SEQ ID NO:180), HSSYPAEVLQK (SEQ ID NO:181) or QSSYQAEEVQK (SEQ ID NO:182).

9. The AAV capsid variant of any one of claims 1 to 8, further comprising [N0], wherein [N0] comprises position X A , X B and X C ,in: (a) Position X A is T, I or N; (b) Position X B is N; and (c) Position X C N, T, S or K.

10. The AAV capsid variant of claim 9, wherein [NO]: (a) contains TN, IN, NN, NT, NS or NK; or (b) Contains TNN, TNT, INN, TNS, NNN or TNK.

11. The AAV capsid variant of claim 9 or 10, wherein [N0]-[N1] comprises TNNQSS (SEQ ID NO: 183), TNNQSK (SEQ ID NO: 184), TNNTSL (SEQ ID NO: 185), TNNSSS (SEQ ID NO: 186), TNNQSR (SEQ ID NO: 187), TNNAGA (SEQ ID NO: 188), TNNIGS (SEQ ID NO: 189), TNNQAS (SEQ ID NO: 190), TNTASS (SEQ ID NO: 191), TNNLGS (SEQ ID NO: 192), TNNQST (SEQ ID NO: 193), TNNHSS (SEQ ID NO: 194), TNNQSK (SEQ ID NO: 184), TNNLSS (SEQ ID NO: 195), INNQSS (SEQ ID NO: 196), TNSQSS (SEQ ID NO: 197), NNNQSR (SEQ ID NO: 198), TNSTSL (SEQ ID NO: 199), TNSQSS (SEQ ID NO: 200), TNNQSR (SEQ ID NO: 201), TNSTSL (SEQ ID NO: 202), TNNQSS (SEQ ID NO: 203), TNSQSS (SEQ ID NO: 204), NO:199), TNNQRS (SEQ ID NO:200) or TNKQAS (SEQ ID NO:201).

12. The AAV capsid variant of any one of claims 9 to 11, wherein [N0]-[N1]-[N2]-[N3] comprises TNNQSSYPAEVVQK (SEQ ID NO: 500), TNNQSKYPAEVVQK (SEQ ID NO: 503), TNNTSLYPAEVVQK (SEQ ID NO: 506), TNNSSSYPAEVVQK (SEQ ID NO: 508), TNNQSRYPAEVVQK (SEQ ID NO: 510), TNNQSSYPPSLVQK (SEQ ID NO: 512), TNNAGAYPAEVVQK (SEQ ID NO: 513), TNNIGSYPAEVVQK (SEQ ID NO: 514), TNNQASYPAEVVQK (SEQ ID NO: 517), TNTASSYPAEVVQK (SEQ ID NO: 520), TNNLGSYPAEVVQK (SEQ ID NO: 521). NO:523), TNNQSTNKAEVVQK (SEQ ID NO:524), TNNHSSYPAEVVQK (SEQ ID NO:525), TNNSSSYTAEVVQK (SEQ ID NO:526), ​​TNNQSKYPAEVEQK (SEQ ID NO:529), TNNTSLYPAEEVQK (SEQ ID NO:530), TNTASSYQAEVVQK (SEQ ID NO:531), TNNQSSYTPSLVQK (SEQ ID NO:533), TNNQSRYPAEEVQK (SEQ ID NO:534), TNNQSSYPPSLEQK (SEQ ID NO:535), TNNQSSYPPSLVKK (SEQ ID NO:536), TNNLSSYQAEVVQK (SEQ ID NO:539), TNNSSSYPAEVVKK (SEQ ID NO:540), TNNQSKYPAEVVHK (SEQ ID NO:542), INNQSSYPAEVVQK (SEQ ID NO:543), TNNHSSYPAAVVQK (SEQ ID NO:545), TNSQSSNPAEVVQK (SEQ ID NO:548), TNNSSSYPAEVVQQ (SEQ ID NO:551), NNNQSRYPAEVVQK (SEQ ID NO:552), TNNQSSYTAEVVQK (SEQ ID NO:553), TNNTSLCPAEVVQK (SEQ ID NO:554), TNSTSLYPAEVVQK (SEQID NO:556), TNNQRSYTAEVVQK (SEQ ID NO:557), TNNQSSYTAEVVKK (SEQ ID NO:558), TNNHSSYPAEVLQK (SEQ ID NO:560), TNNQSSYQAEEVQK (SEQ ID NO:562), or TNKQASYPAEVVQK (SEQ ID NO:563).

13. The AAV capsid variant of any one of claims 1 to 12, further comprising [N4], wherein [N4] comprises position X G and X H ,in: (a) Position X G is T, P or N; and (b) Position X H is A.

14. The AAV capsid variant of claim 13, wherein [N4] comprises TA, PA, or NA.

15. The AAV capsid variant of claim 13 or 14, wherein [N3]-[N4] comprises VQKTA (SEQ ID NO: 564), EQKTA (SEQ ID NO: 565), VKKTA (SEQ ID NO: 566), VQKPA (SEQ ID NO: 567), VHKTA (SEQ ID NO: 568), VQQTA (SEQ ID NO: 569), VQKNA (SEQ ID NO: 570) or LQKTA (SEQ ID NO: 571).

16. The AAV capsid variant of any one of claims 13 to 15, wherein [N0]-[N1]-[N2]-[N3]-[N4] comprises TNNQSSYPAEVVQKTA (SEQ ID NO: 1533), TNNQSKYPAEVVQKTA (SEQ ID NO: 1538), TNNTSLYPAEVVQKTA (SEQ ID NO: 1232), TNNSSSYPAEVVQKTA (SEQ ID NO: 1539), TNNQSRYPAEVVQKTA (SEQ ID NO: 1327), TN NQSSYPPSLVQKTA (SEQ ID NO: 1300), TNNAGAYPAEVVQKTA (SEQ ID NO: 1021), TNNIGSYPAEVVQKTA (SEQ ID NO: 1112), TNNQASYPAEVVQKTA (SEQ ID NO: 1194), TNTASSYPAEVVQKTA (SEQ ID NO: 1236), TNTASSYPAEVVQKTA (SEQ ID NO: 1237). NO:1575), TNNLGSYPAEVVQKTA (SEQ ID NO:1027), TNNQSTNKAEVVQKTA (SEQ ID NO:1578), TNNHSSYPAEVVQKTA (SEQ ID NO:1310), TNNQSKYPAEVVQKTA (SEQ ID NO:1538), TNNSSSYTAEVVQKTA (SEQ ID NO:1214), TNNQSKYPAEVEQKTA (SEQ ID NO:1254), TNNTSLYPAEEVQKTA (SEQ ID NO:1583), TNTASSYQAEVVQKTA (SEQ ID NO:1584), TNNQSSYTPSLVQKTA (SEQ ID NO:1585), TNNQS RYPAEEVQKTA (SEQ ID NO:1342), TNNQSSYPPSLEQKTA (SEQ ID NO:1590), TNNQSSYPPSLVKKTA (SEQ ID NO:1591), TNNLSSYQAEVVQKTA (SEQ ID NO:1592), TNNQSSYPPSLVQ KPA (SEQ ID NO:1593), TNNSSSYPAEVVKKTA (SEQ ID NO:1331), TNNQSKYPAEVVHKTA (SEQ ID NO:1453), TNNSSSYP AEVVQKPA (SEQ ID NO:1453) NO:1142), INNQSSYPAEVVQKTA(SEQ IDNO: 1024), TNNHSSYPAAVVQKTA (SEQ ID NO: 1598), TNSQSSNPAEVVQKTA (SEQ ID NO: 1599), TNNSSSYPAEVVQQTA (SEQ ID NO: 1419), NNNQSRYPAEVVQKTA (SEQ ID NO: 1601), TNNQSSYTAEVVQKNA (SEQ ID NO: 1602), TNNTSLCPAEVVQKTA (SEQ ID NO: 1603), TNSTSLYPAEVVQKTA (SEQ ID NO: 1605), TNNQRSYTAEVVQKTA (SEQ ID NO: 1604), TNNQ SSYTAEVVKKTA (SEQ ID NO: 1606), TNNHSSYPAEVLQKTA (SEQ ID NO: 1607), TNNQSSYQAEEVQKTA (SEQ ID NO: 1608) or TNKQASYPAEVVQKTA (SEQ ID NO: 1587).

17. The AAV capsid variant of any one of claims 1 to 16, wherein: (a) [N2]-[N3] is present in ring VIII; and / or (b) [N0], [N1] and [N4] are present in ring VIII; wherein loop VIII comprises positions 571-599 of SEQ ID NO:

982.

18. The AAV capsid variant of any one of claims 1 to 17, wherein: (i) X of [N0] A X present at position 571, [N0] B Exists at position 572, and [N0]'s X C present at position 573, these positions are numbered according to SEQ ID NO:982; (ii) X of [N1] D Exists at position 574, X of [N1] E exists at position 575, and [N1]'s X F present at position 576, these positions are numbered according to SEQ ID NO:982; (iii) X1 of [N2] is present at position 577, X2 of [N2] is present at position 578, X3 of [N2] is present at position 579, X4 of [N2] is present at position 580, and X5 of [N2] is present at position 581, these positions being numbered according to SEQ ID NO:982; (iv) [N3] is present at positions 582-584, as these positions are numbered according to SEQ ID NO:982; and / or (v) [N4] X G X present at position 585 and [N4] H Present at position 586, these positions are numbered according to SEQ ID NO:

982.

19. An AAV capsid variant comprising: (a) an amino acid sequence of any one of the sequences provided in Tables 1, 2A, 2B, 9 or 15-20; (b) an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive amino acids from any one of the sequences provided in Tables 1, 2A, 2B, 9 or 15-20; or (c) an amino acid sequence comprising one, two or three but not more than four different amino acids relative to the amino acid sequence provided in any one of Tables 1, 2A, 2B, 9 or 15-20.

20. The AAV capsid variant of any one of claims 1 to 19, comprising: (a) the amino acid sequence of any one of SEQ ID NO:943, 1021, 1024, 1027, 1112, 1142, 1214, 1232, 1254, 1300, 1310, 1327, 1331, 1342, 1419, 1453, 1533, 1538, 1539, 1575, 1578, 1583-1587, 1590, 1591-1593, 1598-1608, or 1610-1624; (b) an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive amino acids from any one of SEQ ID NO: 943, 1021, 1024, 1027, 1112, 1142, 1214, 1232, 1254, 1300, 1310, 1327, 1331, 1342, 1419, 1453, 1533, 1538, 1539, 1575, 1578, 1583-1587, 1590, 1591-1593, 1598-1608, or 1610-1624; or (c) an amino acid sequence comprising one, two or three but not more than four different amino acids relative to the amino acid sequence of any one of SEQ ID NO:943, 1021, 1024, 1027, 1112, 1142, 1214, 1232, 1254, 1300, 1310, 1327, 1331, 1342, 1419, 1453, 1533, 1538, 1539, 1575, 1578, 1583-1587, 1590, 1591-1593, 1598-1608 or 1610-1624.

21. The AAV capsid variant of claim 19 or 20, wherein: (i) 3 consecutive amino acids containing YPA; (ii) 4 consecutive amino acids comprising YPAE (SEQ ID NO: 21); (iii) 5 consecutive amino acids comprising YPAEV (SEQ ID NO: 1); (iv) 6 consecutive amino acids comprising YPAEVV (SEQ ID NO: 725); (v) 7 consecutive amino acids comprising YPAEVVQ (SEQ ID NO: 726); and / or (vi) the amino acid sequence comprises YPAEVVQK (SEQ ID NO: 943).

22. The AAV capsid variant of any one of claims 19 to 21, comprising the amino acid sequence YPAEVVQK (SEQ ID NO: 943) or an amino acid sequence comprising one, two or three but not more than four different amino acids relative to the amino acid sequence of YPAEVVQK (SEQ ID NO: 943).

23. The AAV capsid variant of any one of claims 1 to 22, wherein: (i) the AAV capsid variant comprises an amino acid sequence encoded by: a nucleotide sequence of SEQ ID NO: 944; or a nucleotide sequence comprising at least one, two, three, four, five, six or seven but not more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO: 944; and / or (ii) the nucleotide sequence encoding the capsid variant comprises the nucleotide sequence of SEQ ID NO: 944; or a nucleotide sequence comprising at least one, two, three, four, five, six or seven but not more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO:

944.

24. The AAV capsid variant of any one of claims 1 to 23, wherein amino acid Y is present at position 577 and the amino acid sequence of PAEVVQK (SEQ ID NO: 20) is present at positions 578-584, as numbered relative to SEQ ID NO:

982.

25. The AAV capsid variant of any of the preceding claims, comprising the amino acid sequence of SEQ ID NO:

739.

26. An AAV capsid variant as described in any of the preceding claims, comprising the amino acid sequence of SEQ ID NO:738, or an amino acid sequence having at least 95% sequence identity thereto, optionally wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO:

738.

27. The AAV capsid variant of any one of claims 1 to 26, wherein: (i) the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 982, or an amino acid sequence having at least 95% sequence identity thereto, optionally, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 982; and / or (ii) the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of SEQ ID NO: 984, or a nucleotide sequence having at least 90% sequence identity thereto, optionally, wherein the nucleotide sequence is codon-optimized.

28. An AAV capsid variant comprising the amino acid sequence of SEQ ID NO:

982.

29. The AAV capsid variant of any one of claims 1 to 28, wherein the AAV capsid variant (i) has an increased tropism for CNS cells or tissues (e.g., brain cells, brain tissue, spinal cord cells, or spinal cord tissue) relative to the tropism of a reference sequence comprising the amino acid sequence of SEQ ID NO: 138, 139, or 982; (ii) transducing a brain region, e.g., the temporal cortex, perirhinal cortex, globus pallidus, putamen, caudate nucleus, thalamus, hippocampus, geniculate nucleus, Purkinje layer, deep cerebellar nuclei and / or cerebellum, optionally wherein the level of transduction is at least 1.5, 2.2, 2.4, 2.5, 2.6, 2.7, 3.0, 3.2, 3.5, 3.7, 4.0, 4.2, 4.5, 4.7, 4.9, 5, 10, 15, 20, 25, 30, 35-fold greater as compared to a reference sequence of SEQ ID NO: 139, e.g., when measured by an assay, e.g., an immunohistochemistry assay or a qPCR assay, e.g., as described in Example 2; (iii) at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 25, 30, 35, 40, 45, 50, 55, 60, or 65-fold enriched in brain compared to the reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1; (iv) at least about 10, 12, 15, 17, 20, 25, 30, 35, 40, 45, 50, 55, 60, 61, 62, 63, 64, or 65-fold enriched in brain compared to the reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1; (v) at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 25, 30, 35, 40, 45-fold enriched in the brain of at least two to three species (e.g., non-human primate and rodent (e.g., rat or mouse)) compared to the reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Examples 1, 2, and 4; (vi) at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 125, 150, 175, 200, or 225-fold enriched in brain compared to the reference sequence of SEQ ID NO:982, e.g., when measured by an assay as described in Example 4; (vii) delivering increased levels of a payload to a brain region, optionally, wherein the level of the payload is increased by at least 20, 25, 30, 35 fold as compared to a reference sequence of SEQ ID NO: 139, e.g., when measured by an assay such as a qRT-PCR or qPCR assay (e.g., as described in Example 2), optionally, wherein the brain region is the temporal cortex, perirhinal cortex, globus pallidus, putamen, caudate nucleus, thalamus, hippocampus, geniculate nucleus, Purkinje layer, deep cerebellar nuclei and / or cerebellum; (viii) delivering increased levels of viral genomes to a brain region, optionally wherein the level of viral genomes is increased by at least 1.5, 2.2, 2.4, 2.5, 2.6, 2.7, 3.0, 3.2, 3.5, 3.7, 4.0, 4.2, 4.5, 4.7, 4.9 or 5 fold as compared to the reference sequence of SEQ ID NO: 139, e.g., when measured by an assay such as a qRT-PCR or qPCR assay (e.g., as described in Example 2), optionally wherein the brain region is the temporal cortex, perirhinal cortex, globus pallidus, putamen, caudate nucleus, thalamus, hippocampus, geniculate nucleus, Purkinje layer, deep cerebellar nuclei and / or cerebellum; (ix) at least about 3, 3.5, 4.0, 4.5, 5, 5.0, 6.0, or 6.5-fold enriched in the spinal cord region compared to the reference sequence of SEQ ID NO: 139, e.g., when measured by an assay as described in Example 2, optionally wherein the spinal cord region is the cervical region, the lumbar region, the thoracic region, or a combination thereof; (x) showing preferential transduction in brain regions relative to transduction in dorsal root ganglia (DRG); (xi) showing preferential transduction in the brain relative to transduction in the liver; and / or (xii) is capable of transducing neuronal cells and non-neuronal cells, such as glial cells (eg, oligodendrocytes or astrocytes).

30. A polynucleotide encoding the AAV capsid variant of any one of claims 1 to 29.

31. The polynucleotide of claim 30, comprising: (i) a nucleotide sequence comprising at least one, two, three, four, five, six or seven but not more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO: 944; (iii) the nucleotide sequence of SEQ ID NO:944, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98% or 99% sequence identity); and / or (iv) the nucleotide sequence of SEQ ID NO: 984, or a nucleotide sequence having at least 80% (e.g., at least about 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto, Optionally, wherein the polynucleotide comprises a codon-optimized nucleotide sequence.

32. A peptide comprising: (a) an amino acid sequence of any of the sequences provided in Tables 1, 2A, 2B, 9, or 15-20; (b) an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive amino acids from any one of the sequences provided in Tables 1, 2A, 2B, 9 or 15-20; or (c) an amino acid sequence comprising one, two or three but not more than four different amino acids relative to the amino acid sequence provided in any one of Tables 1, 2A, 2B, 9 or 15-20.

33. A peptide comprising: (i) the amino acid sequence of YPAEVVQK (SEQ ID NO: 943); (ii) an amino acid sequence comprising one, two or three but not more than four different amino acids relative to the amino acid sequence of YPAEVVQK (SEQ ID NO: 943); or (iii) at least 3, 4, 5, 6 or 7 consecutive amino acids from the amino acid sequence of YPAEVVQK (SEQ ID NO: 943).

34. An AAV particle comprising the AAV capsid variant of any one of claims 1 to 29, an AAV capsid variant encoded by the polynucleotide of claim 30 or 31, or an AAV capsid variant comprising the peptide of claim 32 or 33.

35. An AAV particle as described in claim 34, comprising a nucleotide sequence encoding a payload, optionally wherein the encoded payload comprises a therapeutic protein or a functional variant thereof; an antibody or antibody fragment; an enzyme; a component of a gene editing system; an RNAi agent (e.g., dsRNA, siRNA, shRNA, pre-miRNA, primary-miRNA, miRNA, stRNA, lncRNA, piRNA or snoRNA); or a combination thereof.

36. The AAV particle of claim 35, wherein: (i) the therapeutic protein or a functional variant thereof (e.g., a recombinant protein) is associated with (e.g., abnormally expressed in) a neurological or neurodegenerative disorder, a muscle or neuromuscular disorder, or a neuroneoplastic disorder, optionally wherein the therapeutic protein or a functional variant thereof is selected from apolipoprotein E (APOE) (e.g., ApoE2, ApoE3, and / or ApoE4); human motor neuron survival protein (SMN) 1 or SMN2; glucocerebrosidase (GBA1); aromatic L-amino acid decarboxylase (AADC); aspartate acylase (ASPA); tripeptidyl peptidase I (CLN2); β-galactosidase (GLB1); N-sulfoglucosamine sulfohydrolase (SGSH); N-acetyl-α-glucosaminidase (NAGLU); idose 2-sulfatase (IDS); intracellular cholesterol transporter (NPC1); giant axonal neuron (GAN); or a combination thereof; (ii) the antibody or antibody binding fragment binds to (a) CNS-related targets, such as antigens associated with neurological or neurodegenerative disorders, such as β-amyloid, APOE, tau, SOD1, TDP-43, huntingtin (HTT), and / or synuclein; (b) a muscle or neuromuscular related target, such as an antigen associated with a muscle or neuromuscular disorder; or (c) neuro-oncology-related targets, such as antigens associated with neuro-oncological disorders, such as HER2 or EGFR (e.g., EGFRvIII); (iii) the enzyme comprises a meganuclease, a zinc finger nuclease, a TALEN, a recombinase, an integrase, a base editor, Cas9 or a fragment thereof; (iv) the components of the gene editing system comprise one or more components of a CRISPR-Cas system, optionally wherein the one or more components of the CRISPR-Cas system comprise Cas9, e.g., a Cas9 ortholog or Cpf1, and a single guide RNA (sgRNA), wherein: (a) the sgRNA is located upstream (5') of the Cas9 enzyme; and / or (b) the sgRNA is located downstream (3') of the cas9 enzyme; and / or (v) the RNAi agent (e.g., dsRNA, siRNA, shRNA, pre-miRNA, primary-miRNA, miRNA, stRNA, lncRNA, piRNA or snoRNA) regulates (e.g., inhibits) the expression of CNS-related genes, mRNAs and / or proteins, optionally wherein the CNS-related genes are selected from SOD1, MAPT, APOE, HTT, C9ORF72, TDP-43, APP, BACE, SNCA, ATXN1, ATXN3, ATXN7, SCN1A-SCN5A, SCN8A-SCN11A or a combination thereof.

37. The AAV particle of any one of claims 34 to 36, comprising a viral genome comprising a promoter operably linked to a nucleic acid sequence encoding the payload, optionally wherein: (i) the promoter is selected from the group consisting of human elongation factor 1α-subunit (EF1α), cytomegalovirus (CMV) immediate early enhancer and / or promoter, chicken β-actin (CBA) and its derivative CAG, β-glucuronidase (GUSB) or ubiquitin C (UBC), neuron-specific enolase (NSE), platelet-derived growth factor (PDGF), platelet-derived growth factor B chain (PDGF-β), intercellular adhesion molecule 2 (ICAM-2), synaptophysin (Syn), methyl-CpG binding protein 2 (MeCP2), Ca2+ / calmodulin-dependent protein kinase II (C aMKII), metabotropic glutamate receptor 2 (mGluR2), neurofilament light chain (NFL) or heavy chain (NFH), β-globin minigene nβ2, preproenkephalin (PPE), enkephalin (Enk) and excitatory amino acid transporter 2 (EAAT2), glial fibrillary acidic protein (GFAP), myelin basic protein (MBP), cardiovascular promoters (e.g., αMHC, cTnT and CMV-MLC2k), liver promoters (e.g., hAAT, TBG), skeletal muscle promoters (e.g., desmin, MCK, C512) or fragments (e.g., truncations) or functional variants thereof; (ii) the promoter is a variant of the EF-1a promoter, such as a truncated EF-1a promoter; or (iii) the promoter comprises the nucleotide sequence of any one of SEQ ID NOs: 987-1007; a nucleotide sequence comprising at least one, two, three, four, five, six or seven but not more than four modifications (e.g., substitutions) relative to the nucleotide sequence of SEQ ID NOs: 987-1007; or a nucleotide sequence having at least 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity with any one of SEQ ID NOs: 987-1007.

38. The AAV particle of claim 37, wherein the viral genome further comprises: (i) polyA signal sequence; (ii) an inverted terminal repeat (ITR) sequence, optionally, wherein the ITR sequence is located 5' relative to the encoded payload and / or the ITR sequence is located 3' relative to the encoded payload; (iii) enhancers, Kozak sequences, intronic regions and / or exonic regions; and / or (iv) a nucleotide sequence encoding a miR binding site, such as a miR binding site that modulates (e.g., reduces) the expression of an antibody molecule encoded by the viral genome in a cell or tissue in which the corresponding miRNA is expressed, optionally wherein the encoded miR binding site modulates (e.g., reduces) the expression of the encoded antibody molecule in cells or tissues of the DRG, liver, heart, hematopoietic lineage, or a combination thereof.

39. The AAV particle of claim 38, wherein the viral genome comprises: (i) at least 1-5 copies, such as at least 1, 2, 3, 4 or 5 copies, of an encoded miR binding site; (ii) at least 3 copies of an encoded miR binding site, optionally wherein: (a) all three copies contain the same miR binding site, or at least one, two, three or all of the copies contain different miR binding sites; and / or (b) the three copies of the encoded miR binding site are contiguous (e.g., are not separated by a spacer) or are separated by a spacer, optionally wherein the spacer comprises a nucleotide sequence of GATAGTTA, or a nucleotide sequence having at least one, two or three modifications (e.g., substitutions (e.g., conservative substitutions)) but not more than four modifications (e.g., substitutions (e.g., conservative substitutions)) relative to GATAGTTA; or (iii) at least 4 copies of the encoded miR binding site, optionally wherein (a) all four copies contain the same miR binding site, or at least one, two, three or all of the copies contain different miR binding sites; and / or (b) the four copies of the encoded miR binding site are contiguous (e.g., are not separated by a spacer) or are separated by a spacer, optionally wherein the spacer comprises a nucleotide sequence of GATAGTTA, or a nucleotide sequence having at least one, two or three modifications (e.g., substitutions (e.g., conservative substitutions)) but not more than four modifications (e.g., substitutions (e.g., conservative substitutions)) relative to GATAGTTA.

40. The AAV particle of claim 38 or 39, wherein the encoded miR binding site comprises a miR122 binding site, a miR183 binding site, a miR-1 binding site, miR-142-3p, or a combination thereof, optionally wherein: (i) the miR122 binding site encoded comprises the nucleotide sequence of SEQ ID NO: 4673, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98% or 99% sequence identity); or a nucleotide sequence comprising at least one, two, three, four, five, six or seven modifications (e.g., substitutions, insertions or deletions) but not more than ten modifications (e.g., substitutions, insertions or deletions) relative to SEQ ID NO: 4673; (ii) the encoded miR183 binding site comprises the nucleotide sequence of SEQ ID NO: 4676, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98% or 99% sequence identity); or a nucleotide sequence comprising at least one, two, three, four, five, six or seven modifications (e.g., substitutions, insertions or deletions) but not more than ten modifications (e.g., substitutions, insertions or deletions) relative to SEQ ID NO: 4676; (iii) the encoded miR-1 binding site comprises the nucleotide sequence of SEQ ID NO:4679, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98% or 99% sequence identity); or a nucleotide sequence comprising at least one, two, three, four, five, six or seven modifications (e.g., substitutions, insertions or deletions) but not more than ten modifications (e.g., substitutions, insertions or deletions) relative to SEQ ID NO:4679; and / or (iv) the encoded miR-142-3p binding site comprises the nucleotide sequence of SEQ ID NO:4675, or a nucleotide sequence substantially identical thereto (e.g., having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 97%, 98% or 99% sequence identity); or a nucleotide sequence comprising at least one, two, three, four, five, six or seven modifications (e.g., substitutions, insertions or deletions) but not more than ten modifications (e.g., substitutions, insertions or deletions) relative to SEQ ID NO:4675.

41. The AAV particle of any one of claims 37 to 40, wherein the viral genome is: (i) single-stranded; or (ii) Self-complementary.

42. The AAV capsid variant, polynucleotide, peptide or AAV particle of any of the preceding claims, which is isolated, such as recombinant.

43. A vector comprising a polynucleotide encoding the AAV capsid variant of any one of claims 1 to 29 or 42, a polynucleotide of any one of claims 30, 31 or 42, or a polynucleotide encoding the peptide of any one of claims 32, 33 or 42.

44. A cell, such as a host cell, comprising an AAV capsid variant according to any one of claims 1 to 29 or 42, a polynucleotide according to any one of claims 30, 31 or 42, a polynucleotide encoding a peptide according to any one of claims 32, 33 or 42, an AAV particle according to any one of claims 34 to 42, or a vector according to claim 43, optionally wherein: (i) the cell is a mammalian cell or an insect cell; (ii) the cell is a cell of a brain region or a spinal cord region, optionally a cell of the brainstem, hippocampus or thalamus; and / or (iii) the cell is a neuron, a sensory neuron, a motor neuron, an astrocyte, a glial cell, an oligodendrocyte, or a muscle cell (eg, a cell of the heart, diaphragm, or quadriceps).

45. A method for preparing AAV particles, comprising (i) providing a host cell comprising a viral genome; and (ii) culturing the host cell under conditions suitable for encapsidating the viral genome into an AAV capsid variant as described in any one of claims 1 to 29 or 42, or an AAV capsid variant encoded by a polynucleotide as described in any one of claims 30, 31 or 32; The AAV particles are thus prepared.

46. ​​A pharmaceutical composition comprising an AAV particle as described in any one of claims 34 to 42, an AAV particle comprising an AAV capsid variant as described in any one of claims 1 to 29 or 42, or an AAV particle comprising a peptide as described in any one of claims 32, 33 or 42, and a pharmaceutically acceptable excipient.

47. A method for delivering a payload to a cell or tissue (e.g., a CNS cell or CNS tissue), comprising administering an effective amount of a pharmaceutical composition as described in claim 46, an AAV particle as described in any one of claims 34 to 42, an AAV particle comprising an AAV capsid variant as described in any one of claims 1 to 29 or 42, or an AAV particle comprising a peptide as described in any one of claims 32, 33 or 42.

48. The method of claim 47, wherein the cell is: (i) cells of a brain region or a spinal cord region, optionally cells of the temporal cortex, perirhinal cortex, globus pallidus, putamen, caudate nucleus, thalamus, hippocampus, geniculate nucleus, Purkinje layer, deep cerebellar nuclei, cerebellum, cervical spinal cord, thoracic spinal cord, lumbar spinal cord, or a combination thereof; (ii) cells of the heart (e.g., atrium or ventricle); (iii) muscle cells (e.g., cells of the quadriceps femoris) or hepatocytes; (iv) a neuron, a sensory neuron, a motor neuron, an astrocyte, a glial cell or an oligodendrocyte; (v) in a subject, optionally wherein the subject has, has been diagnosed with, or is at risk of having a genetic disorder (e.g., a monogenic disorder or a polygenic disorder), a neurological disorder (e.g., a neurodegenerative disorder), a neuro-oncological disorder, a muscular disorder, or a neuromuscular disorder.

49. A method of treating a subject having or diagnosed with a genetic disorder (e.g., a monogenic disorder or a polygenic disorder), the method comprising administering to the subject an effective amount of a pharmaceutical composition as described in claim 46, an AAV particle as described in any one of claims 34 to 42, an AAV particle comprising an AAV capsid variant as described in any one of claims 1 to 29 or 42, or an AAV particle comprising a peptide as described in any one of claims 32, 33 or 42.

50. A method of treating a subject having or diagnosed with a neurological disorder (e.g., a neurodegenerative disorder), a neuro-oncological disorder, a muscle disorder, or a neuromuscular disorder, the method comprising administering to the subject an effective amount of a pharmaceutical composition as described in claim 46, an AAV particle as described in any one of claims 34 to 42, an AAV particle comprising an AAV capsid variant as described in any one of claims 1 to 29 or 42, or an AAV particle comprising a peptide as described in any one of claims 32, 33, or 42.

51. A method of treating a subject having or diagnosed with a muscle disorder or a neuromuscular disorder, the method comprising administering to the subject an effective amount of a pharmaceutical composition as described in claim 46, an AAV particle as described in any one of claims 34 to 42, an AAV particle comprising an AAV capsid variant as described in any one of claims 1 to 29 or 42, an AAV particle comprising a peptide as described in any one of claims 32, 33 or 42.

52. A method of treating a subject having or diagnosed with a neuroneoplastic disorder, the method comprising administering to the subject an effective amount of a pharmaceutical composition as described in claim 46, an AAV particle as described in any one of claims 34 to 42, an AAV particle comprising an AAV capsid variant as described in any one of claims 1 to 29 or 42, or an AAV particle comprising a peptide as described in any one of claims 32, 33 or 42.

53. The method of any one of claims 48 to 52, wherein the genetic disorder, neurological disorder, neurodegenerative disorder, muscular disorder, neuromuscular disorder, or neuro-oncological disorder is Huntington's disease, amyotrophic lateral sclerosis (ALS), Gaucher disease, dementia with Lewy bodies, Parkinson's disease, spinal muscular atrophy, Alzheimer's disease, a leukodystrophy (e.g., Alexander disease, autosomal dominant leukodystrophy with autonomic disease (ADLD), Canavan disease, cerebrotendinous xanthomatosis (CTX), metachromatic leukodystrophy (MLD), Perelman-Merzbacher disease, or Refsum disease), or a cancer (e.g., a HER2 / neu positive cancer or a glioblastoma).

54. The method of any one of claims 49 to 53, wherein treating comprises preventing progression of the disease or disorder in the subject.

55. The method of any one of claims 48 to 54, wherein the subject is a human.

56. The method of any one of claims 48 to 55, wherein the AAV particles are administered to the subject via: (i) intravenously, via intracisternal injection (ICM), intracerebrally, intrathecally, intracerebroventricularly, via intraparenchymal administration, or intramuscularly; (ii) via focused ultrasound (FUS), e.g. combined with intravenous administration of microbubbles (FUS-MB), or MRI-guided FUS combined with intravenous administration; or (iii) Intravenous.

57. A pharmaceutical composition as described in claim 46, an AAV particle as described in any one of claims 34 to 42, an AAV particle comprising an AAV capsid variant as described in any one of claims 1 to 29 or 42, or an AAV particle comprising a peptide as described in any one of claims 32, 33 or 42, for use in a method of delivering a payload to a cell or tissue.

58. A pharmaceutical composition as described in claim 46, an AAV particle as described in any one of claims 34 to 42, an AAV particle comprising an AAV capsid variant as described in any one of claims 1 to 29 or 42, or an AAV particle comprising a peptide as described in any one of claims 32, 33 or 42, for use in a method of treating a genetic disorder, a neurological disorder, a neurodegenerative disorder, a muscular disorder, a neuromuscular disorder, or a neuro-oncological disorder.

59. A pharmaceutical composition as described in claim 46, an AAV particle as described in any one of claims 34 to 42, an AAV particle comprising an AAV capsid variant as described in any one of claims 1 to 29 or 42, or an AAV particle comprising a peptide as described in any one of claims 32, 33 or 42, for use in the manufacture of a medicament.

60. Use of a pharmaceutical composition as described in claim 46, an AAV particle as described in any one of claims 34 to 42, an AAV particle comprising an AAV capsid variant as described in any one of claims 1 to 29 or 42, or an AAV particle comprising a peptide as described in any one of claims 32, 33 or 42 in the manufacture of a medicament.

61. Use of a pharmaceutical composition as described in claim 46, an AAV particle as described in any one of claims 34 to 42, an AAV particle comprising an AAV capsid variant as described in any one of claims 1 to 29 or 42, or an AAV particle comprising a peptide as described in any one of claims 32, 33 or 42 in the manufacture of a medicament for treating a genetic disorder, a neurological disorder, a neurodegenerative disorder, a muscular disorder, a neuromuscular disorder or a neuro-oncological disorder.